UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, ~~2024~~2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period

SCIENTIFIC INDUSTRIES, INC.

(Exact Name of Registrant in Its Charter)

Delaware		04-2217279
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

80 Orville Drive, Suite 102, Bohemia, New York		11716
(Address of principal executive offices)		(Zip Code)

(631) 567-4700

(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Name of each exchange on which registered
None		None

Securities registered pursuant to Section 12(g) of the Exchange Act:

Title of Class

Common stock, $.05 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Yes ☒ ☐ No

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the eﬀectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐ Yes ☒ No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

The aggregate market value of the voting stock held by non-affiliates computed by reference to the average bid and asked prices of such stock, as of June 30, ~~2024~~2025 is $53,~~009~~657,~~326~~073.

The number of shares outstanding of the registrant’s common stock, par value $.05 per share (“Common Stock”) as of March 27, ~~2025~~2026 is 1011,~~503~~928,599 shares.

DOCUMENTS INCORPORATED BY REFERENCE

None.

SCIENTIFIC INDUSTRIES, INC.

Table of Contents

PART I
Item 1.	BUSINESS	3
Item 1A.	RISK FACTORS	6
Item 1B.	UNRESOLVED STAFF COMMENTS	13
Item 1C.	CYBERSECURITY	13
Item 2.	PROPERTIES	14
Item 3.	LEGAL PROCEEDINGS	14
Item 4.	MINE SAFETY DISCLOSURES	14
PART II
Item 5.	MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED ~~STOCKHOLDER~~SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	15
Item 6.	[RESERVED]	16
Item 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	16
Item 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	20
Item 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	20
Item 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	20
Item 9A.	CONTROLS AND PROCEDURES	20
Item 9B.	OTHER INFORMATION	21
Item 9C.	DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	21
PART III
Item 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	22
Item 11.	EXECUTIVE COMPENSATION	2425
Item 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED ~~STOCKHOLDER~~SHAREHOLDER MATTERS	2628
Item 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE	2729
Item 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	2729
PART IV
Item 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	2830
SIGNATURES		3840

Table of Contents

FORWARD-LOOKING STATEMENTS

The Company and its representatives may from time to time make written or oral forward-looking statements with respect to the Company’s annual or long-term goals, including statements contained in its filings with the Securities and Exchange Commission and in its reports to ~~stockholders~~shareholders.

The words or phrases “will likely result”, “will be”, “will”, “are expected to”, “will continue to”, “is anticipated”, “estimate”, “project” or similar expressions identify “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date made.

PART I

Item 1. Business.

General. Incorporated in 1954, Scientific Industries, Inc., a Delaware corporation (“SI” and along with its subsidiaries, the “Company”), is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment (“Benchtop Laboratory Equipment”), and through its wholly-owned subsidiary, Scientific Bioprocessing Holdings, Inc., a Delaware corporation (“SBHI”), the design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”). SBHI has two wholly-owned subsidiaries – Scientific Bioprocessing, Inc., a Delaware corporation (“SBI”), and aquila biolabs GmbH, a German corporation (“Aquila”). The Company’s products are used primarily for research purposes by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research. ~~Until~~On ~~November~~August 307, ~~2020~~2025, the Company ~~was~~sold ~~also~~its ~~engaged~~Genie inproduct ~~the~~line ~~design,~~which ~~manufacture~~was ~~and~~part ~~marketing~~ of ~~customized~~the ~~catalyst~~Benchtop ~~research~~Laboratory ~~instruments~~Equipment ~~through~~operations ~~its~~but ~~wholly-owned~~continues ~~subsidiary,~~to ~~Altamira~~market ~~Instruments,~~and ~~Inc,~~produce ascales ~~Delaware~~and ~~corporation~~pill ~~(“Altamira”).~~counters Onin ~~November 30, 2020,~~ the ~~Company~~Benchtop ~~sold~~Laboratory ~~substantially~~Equipment ~~all~~operating ~~of Altamira’s assets and Altamira’s operations were discontinued~~segment.

Operating Segments. The Company views its operations as two segments: the manufacture ~~and marketing~~ of standard ~~Benchtop~~benchtop ~~Laboratory~~laboratory ~~Equipment~~equipment and weighing instruments which includes various types of equipment used for research and sample preparation in university, pharmacy and industrial laboratories ~~sold primarily through laboratory equipment distributors and online~~, and weight and measurement products including pill counters and digital scales sold through distribution and online; and the design, development, manufacture and marketing of bioprocessing products, principally products incorporating smart sensors and state of the art software analytics, sold primarily on a direct basis through the Company’s internal sales force.

Products.

Benchtop Laboratory Equipment. The Company’s Benchtop Laboratory Equipment products consist of ~~mixers and shakers, rotators/rockers, refrigerated and shaking incubators, and magnetic stirrers sold through the “Genie ™” division, and~~ pharmacy and laboratory balances and scales, force gauges, automated pill counters and moisture analyzers sold through the “Torbal®” division. ~~Sales~~with oftrademark ~~the~~“Torbal” ~~Company’s~~or ~~principal product, the Vortex-Genie~~“VIVID® ~~2 Mixer, excluding accessories, represented approximately 33% and 32% of the Company’s total net revenues for the years ended December 31, 2024 and 2023, respectively~~”.

On August 7, 2025, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company sold substantially all of the assets of the Genie Division of the Company’s Benchtop Laboratory Equipment Operations located in Bohemia, New York to Troemner, LLC (the “Buyer”). Such assets consisted primarily of inventory, fixed assets, and intangible assets. The purchase price was $9,600,000 minus certain working capital adjustments plus an earn-out of up to an aggregate of $1,500,000, of which $1,140,000 is guaranteed if the Seller performs certain obligations under a separate Manufacturing and Supply Agreement (“MSA”) and a separate Transition services agreements (“TSA”), under which the Company agreed to produce and supply products to the Buyer for a period of up to total of twelve months, plus transition services which include training and transfer of knowhow by the Company to the Buyer. The amounts earned by the Company under the earn-out provision of the MSA are recorded as earned based on the contractual services performed and are recorded as a reduction of its operating expenses. As of December 31, 2025 $300,000 has been earned and recorded under the MSA agreement.

Table of Contents

~~The~~Bioprocessing ~~Company’s~~Systems. ~~vortex~~SBHI, ~~mixer~~through isits ~~used~~two towholly-owned ~~mix~~subsidiaries, ~~the~~SBI ~~contents~~and ofAquila, ~~test~~is ~~tubes~~engaged in the design, ~~beakers~~development, manufacture and ~~other~~marketing ~~various~~of ~~containers~~bioprocessing byproducts, ~~placing~~principally ~~such~~products ~~containers~~incorporating onsmart asensors ~~rotating~~and ~~cup~~state orof ~~other~~the ~~attachments~~art ~~which~~software ~~cause~~analytics. Products include the ~~contents~~Cell toGrowth beQuantifier ~~mixed~~(“CGQ”) atfor ~~varying~~biomass ~~speeds.~~monitoring ~~The~~in ~~Company’s~~shake ~~additional~~flasks, ~~mixers~~the ~~and~~Liquid ~~shakers~~Injection ~~include~~System a(“LIS”) ~~high-speed~~for ~~touch~~automated ~~mixer~~feeding in shake flasks, and a ~~mixer~~line ~~with~~of ancoaster ~~integral~~systems ~~timer,~~and aflow-through ~~cell~~cells ~~disruptor,~~for apH ~~bead~~and ~~beater,~~DO ~~microplate~~monitoring ~~mixers~~and analytical software, ~~programmable~~and ~~vortex~~the ~~mixers,~~Multi-Parameter ~~two~~Sensor ~~large~~(“MPS”) ~~capacity~~and ~~multi-vessel~~Dissolved ~~vortex~~Oxygen ~~mixers~~sensor pills which are marketed and aare ~~line~~sold ofunder ~~various~~the ~~orbital~~Bioprocessing ~~shakers~~Systems DOTS brand platform.

Product Development. The Company ~~also~~designs ~~offers~~and ~~various~~develops ~~benchtop~~substantially ~~multi~~all of its products in-~~purpose~~house. ~~rotators~~Company personnel formulate plans and ~~rockers,~~concepts ~~designed~~for new products and improvements or modifications of existing products. The Company engages outside consultants to ~~rotate~~augment its internal engineering capabilities in areas such as industrial and ~~rock~~electronics design. The Company is investing significantly in the product development of its Bioprocessing Systems Operations with a ~~wide~~view ~~variety~~to generating meaningful revenues from its Bioprocessing Systems Operations in the future. To a lesser extent, the Company invested in the development of ~~containers~~its VIVID® product line of the Benchtop Laboratory Equipment Operations’ Torbal division, and as a ~~refrigerated~~result ~~incubator~~introduced ~~and~~a ~~incubated~~major ~~shakers,~~new ~~which~~product ~~are~~in ~~multi-functional~~February ~~benchtop~~2025. ~~environmental~~The ~~chambers~~Company ~~designed~~expects to ~~perform~~continue ~~various~~to ~~shaking~~invest ~~and~~in ~~stirring~~the ~~functions~~VIVID® product ~~under~~line ~~controlled~~which ~~environmental~~the ~~conditions~~Company deems to have sales growth potential.

~~The~~Major Customers. Sales to one customer, principally of the VIVID® Pill counter, represented 31% and 23% of the Company’s ~~line~~consolidated ofnet ~~magnetic~~revenues ~~stirrers~~for ~~includes~~the ayears ~~high/low~~ended ~~programmable~~December ~~magnetic~~31, ~~stirrer~~2025 and 2024, arespectively. ~~four-place~~This ~~high/low~~top ~~programmable~~customer ~~magnetic~~also ~~stirrer,~~represented a42% ~~large~~and ~~volume~~36% ~~magnetic~~of ~~stirrer~~Benchtop Laboratory Equipment product sales, ~~and~~for athe ~~four-place~~years ~~general~~ended ~~purpose~~December ~~stirrer~~31, 2025 and 2024, respectively.

~~The~~Major ~~Company’s~~Vendors. ~~Torbal®~~Purchases ~~division~~from ~~line~~one ofvendor, ~~products~~represented ~~includes~~in ~~pharmacy,~~the ~~laboratory,~~aggregate ~~industrial~~15.2% ~~digital~~and ~~scales,~~15.0% ~~moisture~~of ~~analyzers,~~consolidated ~~mechanical~~net ~~and~~purchases ~~automated~~for ~~pill~~the ~~counters,~~years ~~force~~ended ~~gauges~~December 31, 2025 and ~~test~~2024, ~~stands~~respectively.

Bioprocessing Systems. SBHI, through its two wholly-owned subsidiaries, SBI and Aquila, is engaged in the design, development, manufacture and marketing of bioprocessing products, principally products incorporating smart sensors and state of the art software analytics. Products include the Cell Growth Quantifier (“CGQ”) for biomass monitoring in shake flasks, the Liquid Injection System (“LIS”) for automated feeding in shake flasks, and a line of coaster systems and flow-through cells for pH and DO monitoring and analytical software, and the Multi-Parameter Sensor (“MPS”) and Dissolved Oxygen sensor pills which are marketed and will be sold under the Bioprocessing Systems DOTS brand platform.

Product Development. The Company designs and develops substantially all of its products. Company personnel formulate plans and concepts for new products and improvements or modifications of existing products. The Company engages outside consultants to augment its internal engineering capabilities in areas such as industrial and electronics design. The Company is investing significantly in the product development of its Bioprocessing Systems Operations with the launch of one major product line during the fiscal year ended December 31, 2024 (“Fiscal 2024)” and several new product launches planned for the fiscal year ending December 31, 2025 and thereafter with a view to generating meaningful revenues from its Bioprocessing Systems Operations in the future. To a lesser extent, the Company also invested in product development of its VIVID product line of the Benchtop Laboratory Equipment Operations’ Torbal division, and as a result introduced a major new product in February 2025 and expects to continue to invest in this product line which the Company deems to have sales growth potential.

Major Customers. Sales to the three top customers, principally of the Vortex-Genie 2 Mixer, represented 15% and 16% of consolidated net revenues for the years ended December 31, 2024 and 2023, respectively. The three top customers also represented 18% and 18% of Benchtop Laboratory Equipment product sales, for the year ended December 31, 2024 and 2023, respectively.

Marketing.

Benchtop Laboratory Equipment. The Company’s Benchtop Laboratory Equipment products sold under the “Genie” brand are generally distributed and marketed through an established network of domestic and overseas laboratory equipment distributors who sell the Company’s products through websites, printed catalogs and sales force. In general, due to the reliance on sales through distribution, it takes two to three years for a new Genie brand Benchtop Laboratory Equipment product to begin generating meaningful sales.

The Company’s “Torbal®” brand weighing products are primarily marketed and sold online, and primarily on a direct basis, and distributors. The Company’s VIVID® brand, automated pill counters are sold through two exclusive distributors in North America. The Company markets its products through online and trade publication advertising, brochures and catalogs, the Company’s websites, ~~one sales professional in the North America, Central America,~~ and ~~South America, a consultant in Europe and Middle East and, when practicable,~~ attendance at industry trade shows through its authorized distributors.

Table of Contents

Bioprocessing Systems. The Company’s Bioprocessing Systems products are marketed through a direct sales force consisting of ~~eight~~four sales professionals and four application scientists in the US and Germany, plus a network of 11 distributors that are managed by a distribution manager. Sales are supported via marketing through websites, content creation, application notes, mailings, trade shows, online marketing campaigns, and membership in various public/private research partnerships. The Company invests heavily in the sales and marketing of its Bioprocessing Systems Operations in an effort to attract new customers and sales opportunities for products recently launched and market research for future products.

Assembly and Production. The Company has facilities in Bohemia, New York and Pearl River, New York where it conducts the Benchtop Laboratory Equipment operations. The Company also has a shared-office facility in Pittsburgh, Pennsylvania and its primary operating facility in Baesweiller, Germany, where it conducts the Bioprocessing Systems operations. The Company’s production operations principally involve assembly of components supplied by various domestic and international independent suppliers.

Patents, Trademarks and Licenses.

The Company holds ~~several patents relating to its benchtop laboratory products which include~~ a ~~United States~~ patent ~~that relates to a mixing method which expires in June 2036, and a patent~~ relating to Torbal’s VIVID® automated pill counter which expires in March 2039.

The Company’s Bioprocessing Systems operations’ Aquila subsidiary holds three US patents relating to bioprocessing which expire in May 2036, February 2038 and March 2038, respectively. In addition, Aquila holds several European and German patents and Patent Cooperation Treaty (the “PCT”) patents, and has several other patent applications pending in the United States, Europe, and under the PCT.

The Company does not anticipate any material adverse effect on sales of its patented products following the expiration on any of its patents resulting in the loss of patent protection.

The Company has various proprietary trademarks, including aquila biolabs (in Germany), Bead Genie®, Disruptor Beads™, Disruptor Genie®, DOTS™, Enviro-Genie®, Genie™, Genie Temp-Shaker™, Incubator Genie™, MagStir Genie™, MegaMag Genie®, MicroPlate Genie®, MultiMagStir Genie™, Multi-MicroPlate Genie®, Orbital Genie®, QuadMag Genie®, Rotator Genie®, Roto-Shake Genie®, Torbal®, ~~TurboMix™,~~and VIVID®, ~~and Vortex-Genie®,~~ each of which it considers important to the success of the related product. No representation can be made that any application will be granted or as to the protection that any existing or future trademark registration may provide.

Foreign Sales. The Company’s sales to overseas customers, principally in Asia and Europe, accounted for approximately 3917% and 3423% of the Company’s net revenue for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. Payments were primarily in United States dollars and were therefore not subject to risks of currency fluctuation.

Seasonality. The Company does not consider its business to be materially seasonal.

Backlog. The Company ~~had~~does not have a ~~total~~material backlog inof ~~benchtop equipment~~ orders ofdue ~~approximately~~to ~~$368,300~~the ~~and~~fact ~~$563,800~~that asmost ofproducts ~~December~~are ~~31,~~produced ~~2024~~ and ~~2023,~~shipped ~~respectively.~~within ~~There~~one ~~was~~to notwo ~~significant backlog for the Bioprocessing Systems operations~~weeks.

Competition. Most of the Company’s principal competitors are substantially larger and have greater financial, production and marketing resources than the Company. Competition is generally based upon technical specifications, price, and product recognition and acceptance. The Company’s main competition for its Benchtop Laboratory Equipment products derives from private label brand mixers offered by laboratory equipment distributors in the United States and Europe and products exported from China.

Table of Contents

The Company’s major competitors for its Genie brand Benchtop Laboratory Equipment are Henry Troemner, Inc. (a private label supplier to the two largest laboratory equipment distributors in the U.S. and Europe), IKA-Werke GmbH & Co. KG, a German company, Benchmark Scientific, Inc. (a United States importer of China-produced products), and Heidolph Instruments GmbH, a German company and various other smaller importers (primarily from China). The Company’s main competitors for its Torbal® brand products are Ohaus Corporation, an American company, A&D Company Ltd., a Japanese company, Adam Equipment Co., Ltd., a British company, ~~Avery~~Illinois ~~Weigh-Tronix~~Tool Works, an American company, and Capsa Healthcare, an American company, and Medility Inc., a Korean company, for its VIVID® brand automated pill counters.

Direct competitors for the Company’s Bioprocessing Systems products are ABER Instruments (United Kingdom) and PreSens GmbH (Germany),. ~~indirect~~Indirect (systemic alternatives) competitors include Hamilton Bonaduz AG (Switzerland) and optek-Danulat GmbH (Germany) as well as total solution providers like Sartorius AG (Germany) or Eppendorf SE (Germany). ~~The former direct competitor PyroScience GmbH (Germany) has entered a long-term partnership agreement with aquila.~~

Research and Development. The Company incurred research and development expenses, the majority of which related to its Bioprocessing Systems operations, of $2,~~906~~487,~~100~~700 and $32,~~566~~897,~~200~~900 for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. The Company expects that research and development expenditures in the fiscal year ending December 31, ~~2025~~2026 will continue to be material reflecting continued product development efforts for the Bioprocessing Systems operations.

Government and Environmental Regulation. The Company’s products and claims with respect thereto have not required approval of the Food and Drug Administration or any other governmental authority. The Company’s manufacturing operations, like those of the industry in general, are subject to numerous existing and proposed, if adopted, federal, state, and local regulations to protect the environment, and to establish occupational safety and health standards ~~and~~as ~~cover~~well as certain other matters. The Company believes that its operations are in compliance with existing laws and regulations and the cost to comply is not significant to the Company.

Employees. As of March 2731, ~~2025~~2026, the Company employed 6755 persons (3221 for the Benchtop Laboratory Equipment operations, and 3534 for the Bioprocessing Systems operations, of whom 2730 were located in ~~Germany~~Europe) of whom 6154 were full-time, including its executive officers. The Company augments its internal staff with outside consultants as deemed necessary. None of the Company’s employees are represented by any union.

Available Information. The Company’s reports, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other information filed with, or furnished to, the Securities and Exchange Commission (the “SEC” or the “Commission”), including amendments to such reports, are available on the SEC’s website that contains such reports, proxy and information statements, and other information regarding companies that file electronically with the Commission. This information is available at www.sec.gov. In addition, all the Company’s public filings can be accessed through the Company’s website ~~at https~~athttps://www.scientificindustries.com/pages/sec-filings .

Item 1A. Risk Factors.

In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, important risk factors are identified below that could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to such future periods in any current statements. The Company undertakes no obligation to publicly revise any forward-looking announcements to reflect future events or circumstances.

Risks Relating to Our Financial Position and Capital Requirements

We have limited financial resources and we may need to raise additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.

In order to be successful with our product development and commercialization programs, principally as it pertains to our bioprocessing sector, we believe that we will need to continue to invest substantial capital into such programs in the foreseeable future. We expect our total operating expenses to continue to be material in connection with our ongoing activities, particularly as we continue with our emphasis on the bioprocessing sector. We expect to continue to incur ~~significant commercialization expenses related to product sales, marketing, after-sales support, manufacturing, and distribution. We also expect to continue to incur~~ substantial expenses related to the development of new products and technologies, primarily related to bioprocessing products. Our ability to conduct additional research and development activities and commercialization efforts are dependent upon the availability of funding and cash generated from sales of newly -introduced products.

Table of Contents

In such an event, we may be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements, product line divestitures, or other sources. We do not have any committed external source of funds~~, other than a working line of credit of $300,000 with the Company’s primary bank~~. If additional funding is necessary, adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts and on terms acceptable to us, - we may have to significantly delay, scale back or discontinue the development or commercialization of bioprocessing or any of our other products. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategy.

Our future funding requirements, both short-term and long-term, will depend on many factors, including: the scope, progress, timing, costs and results of our current and future product candidates; our ability to enter into, and the terms and timing of, any collaborations, licensing or other arrangements; the number of future product candidates that we pursue and their development requirements; the costs and timing of establishing product sales, marketing, distribution and commercial-scale manufacturing capabilities; the effect of competing technological and market developments; our headcount growth and associated costs as we expand our research and development; and the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights including enforcing and defending intellectual property related claims.

Raising additional capital may cause dilution to our then-existing ~~stockholders~~shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

To the extent that we raise additional capital through the sale of common shares, convertible securities or other equity securities, the ownership interests of the then-existing equity holders may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of the then-existing common ~~stockholders~~shareholders. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management’s ability to oversee the development of our product candidates.

If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, or product line divestitures, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

We have a history of Operating losses and will likely incur future losses during the next few years as we attempt to grow and develop our bioprocessing sector.

We incurred net losses of $61,~~445~~220,400 and $96,~~086~~445,~~500~~400 for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. As of December 31, ~~2024~~2025, we had an accumulated deficit of $3335,~~930~~150,~~500~~900. We expect to continue to incur operating losses for the foreseeable future as our expenses related to the growth and expansion of our Bioprocessing Systems operations will exceed revenues expected to be generated. ~~Our~~The ~~Benchtop~~Company ~~Laboratory~~sold ~~Equipment~~its ~~operations~~profitable ~~are~~Genie ~~profitable,~~Division ~~but~~of ~~our~~the ~~ability~~Benchtop toLaboratory ~~become~~Equipment Operations in August 2025, and ~~remain~~the ~~profitable~~remaining onTorbal adivision ~~combined~~is ~~basis~~not ~~depends~~yet onprofitable. ~~our~~The ~~ability~~Company toalso ~~generate~~incurs ~~additional~~substantial ~~revenue,~~corporate ~~and~~costs ~~therefore~~including ~~profits~~accounting, ~~from~~auditing, ~~our~~legal, ~~Bioprocessing~~shareholder, ~~Systems~~regulatory, ~~operations~~etc. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of future revenues, and if or when we might achieve profitability. We may never succeed in these activities and, even if we do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

Table of Contents

If we fail to maintain proper and effective internal controls over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our Common Stock.

Pursuant to Section 404 of the Sarbanes Oxley Act of 2002 and related rules, our management is required to report on the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to further upgrade our systems, including information technology, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff, and specialists. If material weaknesses or deficiencies in our internal controls exist and go undetected, our financial statements could contain material misstatements that, when discovered in the future could cause us to fail to meet our future reporting obligations and cause the price of our Common Stock to decline.

Limited public market for our common stock and active trading market may never develop or be sustained.

As of March 27, ~~2025~~2026, there were 1011,~~503~~928,599 shares of Common Stock of the Company outstanding, of which 3235% are held by the ~~top~~ three ~~stockholders~~largest shareholders of the Company. The Common Stock of the Company is traded on the Over-the-Counter Bulletin Board and, historically, has been thinly traded. There have been a number of trading days during Fiscal ~~2024~~2025 and ~~2023~~2024 on which no trades of the Company’s Common Stock were reported. Accordingly, the market price for the Common Stock is subject to great volatility. The lack of an active trading market may impair the value of the shares of our common stock and ~~stockholders~~shareholders’ ability to sell their shares. An inactive trading market may also impair the Company’s ability to raise capital by selling shares of common stock and to enter into strategic partnerships or other business strategies.

Risks Relating to Our Business

The commercial success of our bioprocessing products will largely depend upon attaining significant market acceptance.

Our ability to execute our growth strategy and achieve commercial success in our bioprocessing sector will depend upon the adoption by customers of our products and bioprocessing solutions. We cannot predict how quickly, if at all, our products will be accepted or, if accepted, how frequently they will be used. Our bioprocessing products may never gain broad market acceptance. The market for bioprocessing products is relatively new, subject to rapid innovation and remains uncertain. The degree of market acceptance of any of our products will depend on a number of factors, including the prevalence and severity of any complications associated with our products, the competitive pricing of our products; and the quality of our products meeting customer expectations.

Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations. Further, if we cannot build and maintain strong working relationships with these professionals and seek their advice and input on our product candidates, the development and marketing of our future products could suffer, which could have a material adverse effect on our business, financial condition and results of operations.

If we are unable to obtain and maintain patent and other intellectual property protection for any of our new bioprocessing products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product we may develop may be adversely affected.

The commercial success of our bioprocessing segment will also depend on our ability to obtain and maintain patent, trademark, trade secret and other intellectual property protection of our new bioprocessing products and other technology, methods used to manufacture them and methods of treatment, as well as successfully defending our patent and other intellectual property rights against third-party challenges. It is difficult and costly to protect and enforce intellectual property rights, and we may not be able to ensure the same for every product. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our new organ candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

Table of Contents

We seek to protect our proprietary position by developing a comprehensive intellectual property portfolio including filing patent applications and obtaining granted patents in the United States and abroad related to our bioprocessing products that are important to our business. If we are unable to obtain or maintain patent protection with respect to a product we may develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours and our ability to commercialize that product candidate may be adversely affected.

The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.

If we lose the services of key management personnel, we may not be able to execute our business strategy effectively.

Our future success depends in a large part upon the continued service of key members of our senior management team. The loss of services from any of Ms. Helena Santos, the Company’s President and Chief Executive Officer, ~~Mr. Reginald Averilla, the Company’s Chief Financial Officer,~~ Secretary and Treasurer, Mr. ~~Robert~~Zachary ~~Nichols~~Rovinsky, the ~~President of the~~ Company’s ~~Genie~~Chief ~~Products~~Financial ~~Division~~Officer, ofAssistant ~~the~~Secretary ~~Benchtop~~and ~~Laboratory~~Assistant ~~Equipment Operations~~Treasurer, Mr. Karl Nowosielski, the President of the Torbal Products Division of the Benchtop Laboratory Operations, Mr. Daniel Donadille, the Chief Executive Officer and President of the Bioprocessing Systems Operations, or Mr. John A. Moore, the Company’s Chairman, or any material expansion of the Company’s operations could place a significant additional strain on the Company’s limited management resources and could be materially adverse to the Company’s operating results and financial condition.

Table of Contents

If we lose one or more of our key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully.

We rely on highly skilled personnel and, if unable to retain, fully utilize or hire additional qualified personnel, we may not be able to grow effectively.

Our performance is largely dependent on the talents and efforts of highly skilled individuals. The Company’s future success depends on the continued ability to identify, hire, develop, motivate and retain highly skilled personnel for all areas of the organization. Competition in the industry for qualified employees is intense, and it is likely that certain competitors will directly target some of our employees. The continued ability to compete effectively depends on the ability to retain and motivate existing employees.

Management may also need to hire additional qualified personnel with expertise in the bioprocessing sector, including with respect to research and testing, formulation and manufacturing and sales and marketing. We compete for qualified individuals with numerous biopharmaceutical companies and other emerging entrepreneurial companies, as well as universities and research institutions. Competition for such individuals is intense, and we may not be able to successfully recruit or retain such personnel. Attracting and retaining qualified personnel will be critical to our success.

Our Company’s future depends heavily on international operations.

The Company’s Bioprocessing Systems Operations is substantially operated out of Germany with the management and the majority of research, manufacturing, marketing, accounting, and administration functions located in its Baesweiler, Germany facility. As a result, the Company’s Bioprocessing Systems Operations is physically located in a different geographical location which could pose inherent risks in systems of internal controls, and is subject to various laws and regulations that differ from those of the parent company in the U.S.

We may not successfully manage any experienced growth.

Our success will depend upon the expansion of our operations and the effective management of any such growth will place a significant strain on management and on administrative, operational and financial resources. To manage any such growth, management must expand the facilities, augment operational, financial and management systems, and hire and train additional qualified personnel. If management is unable to manage our growth effectively, our business would be harmed.

Our growth strategy is based on certain assumptions as to the bioprocessing market.

We ~~believe~~have ~~that~~made ~~the~~certain ~~worldwide~~assumptions ~~bioprocess~~on ~~development~~the ~~technologies~~market ~~total~~size ~~available~~and market isacceptance ~~approximately~~of ~~$26 billion1,2, with a serviceable addressable share for~~ our bioprocessing products ~~of $2.1 billion1,2. Our estimates of the TAM and SAM for our products under development are~~ based on amarket ~~number~~studies ~~of internal~~ and ~~third-party~~general ~~estimates,~~knowledge asof ~~well~~the asbioprocessing ~~assumed prices at which we can sell our future products~~market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our assumptions and estimates of the ~~annual~~bioprocessing ~~total addressable~~ market for our product candidates may prove to be incorrect. If the price at which we can sell future products, oris less than the ~~annual~~price ~~total~~we are projecting, or the addressable market for our product candidates is smaller than we have estimated, it could have an adverse impact on our business.

__________________

(1)	Jessica Merrill, “The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall”, Pharma Intelligence UK Limited, a Citeline company, April 2022.
(2)	Estimated on the basis of: Hillary Dukart, Laurie Lanoue, Mariel Rezende, Paul Rutten, “Emerging from disruption: The future of pharma operations strategy”, McKinsey & Company, October 2022.

Table of Contents

Dependence on major customers.

~~Although~~Sales to the ~~Company~~top ~~does~~Benchtop ~~not~~Laboratory ~~depend~~Equipment onoperations ~~any~~customer ~~one~~accounted ~~single~~for ~~major~~approximately ~~customer,~~42% ~~sales~~and to36% of the ~~top~~segment’s ~~three~~total ~~Benchtop~~sales ~~Laboratory~~for ~~Equipment~~the ~~operations~~years ~~customers~~ended ~~accounted~~December ~~for~~31, a2025 ~~combined~~and ~~aggregate~~2024, ofrespectively 23and 31% and 1823% of ~~the~~consolidated ~~segment’s~~net ~~total~~revenues ~~sales~~ for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

No representation can be made that the Company will be successful in retaining ~~any~~this ~~of these customers~~customer, or not suffer a material reduction in sales, either of which could have an adverse effect on future operating results of the Company.

One benchtop laboratory equipment product accounts for a substantial portion of revenues.

The Company has a limited number of Benchtop Laboratory Equipment products with one product, the Vortex-Genie 2 Mixer, accounting for approximately 38% and 36% of Benchtop Laboratory Equipment sales, for the year ended December 31, 2024 and 2023, respectively.

The Company is a small participant in each of the industries in which it operates.

The ~~Benchtop~~Torbal ~~Laboratory~~line ~~Equipment~~of ~~industry~~products is a ~~highly~~small ~~competitive~~market ~~mature~~participant ~~industry.~~in ~~Although~~its ~~the~~industry ~~Vortex-Genie~~with 2significant ~~Mixer~~competition isfrom ~~widely~~well-known accepted, the annual sales of the Benchtop Laboratory Equipment products ($9,022,800 and $9,745,400 for the year ended December 31, 2024 and 2023, respectively) are significantly lower than the annual sales of many of its competitors in the industrybrands. The principal competitors are substantially larger with much greater financial, ~~production~~ and marketing resources ~~than the Company~~. There are constant new entrants into the vortex mixer market, including those offering products imported from China, which the Company is unable to compete with on price. The Torbal line of products is also a small market participant in its industry with significant competition from well-known brands.

The Company’s Bioprocessing Systems operations is a participant in the laboratory-scale sector of the larger bioprocessing products industry, which is dominated by several companies that are significantly larger, and the Company’s bioprocessing operations are still in the start-up phase of operations.

The Company’s ability to grow and compete effectively depends in part on its ability to develop and effectively market new products.

The Company’s ~~continuously invests in the development and marketing of new~~ Benchtop Laboratory Equipment ~~products,~~Operations ~~including~~introduced ~~the~~its ~~Torbal~~first ~~line~~VIVID® ofpill ~~products,~~counter ~~with~~in a2020 ~~view to increase revenues~~ and ~~reduce~~has ~~the~~continuously ~~Company’s~~invested ~~dependence~~in ondevelopment sales of the Vortex-Genie 2 Mixer. However, gross revenues derived from non- Vortex-Genie Benchtop Laboratory Equipment products including Torbal products amounted to $5,538,000 (61% of the segment sales and ~~51%~~marketing of ~~total~~this ~~revenues)~~automated ~~for~~pill ~~the~~counter ~~year ended December 31~~line, ~~2024,~~with ~~and~~one ~~$6,190,800~~significant ~~(64%~~product ofintroduced ~~the~~during ~~segment~~fiscal ~~sales~~2025 and ~~56%~~additional oflaunches ~~total~~planned ~~revenues)~~ for the ~~year~~near ~~ended December 31, 2023~~future. ~~The segment’s ability to compete will depend upon the Company’s success in continuing to develop and market new laboratory equipment and scales as to which no assurance can be given.~~

The success of the Company’s ~~relies~~Bioprocessing Systems operations will depend heavily on ~~distributors~~its ~~and~~ability ~~their~~to ~~catalogs~~successfully todevelop, produce, and market new products. Commencing in the ~~majority~~last quarter of ~~its~~fiscal ~~Benchtop~~year ~~Laboratory~~ended ~~Equipment~~June ~~Genie~~30, ~~products. Accordingly~~2019, ~~sales~~the ofCompany ~~new~~began ~~products~~to ~~are~~commit ~~heavily~~substantial ~~dependent~~resources onto its Bioprocessing Systems operations in the ~~distributors’~~form ~~decisions~~of ~~whether~~employees, materials, supplies, marketing, and facilities to ~~include~~accelerate its product development efforts and ~~retain~~marketing activities. Bioprocessing products are of a ~~new~~complex ~~product~~nature in ~~their~~an ~~catalogs~~industry ~~and~~that onthe ~~their~~Company ~~websites.~~had Itnot ~~may~~traditionally beoperated atin ~~least~~and 24have taken much longer to 36develop ~~months~~than ~~between~~previously ~~the~~anticipated. ~~completion~~In ofaddition, ~~development~~bioprocessing ofproducts awill ~~product~~be subject to beta testing and ~~the~~adoption ~~distribution~~by ofend ~~the~~users, ~~catalog~~which could result in design and/or production changes which itcould isfurther ~~first~~extend ~~offered;~~development ~~furthermore,~~time. ~~not~~On ~~all~~April ~~distributors~~29, ~~feature~~2021, the Company’s ~~products~~acquired Aquila in ~~their~~an ~~catalogs~~effort to accelerate development of its bioprocessing products. The Company continues to incur substantial product development and sales and marketing costs related to its Bioprocessing Systems operations.

The success of the Company’s Bioprocessing Systems operations will depend heavily on its ability to successfully develop, produce, and market new products. Commencing in the last quarter of fiscal year ended June 30, 2019, the Company began to commit substantial resources to its Bioprocessing Systems operations in the form of employees, materials, supplies, marketing, and facilities to accelerate its product development efforts and marketing activities. Bioprocessing products are of a complex nature in an industry that the Company has not traditionally operated in and have taken much longer to develop than previously anticipated. In addition, they will be subject to beta testing and adoption by end users, which could result in design and/or production changes which could further delay development time. On April 29, 2021, the Company acquired Aquila in an effort to accelerate development of its bioprocessing products. The Company continues to incur substantial product development and sales and marketing costs related to its Bioprocessing Systems operations.

Table of Contents

No assurance can be given that the Company will be successful with its new product development or that its sales and marketing programs will be sufficient to develop additional commercially feasible products which will be accepted by the marketplace, or that any distributor will include or retain any new Company products in its catalogs and websites.

Exchange rates — The Company is exposed to foreign exchange rate risk.

Substantially all of the Company’s sales are in US dollars. As a result of the acquisition of Aquila in April 2021, the Company is subject to foreign exchange rate risk, both transactional and translational, which may negatively affect our financial performance. Transactional foreign exchange exposures result from exchange rate fluctuations, including in respect of the U.S. dollar and the Euro. Translational foreign exchange exposures result from exchange rate fluctuations in the conversion of the entity’s functional currency to U.S. dollars, consistent with the Company’s reporting currency, and may affect the reported value of the Company’s assets and liabilities and its income and expenses. In particular, the Company’s translational exposure may be impacted by movements in the exchange rate between the Euro against the U.S. dollar.

The Company may be subject to general economic, political and social factors.

Orders for the Company’s products depend in part, on the customer’s ability to secure funds to finance purchases, especially government funding for research activities. Availability of funds can be affected by budgetary constraints. Factors including a general economic recession, a European crisis, slowdown in Asian economies, or a major terrorist attack may have a negative impact on the availability of funding including government or academic grants to potential customers. ~~Please also see the separate COVID-19 pandemic related discussion in this “Risk Factors” section below.~~

~~Sales~~Tariffs toimposed ~~overseas~~by ~~customers, including sales in China, accounted for approximately 39% and 34% of~~ the ~~Company’s net revenues for the year ended December 31, 2024 and 2023, respectively. The high value of the~~ U.S. also ~~dollar~~has ~~relative to foreign currencies can have~~ a negative impact on ~~sales because~~ the ~~Company’s~~total ~~products,~~cost ~~which~~of ~~are~~our ~~paid~~products inand ~~U.S.~~our ~~dollars,~~gross ~~become more expensive to overseas customers. In addition~~margins, ~~tariffs~~as ~~imposed by importing countries outside~~ the ~~U.S.~~ Company may ~~also~~not ~~have~~be aable ~~negative~~to ~~impact~~fully pass on the ~~total~~added ~~cost of our products overseas~~costs.

Higher material and transportation costs and tariffs over the last few years has resulted in significantly higher costs for some of the Company’s components. Such increased costs could have a negative effect on the Company’s future gross margins, if the Company is unable to pass such cost increases to its customers.

The Company is heavily dependent on outside suppliers for the components of its products.

The Company purchases most of its components from outside suppliers and relies on a few ~~sole~~single-source suppliers for some components, mostly due to cost considerations. Most of the Company’s suppliers, including its U.S. vendors, produce the components directly or indirectly in overseas factories, and orders are subject to long lead times and potential other risks related to production in a foreign country, such as current and potential future tariffs, and electronic parts shortages. To minimize the risk of supply shortages, the Company keeps more than normal quantities on hand of the critical components that cannot easily be procured or, where feasible and cost effective, purchases are made from more than one supplier. However, alternate suppliers are not always feasible for various reasons including complexity and cost of toolings. A shortage of components or vendor inability to deliver due to shipping and cargo issues could halt production and have a material negative effect on the Company’s operations.

The Company’s ability to compete depends in part on its ability to secure and maintain proprietary rights to its products.

The Company has no patent protection for its ~~principal~~ Benchtop Laboratory Equipment ~~product~~products, ~~the Vortex-Genie 2 Mixer, or the Torbal products~~ other than the VIVID® pill counter. There are several competitive products available in the marketplace possessing similar technical specifications and design.

Table of Contents

As discussed above in detail, the Company’s Bioprocessing Operations through its Aquila division holds several patents in Europe and the USUnited States related to its products and underlying technology and has several patent applications pending in Europe and the United States of America, and sublicenses from third parties on a regular basis additional technology needed for its product development.

There can be no assurance that any patent issued or licensed to the Company provides or will provide the Company with competitive advantages or will not be challenged by third parties. Furthermore, there can be no assurance that others will not independently develop similar products or design around the Company’s patents. Any of the foregoing activities could have a material adverse effect on the Company. Moreover, enforcement by the Company of its patent or license rights may require substantial litigation costs.

We currently anticipate that we will retain future earnings, if any, for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Any return to stockholders will therefore be limited to the appreciation in the value of their stock, if any.

Item 1B. Unresolved Staff Comment.

Not required for smaller reporting companies.

Item 1C. Cybersecurity.

Risk Management and Strategy

In accordance with the Securities Exchange Commission ("SEC") rules, the Company is required to assess, identify, and manage material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include, among other things, operational disruption, intellectual property theft, fraud, extortion, harm to employees or customers, violation of privacy or security laws and other litigation and legal risks, and reputational risks.

We have developed, implemented, and maintain certain cybersecurity processes and controls intended to safeguard our information systems and protect the confidentiality, integrity, and availability of our data, based on material risks identified.

We have strategically integrated cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management and as part of our decision-making processes. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, hardware and software, and our critical data, including but not limited to regular network and endpoint monitoring, vulnerability assessments, various system backups of all information, and through policy and procedure inform and train employees on the Company’s underlying practices, and annual assessment and testing of such controls. Our information security function is responsible for identifying, assessing and managing cybersecurity threats and risks and works to monitor and evaluate our threat environment and risk profile.

As of and for the year ended December 31, ~~2024~~2025, we did not identify any cybersecurity threats or incidents that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. However, we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents.

Table of Contents

Governance

Our Board of Directors addresses cybersecurity risk management as part of its general oversight function and delegates cybersecurity risk management oversight to our Audit Committee. Our management team is responsible for assessing and managing our material risks from cybersecurity threats and provides updates to the Audit Committee on major developments regarding cybersecurity matters. The Audit Committee has oversight responsibility for risks and incidents relating to cybersecurity threats, including compliance with disclosure requirements, cooperation with law enforcement, and related effects on financial and other risks, and reports any findings and recommendations, as appropriate, to the Board of Directors for consideration.

Item 2. Properties.

The Company’s ~~executive~~leases ~~office~~certain ~~and~~properties ~~principal~~consisting ~~manufacturing~~principally ~~facility~~of ~~for~~a ~~its~~facility ~~Benchtop~~in ~~Laboratory~~Bohemia, ~~Equipment~~New ~~operations~~York ~~comprises~~(headquarters) ~~approximately~~which awas ~~total~~amended ofin ~~24,000~~September ~~square~~2021 ~~feet.~~to ~~This~~increase ~~facility~~the isspace ~~located~~by inapproximately ~~Bohemia,~~25% ~~New York~~ and isextend ~~held~~the ~~under a~~ lease ~~with a~~ term through October 2028. The Company leased a 1,200 square foot facility in Orangeburg, New York where it conducted its sales and marketing functions, primarily for the Torbal® Products Division of the Benchtop Laboratory Equipment operations, which expired at the end of October 2024 and was not renewed and continued as a monthly lease through the end of December 31, 2024. On January 1, 2025, the Company ~~began~~entered into a lease for a 220 square foot facility in Pearl River, New York where it conducts its sales and marketing functions, primarily for the Torbal® Products Division of the Benchtop Laboratory Equipment operations, expiring in December 2027. The Company’s Bioprocessing Systems ~~Operations~~operations ~~leases~~are aconducted in co-sharing office space in Pittsburgh, Pennsylvania, which expired in March 2025 and is currently on a month-to-month basis, and a 5,252 square foot facility in Baesweiller, Germany, ~~through~~the lease which was renewed in December 2025 to extend the lease term to December 31, ~~2025~~2027, comprised of manufacturing, engineering, and administrative space.

Item 3. Legal Proceedings.

The Company is not a party to any pending legal proceedings.

Item 4. Mine Safety Disclosures.

Not applicable.

Table of Contents

PART II

Common Stock

The Company’s Common Stock is traded on the Over-The-Counter (“OTC”) Market, under the trading symbol “SCND”. The following table sets forth the low and high bid quotations at the end of each quarter for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively, as reported by the National Association of Securities Dealers, Inc. Electronic Bulletin Board. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions:

For Fiscal Quarter Ended	Low Bid($)		High Bid($)
03/31/23		4.93		5.50
06/30/23		4.24		5.00
09/30/23		3.75		4.75
12/31/23		2.06		3.70
03/31/24		1.40		2.35
06/30/24		0.77		1.90
09/30/24		1.07		2.02
12/31/24		0.62		1.25
03/31/25		0.92		1.12
06/30/25		0.53		0.92
09/30/25		0.35		0.87
12/31/25		0.42		0.77

Table of Contents

As of March 27, ~~2025~~2026, there were ~~269~~262 record holders of the Company’s Common Stock.

Recent sales of unregistered securities; use of proceeds from registered securities

~~Refer to Current Reports on Form 8-K filed with the SEC on January 22, 2024 as incorporated by reference for recent sales of unregistered securities.~~None

~~Purchases~~On April 18, 2025, the Company entered into a Securities Purchase Agreement (the “April 2025 Purchase Agreement”) with certain investors (each an “April Investor”) pursuant to which the Company sold in a private placement, and the April Investors purchased, an aggregate of ~~equity~~1,550,000 ~~securities~~units, bywhich comprised of (i) 1,050,000 shares of the ~~issuer~~Company’s Common Stock, (ii) pre-funded warrants to purchase 500,000 shares of Common Stock, and ~~affiliated~~(iii) ~~purchasers~~warrants to purchase 1,550,000 shares of Common Stock, for a total consideration of $1,550,000. The Company recognized $97,800 of issuance costs, which was attributable to legal and placement agent fees.

~~None.~~Purchases of equity securities by the issuer and affiliated purchasers

~~Item 6~~None. ~~[Reserve]~~

Item 6. [Reserved]

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements.

The following discussion and analysis should be read in conjunction with our consolidated financial statements for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, and the related notes thereto, which have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Certain statements contained in this report are not based on historical facts but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward- looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Overview.

Scientific Industries, Inc., a Delaware corporation (“SI” and along with its subsidiaries, the “Company”, “we”, “our”), is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment (“Benchtop Laboratory Equipment”), and through its wholly-owned subsidiary, Scientific Bioprocessing Holdings, Inc., a Delaware corporation (“SBHI”), the design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”). SBHI has two wholly-owned subsidiaries – Scientific Bioprocessing, Inc., a Delaware corporation (“SBI”), and aquila biolabs GmbH, a German corporation (“Aquila”). The Company’s products are used primarily for research purposes by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research.

On November 4, 2022, the Board of Directors approved the change of the Company’s fiscal year end from June 30 to December 31 of each year. In connection with this change, we previously filed a Transition Report on Form 10-KT to report the results of the six-month transition period from July, 1, 2022 to December 31, 2022.

Results of Operations.

The Company’s results ~~are~~reflect ~~from~~the results of the Benchtop Laboratory Equipment operations and the Bioprocessing Systems operations. ~~The~~As ~~Company realized a loss from continuing operations~~ of $6August 7,~~445,400~~ ~~for~~2025 the ~~year~~Genie ~~ended~~Division ~~December~~of ~~31, 2024 compared to $9,089,800 for~~ the ~~year~~Benchtop ~~ended~~Laboratory ~~December~~Equipment ~~31,~~Operations ~~2023.~~became ~~The~~discontinued ~~decrease~~due into the ~~loss~~sale ~~from~~of ~~continuing operations for~~ the ~~year~~GENIE ~~ended~~product ~~December~~line ~~31, 2024 compared~~ to ~~year~~Troemner ~~ended December 31~~LLC, ~~2023~~however isthe ~~primarily~~Company ~~due~~continued to ~~decreased~~produce ~~expenses~~and ~~resulting~~market ~~from~~its ~~operating~~Torbal® ~~cost~~weighing ~~reductions~~and ~~mostly~~measurement ~~in the Bioprocessing Systems Operations segment compared to the prior year period~~products.

The Company realized a loss from continuing operations of $1,780,300 for the year ended December 31, 2025 compared to loss from operations of $8,023,600 for the year ended December 31, 2024. The decrease in the loss from continuing operations for the year ended December 31, 2025 compared to year ended December 31, 2024 is primarily due to the sale of the Genie® product line which resulted in a gain of $5,263,400, and reduced expenses.

Table of Contents

Year Ended December 31, ~~2024~~2025 compared to Year Ended December 31, ~~2023~~2024

Net revenues for the year ended December 31, ~~2024~~2025 ~~decreased~~increased $~~398~~256,~~900~~700 (35.64%) to $105,~~712~~053,~~600~~800 from $114,~~111~~797,~~500~~100 for year ended December 31, ~~2023~~2024, reflecting an increase of approximately $~~323~~645,~~700~~100 in net revenues from the ~~Bioprocessing Systems products derived principally from the new DOTS MPS product introduced during the year ended December 31, 2024, and a decrease of $722,600 from the~~ Benchtop Laboratory Equipment ~~operations~~Operations. ~~The~~Such ~~reduced~~increase ~~net revenue from the Benchtop Laboratory Equipment Operations~~ resulted primarily from ~~decreased~~increased sales of the Torbal ® division, ~~with net revenue of Torbal and VIVID brand~~ products ~~decreasing to $3~~,~~107,300~~ inoffset ~~the~~by ~~year~~decrease ~~ended December 31, 2024, compared to $3,568,700~~ in ~~the prior year, due principally to reduced VIVID pill counter~~ sales ~~resulting primarily~~ from the ~~new~~Bioprocessing ~~regulations~~Systems ~~related~~products ~~to pharmacy direct and indirect renumeration fees “DIR fees” charged by pharmacy benefit managers,~~ which ~~caused~~sales ~~financial~~are ~~hardships~~derived ~~and~~principally ~~cash~~from ~~flow~~the ~~challenges~~new ~~for~~DOTS ~~the~~MPS ~~independent~~product ~~pharmacy~~introduced ~~market~~during in the ~~beginning~~year ofended ~~2024.~~December ~~The~~31, ~~Genie division sales decreased by approximately 4% due to overall market softness in demand for laboratory equipment~~2025.

The gross profit percentage for the year ended December 31, ~~2024~~2025 decreased to 4425.28% from 4541.98% for the year ended December 31, ~~2023~~2024, due primarily to ~~increased~~inventory ~~cost~~write-offs within the Bioprocessing segment of ~~materials,~~slow ~~labor,~~moving and ~~fixed~~obsolete ~~overhead~~items. Without ~~for~~the effect of write-offs, the ~~Benchtop~~gross ~~Laboratory~~profit ~~Equipment~~percentage ~~Operations~~would have been 42.6%.

General and administrative expenses for the year ended December 31, ~~2024~~2025 decreased by $~~595~~850,~~200~~600 (1120.06%) to $43,~~822~~268,~~700~~800 compared to $54,~~417~~119,~~900~~400 for the year ended December 31, ~~2023~~2024 due to decreased ~~non-cash stock-based compensation~~ expenses inof ~~conjunction with~~ the ~~strategic operational plan for the~~ Bioprocessing Systems Operations ~~implemented in the first~~ and ~~second~~corporate ~~quarter~~expenses ofin ~~the~~conjunction ~~year~~with ~~ended~~cost ~~December~~savings ~~31, 2024~~initiatives.

Selling expenses for the year ended December 31, ~~2024~~2025 decreased by $160,~~734,~~800 (321.39%) to $3,~~643~~114,~~000~~900 from $53,~~377~~205,~~800~~700 for the year ended December 31, ~~2023~~2024, primarily due to the decreased ~~non-cash stock-based compensation~~ expenses ~~and reduction~~ of ~~sales and marketing employees in conjunction with~~ the ~~strategic operational plan for the~~ Bioprocessing Systems Operations ~~implemented~~ in ~~the~~conjunction ~~first~~with ~~and~~cost ~~second~~savings ~~quarters of the year ended December 31, 2024~~initiatives.

Research and development expenses for the year ended December 31, ~~2024~~2025 decreased by $~~660~~410,~~100~~200 (1814.52%) to $2,~~906~~487,~~100~~700 from $32,~~566~~897,~~200~~900 for the year ended December 31, ~~2023~~2024, due to cost reductions by the Bioprocessing Systems Operations in conjunction with cost savings initiatives, and the reduction of research and development expenditures related to the completion of a new VIVID automated pill counter in the Benchtop Laboratory Equipment Operations as compared to the prior year period.

Total other income ~~(expense)~~, net for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024 was $~~192~~6,~~800~~114,200 and $~~170~~192,~~100~~800, respectively. The increase was due primarily to ~~increased~~the ~~interest~~sale ~~income~~of ~~earned~~Genie ~~from~~product ~~investment~~line ~~securities~~which resulted in a gain on sale of $5,263,400, and payroll tax related reimbursements in the Bioprocessing Systems Operations segment.

The Company reflected income tax expense for continuing operations of $4,600 and $0 for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. The Company maintains a full valuation allowance of $912,~~839~~928,~~400~~000 against the consolidated net deferred tax asset as the Company determined the net deferred tax assets which includes net operating loss carry-forwards and other tax credits, are more likely not to be realized in the future. In the event in the future the Company changes the determination as to the amount of deferred tax assets that can be realized, the Company will adjust the valuation allowance with a corresponding impact to the provision for income taxes in the period in which such determination is made.

As a result of the foregoing, the Company recorded a ~~reduced~~ loss from continuing operations of $61,~~445~~780,~~400~~300 for the ~~year~~years ended December 31, ~~2024~~2025 compared to a loss from continuing operations of $98,~~089~~023,~~800~~600 for the year ended December 31, ~~2023~~2024.

The Company reflected ~~net~~income ~~gain~~ from discontinued operations related to the sale of the Genie division of the Benchtop Laboratory Equipment Operations of $0559,900 and $31,~~300~~578,200 for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

As a result of the above, the Company recorded a net loss of $61,~~445~~220,400 for the year ended December 31, ~~2024~~2025 compared to a net loss of $96,~~086~~445,~~500~~400 for the year ended December 31, ~~2023~~2024.

Liquidity and Capital Resources.

Cash and cash equivalents ~~decreased~~increased by $~~208~~367,~~200~~100 to $~~587~~955,~~900~~000 as of December 31, ~~2024~~2025 from $~~796~~587,~~100~~900 as of December 31, ~~2023, primarily due to continued operating costs of the Bioprocessing Systems operations and increased corporate overhead. For the year ended December 31,~~ 2024~~, the Company generated negative cash flows from operations of $3,683,500 and has an accumulated deficit of $33,930,500 as of December 31, 2024~~.

Net cash used in operating activities was $8,149,600 for the year ended December 31, 2025 and $3,046,100 for the year ended December 31, 2024. This reflected the sale of the Genie division.

Net cash provided by investing activities was $3,831,000 for the year ended December 31, 2025 compared to $2,866,000 for the year ended December 31, 2024, with the increase reflecting the proceeds from the sale of the Genie division of the Benchtop Laboratory Equipment Operations.

Net cash provided by financing activities was $1,952,200 for the year ended December 31, 2025 compared to $645,700 for the year ended December 31, 2024. The increase is primarily due to the issuance of common stock and exercise of certain warrants in the current year.

Table of Contents

~~The~~Historically at the end of each reporting period, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that ~~raise~~raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date ~~that~~of the Consolidated Financial Statements ~~are~~were issued. ~~Based~~Since onthe ~~its~~fiscal ~~recurring~~year ~~losses~~ended ~~from~~June ~~operations and continued cash outflows from operating activities (all as described below)~~30, 2020 the Company has ~~concluded~~recorded ~~that~~recuring ~~there~~losses isfrom ~~substantial~~operations ~~doubt~~and ~~about~~continued ~~its~~cash ~~ability~~outflow tofrom ~~continue~~operating activities as a ~~going~~result ~~concern~~of ~~for~~its astrategic ~~period~~focus ofon ~~one~~the ~~year~~Bioprocessing ~~from~~Systems ~~the~~Operations, ~~date~~which ~~that~~is ~~these~~still ~~Consolidated~~in ~~Financial~~its ~~Statements~~start-up ~~are issued~~stage.

InHistorically ~~order~~the toCompany ~~continue~~has asrelied aon ~~going~~equity ~~concern,~~financings. For the ~~Company~~year ~~will~~ended ~~need~~December 31, ~~among~~2025, ~~other~~in ~~things~~addition to equity financings, ~~additional~~the ~~capital~~Company ~~resources.~~generated ~~Management~~positive ~~has~~cash ~~developed~~flows as a ~~strategic~~result ~~plan~~of tothe ~~secure~~sale ~~such~~of ~~resources~~the ~~for~~Genie® ~~the~~Product ~~Company~~line which ~~may~~occurred ~~include~~in ~~capital~~August 2025. The Company reflected an accumulated deficit of $35,150,900 as of December 31, 2025 and continues to generate negative cash flows from ~~management~~its operations and ~~significant~~expects ~~shareholders~~to ~~sufficient~~continue to ~~meet~~generate ~~its~~negative ~~operating~~cash ~~expenses~~flows ~~and~~from ~~third-party~~operations ~~equity~~in ~~and/or~~the ~~debt~~foreseeable ~~financing~~future, ~~and~~however ~~exploring~~the Company expects that with the cash generated from the recent division sale ofplus ~~certain~~other ~~assets.~~incoming ~~However,~~cash ~~management~~related ~~cannot~~to ~~provide~~the ~~any~~various ~~assurances~~post ~~that~~sale agreements is sufficient to fund operations of the Company ~~will~~for beat ~~successful~~least inone ~~accomplishing~~year ~~any~~from the date of ~~its~~issuance ~~plans~~of the consolidated financial statements for the year ended December 31, 2025.

~~The~~In ~~Consolidated~~order ~~Financial~~to ~~Statements~~continue doas ~~not~~a ~~include~~going ~~any~~concern, ~~adjustments~~the ~~that~~Company ~~might~~will ~~result~~need ~~from~~to ~~the~~decrease ~~outcome~~expenses ofor ~~this~~materially ~~uncertainty.~~increase ~~Accordingly~~revenues, ~~the~~and/or ~~Consolidated~~secure ~~Financial~~additional ~~Statements~~external ~~have~~capital ~~been~~resources. ~~prepared~~Based on amanagement’s ~~basis~~current ~~that~~operating ~~assumes~~plan, the Company ~~will~~believes ~~continue~~its ascash aon ~~going~~hand, ~~concern~~including ~~and~~its ~~which~~investments, ~~contemplates~~are sufficient to fund the ~~realization~~Company's ofoperations ~~assets~~for ~~and~~a ~~satisfaction~~period of ~~liabilities~~at ~~and~~least ~~commitments~~one inyear ~~the~~subsequent ~~ordinary~~to ~~course~~the issuance of ~~business~~the accompanying consolidated financial statements. However, there is no assurance that management's current operating plan will be successful.

Net cash used in operating activities was $3,683,500 for the year ended December 31, 2024 and $6,155,000 for the year ended December 31, 2023. The decrease is primarily due to decreased operational costs from the Bioprocessing Systems operations and Corporate overhead in the current year period.

Net cash provided or (used) by investing activities was $2,866,000 for the year ended December 31, 2024 compared to $(735,100) for the year ended December 31, 2023. The increase is primarily due to a increase in redemption of investment securities for use in general operations in the current year period.

Net cash provided by financing activities was $645,700 for the year ended December 31, 2024 compared to $5,751,200 for the year ended December 31, 2023. The decrease is primarily due to the prior period $5,751,200 net proceeds from the issuance of common stock and warrants compared to the current period $645,700 net proceeds from the issuance of common stock and warrants.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On an ongoing basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our significant accounting policies are discussed in Note 2 – Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K. Management believes that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require management’s most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain. Management has reviewed these critical accounting estimates and related disclosures with the Audit Committee of our board of directors.

Table of Contents

Fair Value Estimates

Goodwill and Finite Lived Intangible Assets and Long-Lived Assets, Net

Goodwill – Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and long-lived intangible assets are tested for impairment at least annually in accordance with the provisions of Accounting Standards Codification (“ASC”) ~~No.~~ 350, “Intangibles- Goodwill and Other” (“ASC ~~No.~~ 350”). ASC ~~No.~~ 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit.

As of December 31, ~~2024~~2025, the Company had two reporting units, the Benchtop Laboratory Equipment Operations and the Bioprocessing Systems Operations. Goodwill is tested for impairment by reporting unit on an annual basis as of December 31, the last day of its fiscal year, and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered in the Company’s goodwill impairment testing include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. The fair value is determined using the income approach, which utilizes the present value of expected future cash flows for each reporting unit based on ~~estimate~~estimated ~~future~~ cash flows, the timing of these cash flows, and a discount rate based on a weighted average cost of capital. The assumptions used to estimate future cash flows and the development of forecasts used in the fair value determination were based on assumptions made using the best information available at the time, subject to inherent risk and judgement. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. To the extent additional information arises, market conditions change, or our strategies change, it is possible that the conclusion regarding whether our remaining goodwill is impaired could change and result in future goodwill impairment charges that will have a material effect on our consolidated financial position or results of operations.

During the year ended December 31, ~~2024~~2025, the Company performed the annual goodwill impairment analysis. The Company elected to perform the qualitative analysis for the Benchtop Laboratory Equipment Operations reporting unit. These qualitative analyses evaluated factors, including, but not limited to, economic, market and industry conditions, cost factors and the overall financial performance of the reporting unit. In completing these assessments, the Company noted no changes in events or circumstances that indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount. As of December 31, ~~2024~~2025 and ~~2023~~2024 there was no$115,300 ~~remaining~~of goodwill pertaining to the Benchtop Laboratory Operations and $0 of goodwill on the Bioprocessing System reporting unit.

Intangible assets – Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, intellectual property in-process research and development (“IPR&D”), trademarks and trade names. All intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization. The Company reviews the recoverability of our finite-lived intangible assets and long-lived assets, when events or conditions occur that indicate a possible impairment exists. Determining whether impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. The assessment for recoverability is based primarily on our ability to recover the carrying value of its long-lived and finite-lived intangible assets from expected future undiscounted net cash flows. If the total of expected future undiscounted net cash flows is less than the total carrying value of the assets the asset is deemed not to be recoverable and possibly impaired. We then estimate the fair value of the asset to determine whether an impairment loss should be recognized. An impairment loss will be recognized if an asset’s fair value is determined to be less than its carrying value. Fair value is determined by computing the expected future discounted cash flows. There was noan impairment of $291,000 of intangible assets aswithin ofthe Bioprocessing segment for the year ended December 31, ~~2024~~2025 ~~and~~while ~~2023~~the year ended December 31, ~~respectively~~2024 had $0 impairments.

Table of Contents

Income tax

The Company and its subsidiaries file a consolidated U.S. federal income tax return, and a tax return in Germany for Aquila. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.

In accordance with ASC 740 “Accounting for Income Taxes” (“ASC 740”), the Company evaluated the deferred tax assets to determine if valuation allowances are required or should be adjusted. ASC 740 requires that companies assess whether valuation allowances should be established against their deferred tax assets based on consideration of all available evidence, both positive and negative, using a “more likely than not” standard of whether the deferred tax assets will be realized. As of and for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, the Company maintained a full valuation allowance of $912,~~839~~928,~~400~~000 and $9,~~302~~839,~~300~~400, respectively, against the consolidated net deferred tax assets as the Company determined the net deferred tax assets which includes net operating loss carry-forwards and other tax credits, are more likely not to be realized and therefore the Company recorded a full valuation allowance. If in the future the Company changes the determination as to the amount of deferred tax assets that can be realized, the Company will adjust the valuation allowance with a corresponding impact to the provision for income taxes in the period in which such determination is made.

ASC No. 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.

The Company recognizes interest and penalties on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits. The Company is subject to U.S. federal income tax, as well as various state jurisdictions. The Company is currently open to audit under the statute of limitations by the federal and state jurisdictions for the fiscal years ended June 30, ~~2021~~2022 and after. The Company is currently open to audit under the statute of limitations by German tax authorities for the years ended December 31, ~~2019~~2020 and after. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

Inventories

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

Not required for smaller reporting companies.

Item 8. Financial Statements and Supplementary Data.

The consolidated Financial Statements required by this item are attached hereto on pages F1-F33.

Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.

Not applicable.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this Annual Report on Form 10-K, based on an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15I and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive Officer and Chief Financial Officer of the Company have concluded that the Company’s disclosure controls and procedures were effective as of December 31, ~~2024~~2025.

Table of Contents

Management’s Annual Report on Internal Control Over Financial Reporting. Management is responsible for establishing and maintaining adequate internal controls over the Company’s financial reporting, as such term is defined in Securities Exchange Act Rule 13a-15(f) and 15d-15(f). The Company’s internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

The Chief Executive Officer and the Chief Financial Officer of the Company conducted an evaluation of the effectiveness of the Company’s internal controls over financial reporting as of December 31, ~~2024~~2025 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework.

This ~~annual~~Annual ~~report~~Report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this ~~annual~~Annual ~~report~~Report.

Inherent Limitations on Effectiveness of Controls. The Company’s management, including its Chief Executive Officer and its Chief Financial Officer, believes that its disclosure on controls and procedures and internal controls over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, management does not expect that its disclosure on controls and procedures or its internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Item 9B. Other Information.

Not applicable.

Item 9C. Disclosures Regarding Foreign Jurisdictions that Prevent Inspections.

None.

Table of Contents

PART III

Item 10—Directors, Executive Officers and Corporate Governance

The Company's Certificate of Incorporation provides for a classified Board of Directors, consisting of three classes, each class serving a three-year term on a staggered basis. Two are Class A Directors, two are Class B Directors, and two are Class C Directors.

The Company has the following six directors:

Michael Blechman (age 6667), a director since April 2024, through his affiliate Intracoastal Strategies Group LLC, has been a consultant and advisor for various businesses since February 2023. From January 2017 to January 2023 Mr. Blechman was CEO of ACC, Inc., a systems integration and technology product company., Heand he was President from 1996 to 2016, and held various other management roles from 1988 to 1995 at ACC, Inc.

Christopher Cox (age 6061), a director since February 2021, has been a Senior Vice President of Population Health Investment Co., Inc. since September 2020 and a Co-Founder and Managing Partner of Population Health Partners ~~LP.~~LLC since May 2020. Mr. Cox has been on the Board of Directors of Nyrada, Inc. since January 2019. Mr. Cox has been a corporate attorney for over 25 years, most recently at Cadwalader, Wickersham & Taft LLP, which he joined as a partner in January 2012 and where he ~~was~~served a co-chair of the global corporate group and a member of the firm’s management committee until February 2016. From February 2016 to March 2019, Mr. Cox was Executive Vice President and Chief Corporation Development Officer of Medicines Company. Prior to January 2012, Mr. Cox was a partner at Cahill Gordon & Reindel.

John Nicols (age 61), a director since March 2024 and Chairman of the Board of ~~Scientific Bioprocessing~~SBI, ~~Inc.,~~ has been a consultant and advisor to ~~the~~SBI ~~Company's Bioprocessing Systems Operations~~ since September 2023. Mr. Nicols, who is director certified by the National Association of Corporate Directors, is currently ~~serves~~Owner ~~since~~/ ~~April~~CEO ~~2023~~of asOrganicols, ~~chair~~LLC, onan ~~the~~advisory ~~board~~services offirm ~~directors~~supporting a wide range of ~~Antheia,~~mission-driven ~~Inc~~companies globally., aIn ~~synthetic~~addition ~~biology~~to ~~company~~his ~~and~~roles for Scientific Industries, Mr. Nicols serves as chair ofon the ~~Board~~board of directors of both Antheia and Solve ME/CFS Initiative, aas ~~non-profit~~well ~~organization~~as ~~and~~a ~~advocacy~~member ~~group~~on ~~for~~the ~~chronic~~boards ~~diseases~~of ~~since~~several ~~January~~other ~~2015~~private for-profit enterprises. From ~~June~~ 2012 to ~~August~~ 2022, Mr. Nicols was President and CEO of Codexis, Inc., a Nasdaq listed synthetic biology company. Prior to that, he grew a career to become a leading executive at NYSE listed specialty chemical maker, Albemarle Corp, from 1990 to 2012.

John A. Moore (age 5960), a Director since January 2019 and Chairman of the Board since January 2020, and was also the Chairman of Scientific Bioprocessing Industries (“SBI”) from March until March 2024 and prior was President of SBI from January 2020 through April 2022, and had been providing consulting services to SBI since March 2019. Mr. Moore serves as Chairman of Nyrada, Inc., a drug development company since July 2019 and prior to that served as a director with Noxopharm Limited, a drug development company, and is also the Chairman of Trialogics, a clinical trial software provider. Since March 2022 he serves as the Chairman of Cormetech, a leading air emissions provider for power plants. Mr. Moore was President, Chief Executive Officer and director of Acorn Energy, Inc. from 2006 to 2016.

Helena R. Santos (age 6061), a Director since 2009, has been employed by the Company since 1994, and has served since August 2002 as its President, Chief Executive Officer, Treasurer and, until April 2022, its Chief Financial Officer. She ~~had~~ served as Vice President, Controller from 1997 and has served as Secretary from May 2001.

Jurgen Schumacher (age 7072), a Director since May 2021, is currently and over the past five years has been a private investor in various startups and growth phase technology companies ~~over the past five years~~.

Board ~~Committee~~Committees

The Board of Directors (the “Board”) currently has three standing committees: Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. All committee members are appointed by the Board on an annual basis. Each committee operates under a written charter establishing its roles and responsibilities The composition and responsibilities of each committee are described below.

22 Table of Contents

Audit Committee

The Audit Committee is responsible for assisting the Board in its oversight of the integrity of our financial statements, the qualifications and independence of our independent auditors, and our internal financial and accounting controls. The Audit Committee has direct responsibility for the appointment, compensation, retention (including termination) and oversight of our independent auditors, and our independent auditors report directly to the audit committee. The Audit Committee also prepares the audit committee report that the SEC requires to be included in our annual proxy statement. The Audit Committee discusses with the Company’s internal auditors the overall scope and plans for their respective audits and meets with the internal auditors, with and without management present, to discuss the results of their examinations, their evaluations of the Company’s disclosure and internal controls and the overall quality of the Company’s financial reporting. The Audit Committee periodically reviews and approves all “related party transactions,” as defined in SEC regulations.

The members of the Audit Committee are Messrs. Michael Blechman, Christopher Cox and John Nicols. ~~All~~Each ~~members~~member of the Audit Committee ~~qualify~~qualifies as an independent director under the ~~corporate governance standards of the NASDAQ Listing Rules and the~~ independence requirements of Rule 10A-3 of the Exchange Act. ~~The Board has determined that all of the members of the Audit Committee are “financially literate,” as defined under NASDAQ listing standards.~~

Compensation Committee

The Compensation Committee approves the compensation objectives for the Company, approves the compensation of the Chief Executive Officer of the Company and approves or recommends to the Board for approval the compensation for other executives. The Compensation Committee reviews all compensation components, including equity-based compensation plans, base salary, bonus, benefits and other perquisites. The Compensation Committee shall be tasked with issuing a “Compensation Committee Report” to be included in the Company’s annual report, as may be necessary.

The members of the Compensation Committee are Messrs. Blechman, Christopher Cox and John Nicols. Each member of the Compensation Committee is a non-employee director within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act, each is an outside director as defined by Section 162(m) of the U.S. Internal Revenue Code of 1986, as amended, or the Code~~, and each is an independent director as defined by the NASDAQ Listing Rules, including NASDAQ Listing 5605(d)(2)~~.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is responsible for making recommendations to the Board regarding candidates for directorships and the structure and composition of the Board and the board committees in addition to development and maintaining the Company’s corporate governance policies and any related matters required by federal securities laws. In addition, the Nominating and Corporate Governance Committee is responsible for developing and recommending to the Board corporate governance guidelines applicable to the Company and advising the Board on corporate governance matters. The Nominating and Governance Committee identifies and recommends to the Board candidates for election as directors and recommends any changes it believes desirable in the size and composition of the Board as well as Board committee structure and membership.

The members of the Nominating and Corporate Governance Committee are Messrs. Michael Blechman, Christopher Cox and John Nicols. Each member of the Nominating and Corporate Governance Committee is an independent director within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act ~~and an independent director as defined by the NASDAQ Listing Rules~~.

Executive Officers & Significant Employees

See above for the employment history of Ms. Santos and Mr. Moore.

~~Reginald~~Zachary ~~Averilla~~Rovinsky (age 4659), is the Chief Financial Officer of the Company and has been employed by the Company since ~~April~~June ~~2022~~2025. He was the VPDirector ~~Controller~~of Finance of ~~Medical~~Textiles ~~Knowledge~~at ~~Group,~~MillerKnoll (a ~~privately~~publicly-traded ~~held~~ company) from ~~July~~August ~~2020~~2022 to ~~April~~June ~~2022~~2025. From ~~2017~~2020 to ~~July~~August ~~2020~~2025, he was the VPDirector ~~Controller~~of Finance for ~~Film~~Alcott ~~Expo Group~~HR, a privately held company. ~~Prior to 2017, he was the Assistant Controller to SFX Entertainment, previously a publicly traded company.~~

23 Table of Contents

~~Robert~~Karl PD. ~~Nichols~~Nowosielski (age 6447), is the President of the ~~Genie~~Torbal Products Division of the Benchtop Laboratory Equipment operations and ~~Corporate~~Director ~~Secretary~~of ~~and~~Marketing ~~has~~for ~~been~~the ~~employed~~Company. byHe ~~the~~was ~~Company~~Vice ~~since~~President ~~February~~of ~~1998~~Fulcrum, Inc. ~~Previously,~~(the heseller ~~had~~of ~~been~~the ~~since~~Torbal ~~May~~Products ~~2001,~~Division assets to the Company’s) ~~Vice~~from ~~President~~2004 ofuntil ~~Engineering~~February 2014.

~~Karl~~Daniel D.Donadille ~~Nowosielski~~ (age 4738), is the ~~President~~Chief ofExecutive ~~the~~Officer ~~Torbal Products Division~~ of the ~~Benchtop~~Company’s ~~Laboratory~~Bioprocessing ~~Equipment~~ operations. ~~and~~Prior ~~Director~~to ~~of Marketing for~~ the Company.’s Heacquisition ~~was~~of ~~Vice~~aquila ~~President~~biolabs ofGmbH ~~Fulcrum~~(“Aquila”), ~~Inc.~~he ~~(the~~served ~~seller~~as ofAquila’s ~~the~~Chief ~~Torbal~~Executive ~~Products~~Officer ~~Division~~since ~~assets)~~he ~~from~~co-founded ~~2004~~Aquila ~~until~~in ~~February~~ 2014.

Daniel Donadille (age 37), is the Chief Executive Officer of the Company’s Bioprocessing operations. Prior to the Company’s acquisition of Aquila, he served as Aquila’s Chief Executive Officer since he co-founded Aquila in 2014.

Section 16(a) Beneficial Ownership Reporting Compliance

The Company believes that, for the year ended December 31, ~~2024~~2025, its officers, directors and 10% ~~stockholders~~shareholders timely complied with all filing requirements of Section 16(a) of the Securities Exchange Act of 1934, as amended.

Code of Ethics

The Company has adopted a code of ethics that applies to the Executive Officers and Directors. A copy of the code of ethics can be found on the Company’s website.

Insider Trading Policy

The Company has adopted an insider trading policy that applies to the Executive Officers, Directors and other Company insiders. A copy of the insider trading policy iswas filed ~~herewith~~ as Exhibit 19.1 to ~~this~~the Form 10-K for the year ended December 31, 2024 filed on March 31, 2025.

Executive Compensation

Compensation Discussion and Analysis

The Compensation Committee reviews and recommends to the Board of Directors compensation be paid to each executive officer. Executive compensation, in all instances except for the compensation for the Chief Executive Officer (“CEO”), is based on recommendations from the CEO. The CEO makes a determination by comparing the performance of each executive being reviewed with objectives established at the beginning of each fiscal year and with objectives established during the business year with regard to the success of the achievement of such objectives and the successful execution of management targets and goals.

With respect to the compensation of the CEO, the Committee considers performance criteria, 50% of which is related to the direction, by the CEO, of the reporting executives, the establishment of executive objectives as components for the successful achievement of Company goals and the successful completion of programs leading to the successful completion of the Business Plan for the Company and 50% of which is based on the achievement by the Company of its financial and personnel goals tempered by the amount of the income or loss of the Company during the fiscal year.

The compensation at times includes grants of options under its stock option plan to the named executives. Each officer is employed pursuant to a long-term employment agreement, containing terms proposed by the Compensation Committee and approved as reasonable by the Board of Directors. The Board is cognizant that as a relatively small company, the Company has limited resources and opportunities with respect to recruiting and retaining key executives. Accordingly, the Company has relied upon long-term employment agreements and grants of stock options to retain qualified personnel.

Compensation for each of its executive officers provided by their employment agreements were based on the foregoing factors and the operating and financial results of the segments under their management.

Table of Contents

Item 11—Executive Compensation

The following table summarizes all compensation paid by the Company to its Chief Executive Officer, Chief Financial Officer and the two other most highly compensated executive officers for the years ended December 31, ~~2024~~2025 and ~~2023~~2024.

SUMMARY COMPENSATION TABLE

Name and Principal						Stock		Option		Plan		Compensation		All Other
Position	Year	Salary($)		Bonus($)		Award ($)		Awards($)		Compensation ($)		Earnings($)		Compensation ($) (5)		Total($)
(a)	(b)	(c)		(d)		(e)		(f)		(g)		(h)		(i)		(j)
Helena R. Santos, CEO, President (1)	12/31/~~2024~~2025		~~192~~191,~~430~~740		050,000		0		~~204~~56,~~828~~000		0		0		79,~~697~~457		~~404~~307,~~955~~197
Helena R. Santos, CEO, President	12/31/~~2023~~2024		~~218~~192,~~900~~430		0		0		0109,649		0		0		87,~~800~~697		~~227~~309,~~700~~746
John A. Moore, Chairman (2)	12/31/~~2024~~2025		~~149~~150,~~306~~987		050,000		0		~~209~~52,~~491~~000		0		0		5,972		~~364~~252,~~769~~987
John A. Moore, Chairman	12/31/~~2023~~2024		~~188~~149,~~000~~306		0		0		0115,782		0		0		75,~~500~~972		~~195~~271,~~500~~060
Reginald Averilla, CFO (3)	12/31/2024		195,000		19,500		0		69,514		0		0		7,800		291,814
Zachary Rovinsky, CFO (3)	12/31/2025		105,769		0		0		16,000		0		0		2,000		123,769
Reginald Averilla, CFO	12/31/~~2023~~2024		~~182~~195,~~500~~000		1719,~~000~~500		0		019,438		0		0		7,~~300~~800		~~206~~241,~~800~~738
Daniel Donadille,CEO of Bioprocessing Operations (4)	12/31/~~2024~~2025		168,000		0		0		~~168~~40,~~572~~000		0		0		0		~~336~~208,~~572~~000
Daniel Donadille,CEO of Bioprocessing Operations	12/31/~~2023~~2024		~~193~~168,~~700~~000		0		0		0		0		0		0		~~193~~168,~~700~~000

__________________

(1)	The amount of Option Awards for ~~2024~~ represents ~~compensation~~the ~~expense~~value for stock options granted ~~valued~~ utilizing the Black-Scholes-Merton options pricing model disregarding estimates of forfeitures related to service-based vesting considerations.
(2)	The amount of Option Awards for ~~2024~~ represents ~~compensation~~the ~~expense~~value for stock options granted ~~valued~~ utilizing the Black-Scholes-Merton options pricing model disregarding estimates of forfeitures related to service-based vesting considerations.
(3)	The amount of Option Awards for ~~2024~~ represents ~~compensation~~the ~~expense~~value for stock options granted ~~valued~~ utilizing the Black-Scholes-Merton options pricing model disregarding estimates of forfeitures related to service-based vesting considerations.
(4)	The amount of Option Awards for ~~2024~~ represents ~~compensation~~the ~~expense~~value for stock options granted ~~valued~~ utilizing the Black-Scholes-Merton options pricing model disregarding estimates of forfeitures related to service-based vesting considerations.
(5)	The amounts represent the Company’s matching contribution under the Company’s 401(k).

2425 Table of Contents

Employment Agreements

Helena Santos

The Company has an employment agreement with Helena Santos, its President and CEO, which expires on June 30, ~~2025~~2026. The agreement provided for an annual base salary of $~~175~~200,000 for the year ended June 30, ~~2018~~2026, with subsequent annual increases of 3% or the applicable annual percentage increase in the U.S. Consumer Price Index (“CPI”), whichever is higher, plus a discretionary bonus. A $50,000 cash bonus was awarded to Ms. Santos during the year ended December 31, 2025 and none in 2024. The agreement contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for “cause” or the President terminates the employment for “good reason”, the President will have the right to receive a lump sum payment equal to three times the average of their total annual compensation paid for the last five years preceding such termination. The employment agreement also contains a termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if the relevant employee resigns for “good reason” (as such term is defined therein), the Company shall pay severance payments equal to one year’s salary at the rate of the compensation at the time of termination, and continue to pay the regular benefits provided by the Company for a period of one year from termination.

Reginald Averilla

The Company has an employment agreement with its Chief Financial Officer, which expires on June 30, 2025, providing for an annual base salary of $195,000 plus 10% discretionary bonus. The agreement contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for “cause” or the employee terminates the employment for “good reason”, the employee will have the right to receive a lump sum payment equal to one times the average of their total annual compensation paid for the last five years preceding such termination. The employment agreement also contains a termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if the relevant employee resigns for “good reason” (as such term is defined therein), the Company shall pay severance payments equal to one year’s salary at the rate of the compensation at the time of termination, and continue to pay the regular benefits provided by the Company for a period of one year from termination.

John A. Moore

The Company has an employment agreement with its chairman, ~~which~~of ~~expires~~the onboard ~~June 30, 2024, and was extended~~ through June 30, ~~2025~~2026. The agreement provides for an annual base salary of $~~175~~165,000 for the year ended June 30, ~~2021~~2026, with subsequent annual increases of 3% plus discretionary bonuses. ~~The~~A ~~agreement~~bonus ~~also provides for a grant~~ of ~~options to purchase 215~~$50,~~366~~000 ~~shares~~was ~~which~~awarded ~~were~~to ~~authorized~~Mr. byMoore ~~the Board of Directors~~ during the calendar year ended ~~June~~December 3031, ~~2020,~~2025 ~~subject~~and tonone ~~amendment of the Company’s 2012 Stock Option Plan to increase the number of shares authorized for issuance thereunder which was approved~~ in ~~February 2021, following which Mr~~2024. ~~Moore’s options were issued on February 23, 2021.~~ The employment agreement contains termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if the employee resigns for “good reason”(as such term is defined in the agreement) , the Company shall pay severance payments equal to ~~either one year’s salary at the rate of the compensation at the time of termination is employee is terminated within 12 months of the date of the agreement or~~ six months’ salary ~~is the employee is terminated after 12 months of the date of the agreement~~. The Company will continue to pay the regular benefits provided by the Company for the period equal to the length of the severance payments and pay a pro rata portion of any bonus achieved prior to such termination of employment.

Daniel Donadille

The Company has an employment agreements with the Chief Executive Officer of Aquila for an indefinite term, which can be terminated by either party upon a twelve- month written notice, in accordance with German law. The agreement provides for an annual base salary of 213,000 euros, which was reduced by 25% starting April 1, 2024 under the Company’s salary reduction program. The agreement includes a retention bonus of 25,000 euros if the employees do not terminate their employment with the Company within two years after the agreement date or the Company does not terminate their employment for good cause.

OUTSTANDING EQUITY (OPTIONS) AWARDSFor the Year Ended December 31, 2024
OUTSTANDING EQUITY (OPTIONS) AWARDSFor the Year Ended December 31, 2025
Name	Number Of SecuritiesUnderlying UnexercisedOptions (#)Exercisable		Number Of Securities Underlying Unexercised Options(#)Unexercisable		Equity Incentive Plan Awards Number of Securities Underlying Unexercised Unearned Options(#)		Option Exercise Price ($)		Option Expiration Date
(a)	(b)		(c)		(d)		(e)		(f)
Helena Santos		~~101~~191,~~593~~746		~~185~~165,~~873~~718		-	21.5000-3.08		07/2027-0405/~~2034~~2035
John A. Moore		60198,~~446~~749		~~167~~160,~~506~~718		-	21.5000-11.30		03/2029-0405/~~2034~~2035
Reginald Averilla		4,444		15,556		-		2.50	04/2034
Zachary Rovinsky		-		20,000		-		0.80		08/2035
Daniel Donadille		61108,~~790~~108		7781,~~162~~387		-	1.00-2.50	~~2.50~~	0405/~~2034~~2035
Robert Nichols		8,240		10,787		-		2.50	04/2034
Karl Nowosielski		24,056		24,444		-	1.00-2.50		05/2035
Karl Nowosielski		2,222		7,778		-		2.50	04/2034

2526 Table of Contents

DIRECTORS’ COMPENSATIONFor the Year Ended December 31, 2024

DIRECTORS’ COMPENSATIONFor the Year Ended December 31, 2025

Name

Fees Earned or Paid in Cash($)

Stock Awards ($)

Option Awards ($)

Non-Equity Incentive Plan Compensation ($)

Non-qualified Deferred Compensation Earnings ($)

All Other Compensation ($)

Total($)

(a)

(b)

(c)

(d)

(e)

(f)

(h)

(i)

Michael Blechman (1)

1112,~~500~~000

229,~~158~~750

3321,~~658~~750

Christopher Cox (2)

166,~~500~~000

249,~~298~~750

4015,~~798~~750

John Nicols (3)

12,000

589,~~295~~750

96,000

~~166~~117,~~295~~750

Jurgen Schumacher (4)

~~12,000~~0

186,~~916~~500

306,~~916~~500

Marcus Frampton (5)

6,000

13,588

19,588

	(1)	On ~~May 17, 2024, 25,000 stock options were granted to Mr. Blechman, and on the same date 7,186 options were awarded to Mr. Blechman in lieu of $6,000 cash fees owed. On~~ July 1, ~~2024~~2025, 515,000 stock options were granted to Mr. Blechman. Stock option expense was determined utilizing the Black-Scholes-Merton option pricing model.
	(2)	On ~~April 1, 2024, 17,964 stock options were awarded to Mr. Cox in lieu of $15,000 cash fees owed. On~~ July 1, ~~2024~~2025, 15,000 stock options were granted to Mr. Cox. Stock option expense was determined utilizing the Black-Scholes-Merton option pricing model.
	(3)	On ~~April 1, 2024, 10,778 stock options were awarded to Mr. Nicols in lieu of $9,000 cash fees owed. On~~ July 1, ~~2024~~2025, 15,000 stock options were granted to Mr. Nicols. Stock option expense was determined utilizing the Black-Scholes-Merton option pricing model. Please refer to Item 13 below for discussion of “All Other Compensation” amounts.
	(4)	On ~~April 1, 2024, 14,371 stock options were awarded to Dr. Schumacher in lieu of $12,000 cash fees owed. On~~ July 1, ~~2024~~2025, 10,000 stock options were granted to Dr. Schumacher. Stock option expense was determined utilizing the Black-Scholes-Merton option pricing model.
	(5)	On April 1, 2024, 8,962 stock options were awarded to Mr. Frampton in lieu of $7,500 cash fees owed. Mr. Frampton resigned from the Company’s Board of Directors on April 4, 2024. Stock option expense was determined utilizing the Black-Scholes-Merton option pricing model.

The Company paid each Director who is not an employee of the Company or a subsidiary, a ~~quarterly retainer fee of $3,000 and a~~ meeting fee of $3,000 for each meeting attended. In addition, the Company reimburses each Director for out-of-pocket expenses incurred in connection with attendance at board meetings. , if any

~~Item~~27 ~~12—Security~~Table ~~Ownership~~ of ~~Certain Beneficial Owners and Management and Related Stockholder Matters~~Contents

~~The~~Item ~~following~~12—Security ~~table~~Ownership ~~sets forth, as~~ of ~~December~~Certain ~~31,~~Beneficial ~~2024,~~Owners the number of shares of Common Stock beneficially owned by (i) each person known to the Company to beneficially own more than 5% of the outstanding shares of Common Stock, (ii) each director of the Company, (iii) each named executive officer of the Company, and ~~(iv)~~Management ~~all directors~~ and ~~executive~~Related ~~officers~~Shareholders as a group. Shares not outstanding but deemed beneficially owned by virtue of the right of any individual to acquire shares within 60 days are treated as outstanding only when determining the amount of and percentage of outstanding shares of Common Stock owned by such individual. Each person has sole voting and investment power with respect to the shares shown, except as noted. Except as indicated in the table, the address for each of the following is c/o Scientific Industries, Inc., 80 Orville Drive, Bohemia, New York 11716.Matters

AsThe following table sets forth, as of December 31, ~~2024~~2025, ~~there~~the ~~were~~number ~~10,503,599~~of shares of Common Stock beneficially owned by (i) each person known to the Company to beneficially own more than 5% of the outstanding shares of Common Stock, (ii) each director of the Company, (iii) each named executive officer of the Company, and (iv) all directors and executive officers as a group. Shares not outstanding but deemed beneficially owned by virtue of the right of any individual to acquire shares within 60 days are treated as outstanding only when determining the amount of and percentage of outstanding shares of Common Stock owned by such individual. Each person has sole voting and investment power with respect to the shares shown, except as noted. Except as indicated in the table, the address for each of the following is c/o Scientific Industries, Inc., 80 Orville Drive, Bohemia, New York 11716.

Name	Amount and Nature of Beneficial Ownership			% of Class
Bleichroeder LP		2,465,026	(1)		20.95	%
Roy T. Eddleman, Trustee, Roy T. Eddleman Trust UAD 8-7-2000		2,127,264	(2)		18.66	%
Laurence W. Lytton		1,067,946	(3)		9.99	%
Veradace Capital Management LLC		1,452,717	(4)		13.12	%
Brian Pessin		1,303,606	(5)		11.84	%
Thomas A. Satterfield		1,138,055	(6)		10.50	%
North Run Capital, LP		1,089,743	(7)		9.99	%
Lyon Polk		944,000	(8)		8.60	%
Christopher Cox		635,454	(9)		5.86	%
John A. Moore		456,472	(10)		4.21	%
Helena R. Santos		313,388	(11)		2.90	%
Jurgen Schumacher		197,264	(12)		1.86	%
Daniel Donadille		144,465	(13)		1.36	%
John Nicols		90,778	(14)	*
Karl D. Nowosielski		50,498	(15)	*
Robert P. Nichols		49,268	(16)	*
Michael Blechman		37,186	(17)	*
Reginald Averilla		29,768	(18)	*
All directors and executive officers as a group (10 persons)		2,004,541	(19)

As of December 31, 2025, there were 11,928,599 shares of Company Common Stock outstanding.

Name	Amount and Nature of Beneficial Ownership			% of Class
Bleichroeder LP		2,715,026	(1)		20.58	%
Laurence W. Lytton		1,226,086	(2)		9.99	%
Brian Pessin		2,004,700	(3)		16.12	%
North Run Capital, LP		1,231,000	(4)		9.99	%
Veradace Capital Management LLC		1,453,717	(5)		11.63	%
Roy T. Eddleman, Trustee, Roy T. Eddleman Trust UAD 8-7-2000		1,443,414	(6)		11.89	%
Thomas A. Satterfield		1,136,955	(7)		9.18	%
Lyon Polk		944,000	(8)		7.61	%
Christopher Cox		650,454	(9)		5.30	%
John A. Moore		656,871	(10)		5.23	%
Helena R. Santos		383,388	(11)		3.12	%
Jurgen Schumacher		207,264	(12)		1.72	%
Daniel Donadille		194,465	(13)		1.60	%
John Nicols		135,778	(14)		1.13	%
Karl D. Nowosielski		64,498	(15)	*
Robert P. Nichols		69,268	(16)	*
Michael Blechman		72,186	(17)	*
Zachary Rovinsky		20,000	(18)	*
All directors and executive officers as a group (10 persons)		2,454,172	(19)		18.02

____________________

	(1)	~~Based~~Includes ~~upon form Schedule 13D filed with SEC on March 21, 2025, includes~~ 1,261,675 shares issuable upon exercise of warrants
	(2)	~~Based~~Includes ~~upon form Schedule 13D filed with SEC on February 15~~344,700 ~~2023, includes 894,376~~ shares issuable upon exercise of warrants
	(3)	~~Based~~Includes ~~upon form Schedule 13G filed with SEC on February 14~~509,568 ~~2024, includes 186,560~~ shares issuable upon exercise of warrants
	(4)	~~Based~~Includes ~~upon form Schedule 13D filed with SEC on December 29~~396,000 ~~2023, includes 565,789~~ shares issuable upon exercise of warrants
	(5)	~~Includes~~Based ~~509~~upon form Schedule 13D filed with SEC on December 29,~~568~~ 2023, includes 565,789 shares issuable upon exercise of warrants
	(6)	Based upon form Schedule ~~13G~~13D filed with SEC on February 1215, ~~2025~~2023, includes ~~336~~210,~~984~~526 shares issuable upon exercise of warrants
	(7)	~~Based~~Includes ~~upon form Schedule 13D filed with SEC on February 13~~461,984 ~~2025, includes 404,743~~ shares issuable upon exercise of warrants
	(8)	Includes 472,000 shares issuable upon exercise of options and/or warrants
	(9)	Includes ~~334~~349,209 shares issuable upon exercise of options and/or warrants
	(10)	Includes ~~351~~416,690 shares issuable upon exercise of options and/or warrants
	(11)	Includes ~~289~~359,443 shares issuable upon exercise of options and/or warrants
	(12)	Includes ~~104~~114,502 shares issuable upon exercise of options and/or warrants
	(13)	Includes ~~139~~189,002 shares issuable upon exercise of options and/or warrants
	(14)	Includes 7590,778 shares issuable upon exercise of options and/or warrants
	(15)	Includes 3650,605 shares issuable upon exercise of options and/or warrants
	(16)	Includes 2747,579 shares issuable upon exercise of options and/or warrants
	(17)	Includes 3752,186 shares issuable upon exercise of options and/or warrants
	(18)	~~Includes~~Represents 2920,~~768~~000 shares issuable upon exercise of options ~~and/or warrants~~
	(19)	Includes 1,~~425~~689,~~762~~994 shares issuable upon exercise of options and/or warrants

2628 Table of Contents

EQUITY COMPENSATION PLAN INFORMATION

The following table sets forth information with respect to Company options, warrants and rights as of December 31, ~~2024~~2025

Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights

Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights

Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))

Plan Category

(a)

(b)

(c)

Equity Compensation plans approved by security holders

12,~~835~~246,~~447~~144

5.06

~~463~~53,~~848~~151

Equity Compensation plans not approved by security holders

N/A

Total

12,~~835~~246,~~447~~144

5.06

~~463,848~~53.151

Item 13—Certain Relationships and Related Party Transactions, and Director Independence

Mr. John Nicols, a Director since March 2024, provides consulting services to the Company’s Bioprocessing System segment pursuant to consulting agreement which was entered in September 2023 and renews each year automatically unless terminated by either party with 30 days notice. The agreement provided that the consultant be paid a monthly retainer fee of $8,000. For the ~~year~~years ended December 31, ~~2023~~2025 and 2024, the Company paid annual fees of $1996,~~200 and issued 35,~~000 stock options which vested monthly over a one-year period, valued at $114,700 on the grant date using the Black-Scholes-Merton option pricing model. For the year ended December 31, 2024, the Company paid fees under the consulting agreement ~~aggregating $96,000~~.

Item 14—Principal Accountant Fees and Services

Introductory Statement

Our Current Report on Form 8-K relating to our change in certifying accountant as filed with the United States Securities and Exchange Commission on ~~June~~January 626, ~~2024,~~2026 is incorporated by reference herein.

Fees

~~Forvis~~The ~~Mazars~~Company ~~serves~~has engaged Carr, Riggs & Ingram, LLC (“CRI”) as its registered public accounting firm, which acquired effective as of January 1, 2026, certain assets related to the capital markets practice of Berkowitz Pollack Brant Advisors + CPAs, LLP (“BPB”). On January 14, 2026, the Audit Committee of the Company’s Board of Directors simultaneously dismissed BPB as the Company’s independent registered public accounting firm. and approved the appointment of CRI as the Company’s independent registered public accounting firm.

The ~~Company~~fees incurred ~~fees~~for ~~in connection with~~ the ~~audit~~services ~~and~~of ~~quarterly~~BPB ~~reviews~~related ofto the ~~Company’s~~quarterly ~~annual~~reviews ~~consolidated~~during ~~financial statements. The fees for~~ the ~~services~~year ofended ~~Forvis~~December ~~Mazars~~31, ~~and~~2025 ~~Mazars~~amounted ~~USA~~to ~~were approximately~~ $~~274~~41,~~000~~600 ~~and~~plus $375,~~000,~~200 ~~respectively~~related ~~for~~to ~~the~~a ~~year~~Form ~~ended December 31, 2024~~8-K/A. The ~~Company incurred~~ fees for the services of ~~Mazars~~CRI ~~USA~~are ofexpected to be approximately $~~188~~150,~~300~~000 ~~for~~to ~~the~~$175,000 ~~year~~related ~~ended~~to the December 31, ~~2023~~2025 year end audit.

Prior to the engagement of BPB and subsequently CRI, Forvis Mazars, LLP served as the Company’s independent registered public accounting firm from January 1, 2025 through August 22, 2025. Prior to that, the Company engaged Mazars USA, which was acquired by Forvis Mazars, LLP. The fees for the services of Forvis Mazars related to quarterly reviews during the year ended December 31, 2025 reviews were approximately $73,500, plus $19,950 related to registration statements and other services. The Company incurred fees for the services of Forvis Mazars, LLP and Mazars USA of $274,000 for the year ended December 31, 2024.

In approving the engagement of the independent registered public accounting firm to perform the audit and non-audit services, the Company’s Audit Committee evaluates the scope and cost of each of the services to be performed including a determination that the performance of the non-audit services will not affect the independence of the firm in the performance of the audit services.

2729 Table of Contents

PART IV

Item 15. Exhibits and Financial Statement Schedules.

Financial Statements. The required financial statements of the Company are attached hereto on pages F1-F33.

Exhibits. The following Exhibits are filed as part of this report on Form 10-K:

Exhibit Number		Exhibit

3		Certificate of Incorporation and By-Laws:

3(a)		Certificate of Incorporation of the Company as amended (filed as Exhibit 1(a-1) to the Company's General Form for Registration of Securities on Form 10 dated February 14, 1973 and incorporated by reference thereto.)

3(b)		Certificate of Amendment of the Company’s Certificate of Incorporation, as filed on January 28, 1985 (filed as Exhibit 3(a) to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 1985 and incorporated by reference thereto.)

3(c)		By-Laws of the Company, as restated and amended (filed as Exhibit 3(ii) to the Company’s Current Report on Form 8-K filed on January 6, 2003 and Exhibit 3(ii) to the Company’s Current Report on Form 8-K filed on December 5, 2007 and incorporated by reference thereto).

3(d)		Second Amended and Restated By-Laws of Scientific Industries, Inc. (filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on August 10, 2020 and incorporated by reference thereto).

3(e)		Certificate of Amendment of Certificate of Incorporation of Scientific Industries, Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 1, 2021 and incorporated by reference thereto).

3(f)		Certificate of Amendment of Certificate of Incorporation of Scientific Industries, Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 21, 2021 and incorporated by reference thereto).

3(g)		Certificate of Amendment of Certificate of Incorporation of Scientific Industries, Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on February 25, 2022 and incorporated by reference thereto).

2830 Table of Contents

3(h)

By-Laws of the Company, as restated and amended (filed as Exhibit 3(i) to the Company’s Current Report on Form 8-K filed on November 9, 2022 and incorporated by reference thereto).

3(g)		Certificate of Amendment of Certificate of Incorporation of Scientific Industries, Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 11, 2023 and incorporated by reference thereto).

4		Instruments defining the rights of security holders:

4(a)		2002 Stock Option Plan (filed as Exhibit 99-1 to the Company’s Current Report on Form 8-K filed on November 25, 2002 and incorporated by reference thereto).

4(b)		2012 Stock Option Plan (filed as Exhibit 10 to the Company’s Current Report on Form 8-K filed on January 23, 2012 and incorporated by reference thereto).

4(c)		Amendment to the Company’s 2012 Stock Option Plan (Filed as Exhibit 4(c) to the Company’s Quarterly Report on Form 10-Q filed on May 12, 2016 and incorporated by reference thereto).

4(d)		Form of Warrant issued by the Company to Investors (Filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 19, 2020, and incorporated by reference thereto).

4(e)		Amendment No. 2 to Scientific Industries, Inc. 2012 Stock Option Plan (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 1, 2021 and incorporated by reference thereto).

4(f)		2022 Equity Incentive Plan to the Company’s Current Report on Form 8-K filed on February 25, 2022 and incorporated by reference thereto).

4(g)

Form of Warrant issued by the Company to Investors (Filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 13, 2023, and incorporated by reference thereto).

4(h)		Amendment No.1 to 2022 Equity Incentive Plan filed as Exhibit 4(h) within this Form 10-K.
4(i)		Amendment No. 2 to 2022 Equity Incentive Plan filed as Exhibit 4(i) within this Form 10-K.
4(j)		Form of Warrant issued by the Company to Investors (Filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 22, 2025, and incorporated by reference thereto).
10		Material Contracts:
10(a)		Lease between Registrant and AIP Associates, predecessor-in-interest of current lessor, dated October, 1989 with respect to Company's offices and facilities in Bohemia, New York (filed as Exhibit 10(a) to the Company’s Annual Report on Form 10-KSB filed on September 28, 2005 and incorporated by reference thereto).
10(a)-1		Amendment to lease between Registrant and REP A10 LLC, successor in interest of AIP Associates, dated September 1, 2004 (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on September 2, 2004, and incorporated by reference thereto).
10(a)-2		Second amendment to lease between Registrant and REP A10 LLC dated November 5, 2007 (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on November 8, 2007, and incorporated by reference thereto).
10(a)-3		Lease agreement dated August 8, 2014 by and between the Company and 80 Orville Drive Associates LLC. (filed as Exhibit 10 to the Company's Form 10-K filed on September 26, 2014, and incorporated by reference thereto).

2931 Table of Contents

10(a)-3(i)		First amendment to lease dated September 20, 2021 by and between the Company and REP 2035 LLC. (filed as Exhibit 10(a)-3(i) to the Company's Form 10-K filed on October 14, 2021, and incorporated by reference thereto).

10(b)		Employment Agreement dated January 1, 2003, by and between the Company and Ms. Santos (filed as Exhibit 10(a) to the Company’s Current Report on Form 8-K filed on January 22, 2003, and incorporated by reference thereto).

10(b)-1		Employment Agreement dated September 1, 2004, by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on September 1, 2004, and incorporated by reference thereto).

10(b)-2		Employment Agreement dated December 29, 2006, by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on December 29, 2006, and incorporated by reference thereto).

10(b)-3		Employment Agreement dated July 31, 2009 by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on August 7, 2009, and incorporated by reference thereto).

10(b)-4		Employment Agreement dated May 14, 2010 by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on May 18, 2010, and incorporated by reference thereto).

10(b)-5		Employment Agreement dated September 13, 2011 by and between the Company and Ms. Santos (filed as exhibit 10(b)-5 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011, and incorporated by reference thereto).

10(b)-6		Amended Employment Agreement dated May 20, 2013 by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on May 20, 2013, and incorporated by reference thereto).

10(b)-7		Agreement extension dated June 9, 2015 to amend employment agreement by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on June 9, 2015, and incorporated by reference thereto)

10(b)-8		Agreement extension dated May 25, 2016 to amend employment agreement by and between the Company and Ms. Santos (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on May 31, 2016, and incorporated by reference thereto).

10(b)-9		Employment agreement dated July 1, 2017 by and between the Company and Ms. Santos (filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2017, and incorporated by reference thereto).

10(b)-10		Amendment No.1 to Employment Agreement dated June 23, 2022, by and between the Company and Ms. Santos (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on June 27, 2022, and incorporated by reference thereto).

3032 Table of Contents

10(c)		Employment Agreement dated January 1, 2003, by and between the Company and Mr. Robert P. Nichols (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on January 22, 2003, and incorporated by reference thereto).

10(c)-1		Employment Agreement dated September 1, 2004, by and between the Company and Mr. Nichols (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on September 1, 2004, and incorporated by reference thereto).

10(c)-2		Employment Agreement dated December 29, 2006, by and between the Company and Mr. Nichols (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on December 29, 2006, and incorporated by reference thereto).

10(c)-3		Employment Agreement dated July 31, 2009 by and between the Company and Mr. Nichols (filed as Exhibit 10A-2 to the Company’s Current Report on Form 8-K filed on August 7, 2009, and incorporated by reference thereto).

10(c)-4		Employment Agreement dated May 14, 2010 by and between the Company and Mr. Nichols (filed as Exhibit 10A-2 to the Company’s Current Report on Form 8-K filed on May 18, 2010, and incorporated by reference thereto).

10(c)-5		Employment Agreement dated September 13, 2011 by and between the Company and Mr. Nichols (filed as Exhibit 10(c)-5 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011, and incorporated by reference thereto).

10(c)-6		Amended Employment Agreement dated May 20, 2013 by and between the Company and Mr. Nichols (filed as Exhibit 10A-2 to the Company’s current Report on Form 8-K filed on May 20, 2013, and incorporated by reference thereto).

10(c)-7		Agreement extension dated June 9, 2015 to amend employment agreement with Mr. Nichols (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on June 9, 2015, and incorporated by reference thereto).

10(c)-8		Agreement extension dated May 25, 2016 to amend employment agreement with Mr. Nichols (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on May 31, 2016, and incorporated by reference thereto).

10(c)-9		Employment agreement dated July 1, 2017 by and between the Company and Mr. Nichols (filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2017, and incorporated by reference thereto).

10(c)-10		Amendment No.1 to Employment Agreement dated June 23, 2022, by and between the Company and Mr. Nichols (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on June 27, 2022, and incorporated by reference thereto).

10(d)		Consulting Agreement dated January 1, 2003 by and between the Company and Mr. Cremonese and his affiliate, Laboratory Innovation Company, Ltd. (filed as Exhibit 10(b) to the Company’s Current Report on Form 8-K filed on January 6, 2003, and incorporated by reference thereto).

10(d)-1		Amended and Restated Consulting Agreement dated March 22, 2005, by and between the Company and Mr. Cremonese and Laboratory Innovation Company, Ltd. (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on March 23, 2005, and incorporated by reference thereto).

3133 Table of Contents

10(d)-2		Second Amended and Restated Consulting Agreement dated March 15, 2007, by and between the Company and Mr. Cremonese and Laboratory Innovation Company Ltd. (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on March 16, 2007, and incorporated by reference thereto).

10(d)-3		Third Amended and Restated Consulting Agreement dated September 23, 2009, by and between the Company and Mr. Cremonese and Laboratory Innovation Company, Ltd. (filed as Exhibit 10 to the Company’s Annual Report on Form 10-K field on September 24, 2009, and incorporated by reference thereto).

10(d)-4		Fourth Amended and Restated Consulting Agreement dated January 7, 2011 (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K (filed on January 18, 2011, and incorporated by reference thereto).

10(d)-5		Fifth Amendment and Restated Consulting Agreement dated January 20, 2012 (filed as Exhibit 10 to the Company’s Current Report on Form 8-K (filed on January 23, 2012, and incorporated by reference thereto).

10(d)-6		Agreement extension dated November 29, 2012 to Amended and Restated Consulting Agreement (filed as Exhibit 10 to the Company’s Current Report on Form 8-K filed on December 4, 2012, and incorporated by reference thereto).

10(d)-7		Agreement extension dated December 12, 2013 to Amended and Restated Consulting Agreement (filed as Exhibit 10 to the Company’s Current Report on Form 8-K filed on December 12, 2013, and incorporated by reference thereto).

10(d)-8		Agreement extension dated January 14, 2015 to Amended and Restated Consulting Agreement by and between the Company and Mr. Cremonese and affiliates (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on January 15, 2015, and incorporated with reference thereto).

10(d)-9		Agreement extension dated January 7, 2016 to Amended and Restated Consulting Agreement by and between the Company and Mr. Cremonese and affiliates (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on January 26, 2016, and incorporated with reference thereto).

10(d)-10		Agreement extension dated February 16, 2018 to Amended and Restated Consulting Agreement by and between the Company and Mr. Cremonese and affiliates (filed as Exhibit 10-A1 to the Company’s Current Report on Form 8-K filed on March 9, 2018, and incorporated with reference thereto).

10(d)-11		Agreement extension dated January 23, 2019 to Amended and Restated Consulting Agreement by and between the Company and Mr. Cremonese and affiliates (filed as Exhibit 10-1 to the Company’s Current Report on Form 8-K filed on January 25, 2019, and incorporated with reference thereto).

10(d)-12		Monthly Retainer Agreement between Scientific Bioprocessing, Inc. and Mr. Cremonese and affiliates (filed as Exhibit 10(d)-12 to the Company’s Quarterly Report on Form 10-Q on February 13, 2020, and incorporated by reference thereto).

10(d)-13		Extension of Monthly Retainer Agreement between Scientific Bioprocessing, Inc. and Mr. Cremonese and affiliates (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 8, 2021, and incorporated with reference thereto).

3234 Table of Contents

10(e)		Sublicense from Fluorometrix Corporation (filed as Exhibit 10(a)1 to the Company’s Current Report on Form 8-K filed on June 14, 2006, and incorporated by reference thereto).

10(f)		Stock Purchase Agreement, dated as of November 30, 2006, by and among the Company and Grace Morin, Heather H. Haught and William D. Chandler (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 5, 2006, and incorporated by reference thereto).

10(g)		Escrow Agreement, dated as of November 30, 2006, by and among the Company and Grace Morin, Heather H. Haught and William D. Chandler (filed as Exhibit 10(a) to the Company’s Current Report on Form 8-K filed on December 5, 2006, and incorporated by reference thereto).

10(h)		Registration Rights Agreement, dated as of November 30, 2006, by and among the Company and Grace Morin, Heather H. Haught and William D. Chandler (filed as Exhibit 10(b) to the Company’s Current Report on Form 8-K filed on December 5, 2006, and incorporated by reference thereto).

10(i)		Employment Agreement, dated as of November 30, 2006, between Altamira Instruments, Inc. and Brookman P. March (filed as Exhibit 10(c) to the Company’s Current Report on Form 8-K filed on December 5, 2006, and incorporated by reference thereto).

10(i)-1		Employment Agreement, dated as of October 30, 2008, between Altamira Instruments, Inc. and Brookman P. March (filed as Exhibit 10A-2 to the Company’s Current Report on Form 8-K filed on October 30, 2008, and incorporated by reference thereto).

10(i)-2		Employment Agreement, dated as of October 1, 2010, between Altamira Instruments, Inc., and Brookman P. March (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on October 13, 2010, and incorporated by reference thereto).

10(i)-3		Employment Agreement, dated as of May 18, 2012 between Altamira Instruments, Inc. and Brookman P. March (filed as Exhibit 10(i)-3 to the Company’s Annual Report on Form 10-K filed on September 27, 2012, and incorporated by reference thereto).

10(i)-4		Agreement Extension, dated as of May 21, 2014 between Altamira Instruments, Inc. and Brookman P. March (filed as Exhibit 10 to the Company’s Current Report on Form 8-K filed on May 21, 2014, and incorporated by reference thereto).

10(i)-5		Agreement extension dated June 9, 2015 to amend employment agreement (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on June 9, 2015, and incorporated by reference thereto).

10(i)-6		Agreement extension dated May 25, 2016 to amend employment agreement (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on May 31, 2016, and incorporated by reference thereto).

10(i)-7		Employment agreement dated July 1, 2017 by and between the Company and Brookman. March (filed as an exhibit to the Company's Annual Report on Form 10-K filed on June 30, 2017, and incorporated by reference thereto).

10(i)-8		Termination notice dated February 14, 2020 to Mr. March (filed as Exhibit 10(I-8) to the Company’s Current Report on Form 8-K filed on February 18, 2020, and incorporated by reference thereto).

3335 Table of Contents

10(j)		Indemnity Agreement, dated as of April 13, 2007 by and among the Company and Grace Morin, Heather H. Haught and William D. Chandler (filed as Exhibit 10(j) to the Company’s Annual Report on Form 10-KSB filed on September 28, 2007 and incorporated by reference thereto).

10(k)		Lease between Altamira Instruments, Inc. and Allegheny Homes, LLC, with respect to the Company’s Pittsburgh, Pennsylvania facilities (filed as Exhibit 10(k) to the Company’s Annual Report on Form 10-KSB filed on September 28, 2007 and incorporated by reference thereto).

10(k)-1		Lease between Altamira Instruments, Inc. and Allegheny Homes, LLC, with respect to the Company’s Pittsburgh, Pennsylvania facilities (filed as Exhibit 10(k)-1 to the Company’s Quarterly Report on Form 10-Q filed on February 14, 2013, and incorporated by reference thereto).

10(l)		Line of Credit Agreements dated October 30, 2008, by and among the Company and Capital One, N.A. (filed as Exhibits 10-A1(a) through (f) to the Company’s Current Report on Form 8-K filed on October 30, 2008, and incorporated by reference thereto.

10(l)-1		Restated Promissory Note Agreement dated January 20, 2010 by and among the Company and Capital One N.A. (filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on January 20, 2010, and incorporated by reference thereto).

10(I)-2		Consulting Agreement dated April 1, 2009 by and between the Company and Grace Morin (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on April 1, 2009, and incorporated by reference thereto).

10(m)-1		Agreement dated January 12, 2015 to extend Consulting Agreement (filed as Exhibit 10A-2 to the Company’s Current Report on Form 8-K filed on January 15, 2015, and incorporated by reference thereto).

10(m)-2		Agreement dated January 7, 2016 to extend Consulting Agreement (filed as Exhibit 10A-2 to the Company’s Current Report on Form 8-K filed on January 26, 2016, and incorporated by reference thereto).

10(m)-3		Agreement dated February 16, 2018 to extend Consulting Agreement (filed as Exhibit 10A-2 to the Company’s Current Report on Form 8-K filed on March 9, 2018, and incorporated by reference thereto).

10(m)-4		Agreement dated January 23, 2019 to extend Consulting Agreement (filed as Exhibit 10-2 to the Company’s Current Report on Form 8-K filed on January 25, 2019, and incorporated by reference thereto).

10(n)		Line of Credit Agreements dated June 14, 2011, by and among the Company and JPMorgan Chase Bank, N.A. (filed as Exhibits 99.1 through 99.3 to the Company’s Current Report on Form 8-K filed on June 16, 2011, and incorporated by reference thereto).

10(n)-1		Promissory Note dated June 5, 2013 by and among the Company and JP Morgan Chase Bank, N.A. (filed as Exhibit 99 to the Company’s Current Report on Form 8-K filed on June 7, 2013, and incorporated by reference thereto).

10(o)

Purchase Agreement, dated as of November 14, 2011, by and among the Company, Scientific Bioprocessing, Inc., and Fluorometrix Corporation (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on November 17, 2011, and incorporated by reference thereto).

3436 Table of Contents

10(p)		Escrow Agreement, dated as of November 14, 2011, by and among the Company, Scientific Bioprocessing, Inc., and Fluorometrix Corporation (filed as Exhibit 10(A) to the Company’s Current Report on Form 8-K filed on November 17, 2011, and incorporated by reference thereto).

10(q)		Research and Development Agreement dated as of November 14, 2011, by and between Scientific Bioprocessing, Inc. and Biodox R&D Corporation (filed as Exhibit 10(B) to the Company’s Current Report on Form 8-K filed on November 17, 2011, and incorporated by reference thereto).

10(q)-1		Notice of termination of Research and Development Agreement dated June 12, 2013 (filed as Exhibit 99 to the Company’s Current Report on Form 8-K filed on June 27, 2013, and incorporated by reference thereto)

10(r)		Non-Competition Agreement, dated as of November 14, 2011, by and among the Company, Scientific Bioprocessing, Inc., and Joseph E. Qualitz (filed as Exhibit 10(D) to the Company’s Current Report on Form 8-K filed on November 17, 2011, and incorporated by reference thereto).

10(s)		Promissory Note, dated as of November 14, 2011, by and between the Company and the University of Maryland, Baltimore County (filed as Exhibit 10(c) to the Company’s Current Report on Form 8-K filed on November 17, 2011, and incorporated by reference thereto).

10(t)		License Agreement, dated as of January 31, 2001 by and between University of Maryland, Baltimore County and Fluorometrix Corporation (filed as Exhibit 10(E) to the Company’s Current Report on Form 8-K filed on November 21, 2011, and incorporated by reference thereto).

10(u)		Line of Credit Agreements dated June 25, 2014, by and among the Company and Bank of America Merrill Lynch (filed as Exhibits 99.1 through 99.2 (to the Company’s Current Report on Form 8-K filed on July 2, 2014, and incorporated by reference thereto).

10(v)		Asset Purchase Agreement, dated as of February 26, 2014, by and among the Company and Fulcrum, Inc. (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on February 28, 2014, and incorporated by reference thereto).

10(v)-1		Escrow Agreement, dated as of February 26, 2014, by and among the Company, and Fulcrum, Inc. (filed as Exhibit 10(e) to the Company’s Current Report on Form 8-K filed on February 28, 2014, and incorporated by reference thereto).

10(v)-2		Non-Competition Agreements, dated as of February 26, 2014, by and among the Company, and James Maloy and Karl Nowosielski (filed as Exhibits 10(b) and 10(c) to the Company’s Current Report on Form 8-K filed on February 28, 2014, and incorporated by reference thereto).

10(v)-3		Registration Rights Agreement, dated as of February 26, 2014, by and among the Company, and Fulcrum, Inc. (filed as Exhibit 10(d) to the Company’s Current Report on Form 8-K filed on February 28, 2014, and incorporated by reference thereto).

10(v)-4		Supply Agreement, dated as of February 20, 2014, by and among the Company, and Axis Sp 3.O.O. (filed as Exhibit 10(g) to the Company’s Current Report on Form 8-K filed on February 28, 2014, and incorporated by reference thereto).

10(w)		Line of Credit Agreements dated June 26, 2015, by and among the Company and First National Bank of Pennsylvania (filed as Exhibit 10.1 through 10.4 to the Company’s Current Report on Form 8-K filed on June 30, 2015, and incorporated by reference thereto).

3537 Table of Contents

10(w)-1		Commercial Security Agreement dated July 5, 2016 by and among the Company, and First National Bank of Pennsylvania (filed as Exhibit 10 on Form 10-K on October 10, 2016, and incorporated by reference thereto).
10(y)		Note Purchase Agreements with James Maloy dated May 7, 2015 (filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on June 30, 2015, and incorporated by reference thereto).
10(z)		Note Purchase Agreements with Grace March dated May 19, 2015 (filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on June 30, 2015, and incorporated by reference thereto).
10(aa)		Consulting Agreement dated March 1, 2019 between the Company and Mr. John A. Moore (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on March 6, 2019, and incorporated by reference thereto).
10(aa)-1		Amendment to Consulting Agreement dated November 7, 2019 between the Company and Mr. John A. Moore (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 11, 2019, and incorporated by reference thereto).

10(aa)-2

Employment Agreement dated July 1, 2020 between Scientific Bioprocessing, Inc. and John A. Moore (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 25, 2020, and incorporated by reference thereto).

10(bb)		Consulting Agreement dated July 20, 2020 between the Company and Mr. Reinhard Vogt and his affiliate Societat Reinhard and Noah Vogt AG (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on July 22, 2020, and incorporated by reference thereto.)

10(bb)-1		Amendment to Consulting Agreement between the Company and Societät Reinhard and Noah Vogt AG GmbH and Reinhard Vogt (filed as Exhibit 10A-1 to the Company’s Current Report on Form 8-K filed on March 8, 2021, and incorporated by reference thereto.

10(cc)		Employment Agreement dated July 1, 2020 between Scientific Bioprocessing, Inc. and James Polk (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on June 25, 2020, and incorporated by reference thereto).

10(dd)		Securities Purchase Agreement dated June 18, 2020 between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 19, 2020, and incorporated by reference thereto).

10(dd)-1		Form of Amendment of Securities Purchase Agreement, by and between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 13, 2021, and incorporated by reference thereto).

10(ee)		Loan Agreement under the U.S. Small Business Administration Paycheck Protection Program dated April 14, 2020 between the Company and First National Bank (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 21, 2020, and incorporated by reference thereto).

10(ff)		Asset Purchase Agreement dated November 30, 2020 between Altamira Instruments, Inc. and Beijing JWGB Sci. & Tech. Co., Ltd (filed as Exhibit 2 to the Company’s Current Report on Form 8-K filed on December 1, 2020, and incorporated by reference thereto).

3638 Table of Contents

10(gg)		Asset Purchase Agreement dated April 28, 2021 between the Company and the sellers of aquila biolabs GmbH (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 30, 2021, and incorporate by reference thereto).

10(gg)-1		Directors’ Service Contract dated April 29, 2021 between the Company and the sellers of aquila biolabs GmbH (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 30, 2021, and incorporate by reference thereto).

10(gg)-2		Directors’ Service Contract dated May 24, 2022 between the Company and a seller of aquila biolabs GmbH (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 27, 2022, and incorporate by reference thereto).

10(hh)		Securities Purchase Agreement dated April 29, 2021 between the Company and Investors (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 30, 2021, and incorporated by reference thereto).

10(hh)-1		Registration Rights Agreement dated April 29, 2021 between the Company and Investors (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on April 30, 2021, and incorporated by reference thereto).

10(hh)-2		Amendment No. 1 to Registration Rights Agreement dated April 29, 2021 between the Company and Investors (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on June 21, 2021, and incorporated by reference thereto).

10(ii)		Securities Purchase Agreement dated June 18, 2021 between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 21, 2021, and incorporated by reference thereto).

10(jj)		Securities Purchase Agreement dated March 2, 2022 between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 2, 2022, and incorporated by reference thereto).

10(kk)

Securities Purchase Agreement dated March 2, 2022 between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 2, 2022, and incorporated by reference thereto).

10(ll) Employment Agreement dated June 30, 2023, by and between the Company and Mr. Averilla (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 07, 2023, and incorporated by reference thereto).

10(mm) Securities Purchase Agreement dated December 13, 2023 between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 15, 2023, and incorporated by reference thereto).

10(mm)		Securities Purchase Agreement dated December 13, 2023 between the Company and Investors (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 15, 2023, and incorporated by reference thereto).

10(nn)		Asset Purchase Agreement dated as of August 7, 2025 between the Company and Troemner, LLC (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on August 11, 2025, and incorporated by reference thereto).

10(nn-1)		Manufacturing and Supply Agreement dated as of August 7, 2025 between the Company and Troemner, LLC (filed as exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 11, 2025, and incorporated by reference thereto).

10(nn-2)		Transition Services Agreement dated as of August 11, 2025 between the Company and Troemner, LLC (filed as exhibit 10.2 to the Company’s Current Report on Form 8-K filed on August 11, 2025, and incorporated by reference thereto).

10(pp)		Registration Rights Agreement by and among the Company and the Investors (filed as exhibit 4.2 to the Company’s Current Report on Form 8-K filed on April 22, 2025, and incorporated by reference thereto).

10(pp-1)		Securities Purchase Agreement by and among the Company and the investors (filed as exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 22, 2025, and incorporated by reference thereto).

10(pp-2)		Form of Alternate Warrant (filed as exhibit 10.2 to the Company’s Current Report on Form 8-K filed on April 22, 2025, and incorporated by reference thereto).

10(pp-3)		Form of Pre-Funded Warrant (filed as exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 22, 2025, and incorporated by reference thereto).

19.1		Policy on Insider Trading (~~Filed~~filed ~~herewith~~as exhibit 19.1 to the Company’s Annual Report on Form 10-K filed on March 31, 2025, and incorporated by reference thereto)
31.1		Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Filed herewith)
31.2		Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Filed herewith)
32.1		Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Filed herewith)
32.2		Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Filed herewith)

3739 Table of Contents

SIGNATURES

Pursuant to the requirements of Section13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 31, 2025	SCIENTIFIC INDUSTRIES, INC.
Date: March 31, 2026	SCIENTIFIC INDUSTRIES, INC.
	(Registrant)
	/s/ Helena R. Santos
	Helena R. Santos
	President, Chief Executive Officer, and Treasurer
Date: March 31, 2025	SCIENTIFIC INDUSTRIES, INC.
Date: March 31, 2026	SCIENTIFIC INDUSTRIES, INC.
	(Registrant)
	/s/ Reginald Averilla
	/s/ Zachary Rovinsky
	Reginald Averilla Chief Financial Officer
	Zachary RovinskyChief Financial Officer, Asst. Treasurer, Asst. Secretary

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name	Title	Date
Helena R. Santos	President, Chief Executive Officer, and Treasurer	March 31, ~~2025~~2026
Reginald Averilla	Chief Financial Officer	March 31, 2025
Zachary Rovinsky	Chief Financial Officer, Asst Treasurer, Asst Secretary	March 31, 2026
John A. Moore	Chairman of the Board	March 31, ~~2025~~2026
Christopher Cox	Director	March 31, ~~2025~~2026
Michael Blechman	Director	March 31, ~~2025~~2026
Jurgen Schumacher	Director	March 31, ~~2025~~2026
John Nicols	Director	March 31, ~~2025~~2026

3840 Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONTENTS

		Page
Report of Independent Registered Public Accounting Firm (PCAOB firm ID 686)		F-2
Report of Independent Registered Public Accounting Firm (PCAOB firm ID 213)		F-2
Report of Independent Registered Public Accounting Firm (PCAOB firm ID 339)		F-3
Report of Independent Registered Public Accounting Firm (PCAOB firm ID 686)		F-3
Consolidated financial statements:
Consolidated Balance Sheets as of December 31, 2024 and 2023		F-4
Consolidated Balance Sheets as of December 31, 2025 and 2024		F-4
Consolidated Statements of Operations and Comprehensive Loss for the Year Ended December 31, 2024 and 2023		F-5
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024		F-5
Consolidated Statements of Changes in Stockholders’ Equity for the Year Ended December 31, 2024 and 2023		F-6
Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended December 31, 2025 and 2024		F-6
Consolidated Statements of Cash Flows for the Year Ended December 31, 2024 and 2023		F-7
Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024		F-7
Notes to financial statements		F-8 – F-33
Notes to Consolidated Financial Statements		F-8 – F-33

F-1

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Scientific Industries, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Scientific Industries, Inc. (the “Company”) as of December 31, ~~2024~~2025, and the related consolidated statements of operations and comprehensive loss, ~~stockholders~~changes in shareholders’ equity, and cash flows, for the year then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, ~~2024~~2025, and the results of its operations and its cash flows for the ~~years~~year then ended, in conformity with accounting principles generally accepted in the United States of America.

We ~~also~~ have also audited the adjustments todescribed ~~the 2023 financial statements to retrospectively apply the change~~ in ~~accounting~~Notes ~~related~~1 toand ~~the~~17 ~~Company’s~~that ~~adoption~~were ofapplied ~~ASU 2023-07, Segment Reporting (Topic 280) - Improvements~~ to ~~Reportable~~restate ~~Segment~~the ~~Disclosures~~2024 asconsolidated ~~described~~financial ~~in Note 14~~statements. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures to the ~~2023~~2024 consolidated financial statements of the Company other than with respect to the adjustments, and, accordingly, we do not express an opinion or any other form of assurance on the ~~2023~~2024 consolidated financial statements ~~taken~~ as a whole.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

/s/ Carr, Riggs & Ingram L.L.C.

We have served as the Company’s auditor since 2026.

Palm Beach Gardens, Florida

March 31, 2026

F-2

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Scientific Industries, Inc.

Opinion on the Financial Statements

We have audited before the effects of the adjustments to retrospectively apply the effects of discontinued operations discussed in Notes 1 and 17, the accompanying consolidated balance sheet of Scientific Industries, Inc. (the “Company”) as of December 31, 2024 and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows, for the year then ended, and the related notes (collectively referred to as the “financial statements”). (the 2024 financial statements before the effects of the adjustment discussed in Note 17 are not presented herein). In our opinion, the financial statements, before the effects of the adjustment to retrospectively apply the effects of discontinued operations described in Notes 1 and 17, present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

We were not engaged to audit, review, or apply any procedures to the adjustments to retrospectively apply the effects of discontinued operations described in Notes 1 and 17 and, accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by Carr, Riggs & Ingram, LLC.

Explanatory Paragraph Regarding Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred significant operating losses, has continued cash outflows from operating activities, and has an accumulated deficit. These conditions raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters also are described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit.

We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

~~Critical~~We ~~Audit~~served ~~Matters~~as the Company’s auditor from 2024 to 2025.

Critical audit matters are matters arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ Forvis Mazars, LLP

WeNew ~~have~~York, ~~served~~New ~~as the Company’s auditor since 2024.~~York

New York, NY

March 31, 2025

F-2 Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Scientific Industries, Inc.

Opinion on the Financial Statements

We have audited, before the effects of the adjustments to retrospectively apply the change in accounting described in Note 14, the accompanying consolidated balance sheet of Scientific Industries, Inc. (the “Company”) as of December 31, 2023 and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows, for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above, before the effects of the adjustments to retrospectively apply the change in accounting (as described in Note 14), present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

We were not engaged to audit, review, or apply any procedures to the adjustments to retrospectively apply the change in accounting (as described in Note 14) and, accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by Forvis Mazars.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

/s/ Mazars USA LLP

We served as the Company’s auditor from 2023 to 2024.

New York, NY

March 31, 2024

F-3

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	As of December 31, 2024			As of December 31, 2023
	As of December 31, 2025			As of December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	~~587~~955,~~900~~000		$	~~796~~587,~~100~~900
Investment securities		15,~~985~~705,000			41,~~928~~985,~~700~~000
Trade accounts receivable, less allowance for doubtful accounts of $15,600 at December 31, 2024 and 2023		1,202,600			1,157,100
Trade accounts receivable, less allowance for doubtful accounts of $8,300 and $15,600 at December 31, 2025 and 2024, respectively		865,800			581,900
Inventories		41,~~085~~401,~~900~~300			42,~~883~~059,~~900~~100
Income tax receivable		73,600			~~161~~73,~~400~~600
Prepaid expenses and other current assets		~~352~~1,~~700~~115,300			~~413~~324,~~500~~200
Total current assets		8,287,700			12,340,700
Current assets of discontinued operations		272,900			2,676,000
Property and equipment, net		885,000			1,082,300
Total current assets		10,388,900			8,287,700
Property and equipment, net		690,900			796,300
Goodwill		115,300			115,300
Other intangible assets, net		~~752~~103,~~300~~500			1746,~~249,900~~000
Inventories		~~509~~346,~~500~~700			~~609~~509,~~000~~500
Operating lease right-of-use assets		~~947~~924,~~900~~000			1947,~~273,~~900
Other assets		6338,~~100~~300			5963,~~400~~100
Total assets	$	11,560,800		$	16,730,500
Other assets of discontinued operations		-			95,000
Total assets	$	12,607,600		$	11,560,800
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	~~586~~449,100		$	~~711~~282,700
Accrued expenses		~~790~~416,~~100~~700			~~777~~629,~~900~~100
Contract liabilities		6399,~~500~~800			2363,~~600~~500
Lease liabilities, current portion		~~307~~371,~~300~~400			~~324~~307,~~100~~300
Total current liabilities		1,747,000			1,837,300
Current liabilities of discontinued operations		12,300			464,400
Lease liabilities, less current portion		694,400			1,007,800
Total current liabilities		1,349,300			1,747,000
Total liabilities		2,441,400			2,845,100
Lease liabilities, less current portion		595,300			694,400
Total liabilities		1,944,600			2,441,400
Commitments and contingencies (Note 8)
Shareholders’ equity:
Common stock, $0.05 par value; 30,000,000, shares authorized; 10,503,599 and 10,145,211, shares issued and outstanding at December 31, 2024 and 2023		525,200			507,300
Common stock, $0.05 par value; 30,000,000, shares authorized; 11,928,599 and 10,503,599, shares issued and outstanding at December 31, 2025 and 2024		596,400			525,200
Additional paid-in capital		4245,~~637~~039,~~800~~500			4042,~~844~~637,~~600~~800
Accumulated comprehensive income (loss)		~~(113~~178,~~100~~000	)		18(113,~~600~~100	)
Accumulated deficit		(3335,~~930~~150,~~500~~900	)		(2733,~~485~~930,~~100~~500	)
Total shareholders’ equity		910,~~119~~663,~~400~~000			139,~~885~~119,400
Total liabilities and shareholders’ equity	$	1112,~~560~~607,~~800~~600		$	1611,~~730~~560,~~500~~800

See notes to consolidated financial statements

F-4

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Year Ended December 31,			Year Ended December 31,
	2024			2023
	2025			2024
Revenues	$	105,~~712~~053,~~600~~800		$	114,~~111~~797,~~500~~100
Cost of revenues		53,~~979~~750,~~000~~700			62,~~009~~790,500
Gross profit		41,~~733~~303,~~600~~100			52,~~102~~006,~~000~~600
Operating expenses:
General and administrative		43,~~822~~268,~~700~~800			54,~~417~~119,~~900~~400
Selling		3,~~643~~144,~~000~~900			53,~~377~~205,~~800~~700
Research and development		2,~~906~~487,~~100~~700			32,~~566~~897,~~200~~900
Total operating expenses		11,371,800			14,361,900
Impairment of intangible assets		291,600			-
Loss from operations		(6,638,200	)		(9,259,900	)
Total operating expenses		9,193,000			10,223,000
Loss from operations		(7,889,900	)		(8,216,400	)
Other income:
Other income, net		12710,~~400~~900			6212,~~900~~400
Interest income		180,400			107,200
Gain on disposition of discontinued operations		5,263,400			-
Total other income, net		192,800			170,100
Interest income		139,900			180,400
Loss from continuing operations before income tax expense		(6,445,400	)		(9,089,800	)
Total other income, net		6,114,200			192,800
Income tax, current		-			-
Loss from continuing operations before income tax expense		(1,775,700	)		(8,023,600	)
Income tax expense		-			-
Income tax expense, current		(4,600	)		-
Total income tax expense		-(4,600	)		-
Loss from continuing operations		(61,~~445~~780,~~400~~300	)		(98,~~089~~023,~~800~~600	)
Discontinued operations:
Gain from discontinued operations, net of tax		-			3,300
Income from discontinued operations, net of tax		559,900			1,578,200
Net loss		(61,~~445~~220,400	)		(96,~~086~~445,~~500~~400	)
Comprehensive gain (loss):
Other comprehensive gain (loss):
Unrealized holding gain on investment securities, net of tax	-				1,600
Foreign currency translation gain (loss)		240,900			(131,700	)
Foreign currency translation gain (loss)		(131,700	)		25,400
Other comprehensive gain (loss)		240,900			(131,700	)
Comprehensive gain (loss)		(131,700	)		27,000
Total comprehensive loss	$	(979,500	)	$	(6,577,100	)
Total comprehensive loss	$	(6,577,100	)	$	(9,059,500	)
Basic and Diluted gain (loss) per common share
Basic and Diluted loss per common share
Continuing operations	$	(0.16	)	$	(0.76	)
Continuing operations	$	(0.61	)	$	(1.27	)
Discontinued operations	$	0.05		$	0.15
Discontinued operations	$	-		$	-
Consolidated operations	$	(0.11	)	$	(0.61	)
Consolidated operations	$	(0.61	)	$	(1.27	)
Weighted Average Shares Outstanding		11,344,823			10,503,599

See notes to consolidated financial statements

F-5

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN ~~STOCKHOLDERS~~SHAREHOLERS’ EQUITY

							Additional			Accumulated Other												Total
	Common Stock						Paid-in			Comprehensive			Accumulated			Treasury Stock						Stockholders’
	Shares			Amount			Capital			Income (Loss)			Deficit			Shares			Amount			Equity
Balance December 31, 2022		7,023,401		$	351,200		$	32,900,800		$	(8,400	)	$	(18,398,600	)		19,802		$	52,400		$	14,792,600
Net loss		-			-			-			-			(9,086,500	)		-			-			(9,086,500	)
Issuance of Common Stock and Warrants, net of issuance costs (Note 12)		3,141,612			157,100			3,481,300			-			-			-			-			3,638,400
Fair value modification of warrants recorded as stock issuance costs		-			-			2,112,800			-			-			-			-			2,112,800
Issuance of warrants		-			-			161,000			-			-			-			-			161,000
Foreign currency translation adjustment		-			-			-			25,400			-			-			-			25,400
Unrealized holding gain on investment securities, net of tax		-			-			-			1,600			-			-			-			1,600
Retirement of treasury stock		(19,802	)		(1,000	)		(51,400	)		-			-			(19,802	)		(52,400	)		-
Stock-based compensation		-			-			2,240,100			-			-			-			-			2,240,100
Balance December 31, 2023		10,145,211		$	507,300		$	40,844,600		$	18,600		$	(27,485,100	)		0		$	-		$	13,885,400
Net loss		-			-			-			-			(6,445,400	)		-			-			(6,445,400	)
Issuance of Common Stock and Warrants, net of issuance costs (Note 12)		358,388			17,900			204,000			-			-			-			-			221,900
Fair value modification of warrants recorded as stock issuance costs		-			-			423,800			-			-			-			-			423,800
Foreign currency translation adjustment		-			-			-			(131,700	)		-			-			-			(131,700	)
Stock-based compensation		-			-			1,165,400			-			-			-			-			1,165,400
Balance December 31, 2024		10,503,599		$	525,200		$	42,637,800		$	(113,100	)	$	(33,930,500	)		0		$	-		$	9,119,400

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

					Additional		Accumulated Other						Total
	Common Stock				Paid-in		Comprehensive			Accumulated			Shareholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Equity

Balance December 31, 2023		10,145,211	$	507,300	$	40,844,600	$	18,600		$	(27,485,100	)	$	13,885,400

Loss from Continuing Operations		-		-		-		-			(8,023,600	)		(8,023,600	)

Income from discontinued operations		-		-		-		-			1,578,200			1,578,200

Issuance of Common Stock and Warrants, net of issuance costs (Note 12)		358,388		17,900		204,000		-			-			221,900

Fair value modification of warrants recorded as stock issuance costs		-		-		423,800		-			-			423,800

Foreign currency translation adjustment		-		-		-		(131,700	)		-			(131,700	)

Stock-based compensation		-		-		1,165,400		-			-			1,165,400

Balance December 31, 2024		10,503,599	$	525,200	$	42,637,800	$	(113,100	)	$	(33,930,500	)	$	9,119,400

Loss from Continuing Operations		-		-		-		-			(1,780,300	)		(1,780,300	)

Income from discontinued operations		-		-		-		-			559,900			559,900

Issuance of Common Stock and Warrants, net of issuance costs (Note 12)		1,425,000		71,200		1,881,000		-			-			1,952,200

Foreign currency translation adjustment		-		-		-		291,100			-			291,100

Stock-based compensation		-		-		520,700		-			-			520,700

Balance December 31, 2025		11,928,599	$	596,400	$	45,039,500	$	178,000		$	(35,150,900	)	$	10,663,000

See notes to consolidated financial statements

F-6

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year ended December 31,			Year ended December 31,
	2024			2023
	2025			2024
Operating activities:
Net loss	$	(61,~~445~~220,400	)	$	(96,~~086~~445,~~500~~400	)
Less: Income from discontinued operations, net of tax		559,900			1,578,200
Loss from continuing operations		(1,780,300	)		(8,023,600	)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for bad debt		2,000			-
Gain on disposition of discontinued operations		(5,263,400	)		-
Provision for inventory reserves		359,800			-
Provision for bad debt		7,300			2,000
Depreciation and amortization		750,700			754,000
Provision for inventory reserves		(757,400	)		359,800
Stock-based compensation		1,165,400			2,240,100
Depreciation and amortization		610,000			750,700
Fair value on issuance of warrants		-			161,000
Impairment of intangible assets		291,600			-
Loss on sale of investment securities		6,700			92,300
Stock-based compensation		520,700			1,165,400
Unrealized holding gain on investment securities		(25,900	)		(143,400	)
(Gain) loss on sale of investment securities		(20,100	)		6,700
Noncash lease expense		326,600			105,200
Unrealized holding loss (gain) on investment securities		2,400			(25,900	)
Noncash lease expense		257,100			326,600
Changes in operating assets and liabilities:
Trade accounts receivable		(42291,~~600~~200	)		~~119~~578,100
Inventories		~~450~~(682,~~800~~100	)		~~(13~~2,~~100~~477,600	)
Prepaid expense and other current assets		59(791,~~000~~100	)		4787,~~400~~500
Income tax receivable		~~87,800~~-			-87,800
Other assets		(324,~~700~~800	)		(12,~~200~~600
Accounts payable		~~(114~~166,~~600~~400	)		(~~222~~418,~~400~~000	)
Accrued expenses		30(212,~~000~~400	)		10(133,~~100~~300	)
Contract liabilities		4036,~~100~~300			~~(110~~40,~~800~~100
Lease liabilities		(~~330~~268,200	)		(~~106~~330,~~800~~200	)
Net cash used in operating activities		(38,~~683~~149,~~500~~600	)		(63,~~155~~046,~~000~~100	)
Investing activities:
Redemption of investment securities		3,~~527~~745,~~500~~700			53,~~314~~527,~~000~~500
Purchase of investment securities		(~~562~~7,~~600~~465,700	)		(5562,~~917,400~~600	)
Capital expenditures		(98,900	)		(131,700	)
Proceeds from disposition of discontinued operations		7,614,200			-
Net cash provided by (used) in investing activities		2,866,000			(735,100
Capital expenditures		(63,200	)		(98,900	)
Net cash provided by investing activities		3,831,000			2,866,000
Financing activities:
Proceeds from issuance of common stock		~~716~~2,~~800~~050,000			6716,~~283,200~~800
Issuance cost of common stock and warrants		(7197,~~100~~800	)		(~~532~~71,~~000~~100	)
Net cash provided by financing activities		~~645~~1,~~700~~952,200			5645,~~751,200~~700
Effect of changes in foreign currency exchange rates on cash and cash equivalents		(36,400	)		7,900
Discontinued Operations:
Net decrease in cash and cash equivalents		(208,200	)		(1,131,000	)
Net cash provided by (used in) operating activities of discontinued operations		2,694,800			(637,400	)
Cash and cash equivalents, beginning of period		796,100			1,927,100
Net change in cash		328,400			(171,800	)
Cash and cash equivalents, end of period	$	587,900		$	796,100
Effect of changes in foreign currency exchange rates on cash and cash equivalents		38,700			(36,400	)
Cash and cash equivalents, beginning of year		587,900			796,100
Cash from discontinued operations beginning of year		-			-
Less cash from discontinued operations end of year		-			-
Cash and cash equivalents, end of year	$	955,000		$	587,900
SUPPLEMENTAL DISCLOSURES:
Cash paid during the period for:
Income taxes	$	-		$	-
Interest
Noncash financing activities:
Record right-of-use assets	$	-254,600		$	~~166,400~~-
Record lease liabilities	$	-254,600		$	~~166,400~~-

See notes to consolidated financial statements

F-7

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO ~~SOLIDATED~~CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of the Business and Basis of Presentation

Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment, weight and measurement, and bioprocessing products. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory and pharmacy equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania and Baesweiller, Germany, where it designs and produces a variety of bioprocessing products, and an administrative facility in ~~Orangeburg~~Pearl River, New York related to sales and marketing. The products, which are sold to customers worldwide, include ~~mixers, shakers, stirrers, refrigerated incubators,~~ pharmacy balances and analytical scales, force gauges, pill counters, bioprocessing sensors and analytical tools.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Bioprocessing Holdings, Inc. (“SBHI”), a Delaware corporation and wholly-owned subsidiary, which holds 100% of the outstanding stock of Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and aquila biolabs GmbH (“Aquila”), a German corporation, since its acquisition on April 29, 2021, ~~Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, and Altamira Instruments, Inc., an inactive wholly-owned subsidiary~~ (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation.

In accordance with Accounting Standards Codification (“ASC”) 205-20, “Presentation of Financial Statements – Discontinued Operations”, the Company has classified the Genie Division of Scientific Industries, Inc. as discontinued operations. The results of discontinued operations are presented separately in the consolidated statements of operations and comprehensive income (loss) for all periods presented, and the assets and liabilities of the Genie Division have been reflected as assets and liabilities of discontinued operations in the accompanying consolidated balance sheets for all periods presented.

Going Concern

~~The~~Historically at the end of each reporting period, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that ~~raise~~raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date ~~that~~of the Consolidated Financial Statements ~~are~~were issued. The ~~Based~~Company onhas ~~its~~recorded recurring losses from operations and continued cash outflows from operating activities ~~(all~~ as ~~described~~a ~~below),~~result ~~the~~of ~~Company has concluded that there is substantial doubt about~~ its ~~ability~~strategic tofocus ~~continue~~on asthe aBioprocessing ~~going~~Systems ~~concern~~Operations, ~~for~~which ais ~~period~~still ofin ~~one~~its ~~year~~start-up ~~from the date that these Consolidated Financial Statements are issued~~stage.

Historically the Company has relied on equity financings to support recurring business operations. For the year ended December 31, ~~2024~~2025, in addition to equity financings, the Company generated ~~negative~~positive cash flows ~~from~~as ~~operations~~a result of ~~$3,683,500~~the ~~and~~sale ~~has~~of the Genie Product line which occurred in August 2025. The Company has an accumulated deficit of $3335,~~930~~150,~~500~~ 900 as of December 31, ~~2024~~2025 and continues to generate negative cash flows from its operations and expects to continue to generate negative cash flows from operations in the foreseeable future; however, the Company expects that with the cash generated from the recent division sale plus other incoming cash related to the various post-sale agreements is sufficient to fund operations of the Company for at least one year from the date of issuance of the consolidated financial statements for the year ended December 31, 2025.

In order to continue as a going concern, the Company will need to decrease expenses or materially increase revenues, and/or secure additional external capital resources. Based on management’s current operating plan, the Company believes its cash on hand, including its investments, are sufficient to fund the Company's operations for a period of at least one year subsequent to the issuance of the accompanying consolidated financial statements; however, there is no assurance that management's current operating plan will be successful.

F-8

Table of Contents

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management has developed a strategic plan to secure such resources for the Company which may include capital from management and significant shareholders sufficient to meet its operating expenses and third-party equity and/or debt financing and exploring the sale of certain assets. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the Consolidated Financial Statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the valuation allowance of net, deferred taxes. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

Revenue Recognition

The Company recognizes revenue in accordance with ~~Accounting Standards Codification (~~“ASC”) Topic 606, “Revenue from Contracts with Customers”. The Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.

The Company determines revenue recognition through the following steps:

· Identification of the contract, or contracts, with a customer · Identification of the performance obligations in the contract · Determination of the transaction price · Allocation of the transaction price to the performance obligations in the contract; and · Recognition of revenue when, or as, a performance obligation is satisfied.

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the Financial Accounting Standards Board (“FASB”), in applying ASC Topic 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; and 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

The Company’s subscription revenue as further discussed below is recognized ratably over the subscription period, which is 12 months.

F-9

Table of Contents

Nature of Products and Services

The Company generates revenues from the following sources: (1) Benchtop Laboratory Equipment Operations and (2) Bioprocessing Systems Operations.

Benchtop Laboratory Equipment ~~Sales~~ Operations' ~~comprise~~revenues are comprised primarily of ~~standard~~ benchtop ~~laboratory~~weighing ~~equipment~~and ~~from~~measurement ~~its~~equipment ~~stock~~sold to ~~laboratory equipment~~ distributors, or to end users primarily via e- commerce. The sales cycle from time of receipt of order to shipment is very, short varying from a day to a few weeks. Customers either pay by credit card (~~online~~e-commerce sales) or Net 30-9060, depending on the customer. Revenue is recognized at the point in time when the item is shipped. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually ~~comprises~~consists of one ~~to two~~ year parts and labor and is deemed immaterial. In addition, the Company recently introduced subscription plans, exclusively to the Benchtop Laboratory Equipment Operations' VIVID ONE/WORKSTATION customers, providing them with access to certain cloud-based information through payment of an annual subscription fee. The Company recognized revenue related to these subscriptions amounting to $115,100 and $67,000 for the years ended December 31, 2025 and 2024, respectively.

Bioprocessing Systems Operations revenues ~~sales~~are ~~comprise~~comprised primarily of bioprocessing products, principally products incorporating smart sensors and state of the art software analytics. Products offered for sale include the Cell Growth Quantifier (“CGQ”) for Biomass monitoring in shake flasks, the Liquid Injection System (“LIS”) for automated feeding in shake flasks, and a line of coaster systems and flow-through cells for pH and DO monitoring. Revenue is recognized at the point in time when the item is shipped.

Segment Reporting

~~Effective~~The ~~December 31, 2024, the~~ Company ~~adopted~~views ~~Accounting~~its ~~Standards~~operations ~~Update~~as ~~ASU~~two ~~2023-07~~operating segments, ~~"Segment~~that ~~Reporting~~are ~~(Topic~~also ~~280):~~the ~~Improvements~~two toreporting ~~Reportable Segment Disclosures." Operating~~ segments: ~~are~~the ~~defined~~manufacture asand ~~components~~marketing of anbenchtop ~~entity~~laboratory ~~for~~equipment ~~which~~sold ~~separate~~primarily ~~financial~~through ~~information~~distributors isconsisting ~~available~~of ~~and~~balances, ~~that~~scales, ismoisture ~~regularly~~analyzers, ~~reviewed~~force bygauges, ~~the~~pill ~~Chief~~counters ~~Operating~~(“Benchtop ~~Decision~~Laboratory ~~Maker~~Equipment ~~(the “CODM~~Operations”), ~~in deciding how to allocate resources to an individual segment~~ and ~~in assessing performance. The Company’s Chief Executive Officer is~~ the ~~Company’s~~manufacture, ~~CODM.~~design, ~~The~~and ~~CODM~~marketing ~~reviews financial information presented on a consolidated basis for purposes~~ of ~~making~~bioprocessing ~~operating~~systems ~~decisions, allocating resources,~~ and ~~evaluating~~products ~~financial~~(“Bioprocessing ~~performance.~~Systems Operations”).

The Company views its operations as two operating segments, that are also the two reporting segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the manufacture, design, and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems Operations”).

The Company’s chief operating decision maker (“CODM”) regularly reviews revenue and operating income/loss for each segment in determination of allocating resources and assessing financial performance results for each operating segment. In their combined capacity as a group of top executives, the Company’s President and Chief Executive Officer and the Chief Executive Officer and President of the Bioprocessing Systems Operations, have been identified as the Company’s CODM. Significant segment expenses regularly provided to the CODM relate to employee compensation expenses which are included within the reported measure(s) of the Company’s segments profit or loss.

The Company eliminates inter-segment activity in the Company’s reporting segment results to be consistent with the information that is presented to the CODM, in accordance to ASC 280-10-580-28A. The Company also included a Non-operating Corporate segment in the Company’s reporting segment results.

F-10

Table of Contents

Cash and Cash Equivalents

The Company considers all highly liquid ~~debt~~ instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of December 31, ~~2024~~2025 and ~~2023~~2024, $090,400 and $~~166~~0,~~000,~~ respectively, of cash balances were in excess of the FDIC limit.

Allowance for Credit Losses - Accounts Receivable

The allowance for credit losses required under ASC 326 is a valuation account that is deducted from the accounts receivables’ ~~amortized~~ cost basis on the Company’s ~~condensed~~ consolidated balance sheets. The Company’s accounts receivables are generated from the sales revenue derived from the Company’s Benchtop Laboratory Equipment and Bioprocessing Systems segments. The Company elected to estimate expected losses using an analytical model based on methods that utilize the accounts receivable aging schedule. This analytical model incorporates historical loss activity, geographic location, customer-specific information, collection terms and customer amounts. The Company evaluates the estimated allowance on an aggregate basis as each individual account receivable shares similar risk characteristics. Upon adoption of ASC 326 using the modified retrospective transition method and as of December 31, 2023, the Company determined that the allowance for credit losses, if any, is immaterial as of adoption date and the Company will continue to evaluate the accounts receivable portfolio on an on-going basis.

The allowance for credit ~~doubtful accounts~~ losses as of December 31, ~~2024~~2025 and ~~2023~~2024 was $8,300 and $15,600, respectively.

Investment Securities

The Company’s investment securities are classified as mutual funds and ~~are held as available-for-sale and~~ recorded at fair value. Changes in fair value of mutual funds are recorded as net unrealized gains or losses in other income (loss), net on the consolidated statement of operations and comprehensive loss.

The Company determines the cost of the investment sold based on an average cost basis at the individual security level and ~~record~~records the interest income and realized gains or losses on the sale of these investments in other income, net on the consolidated statement of operations and comprehensive loss.

Inventories

Current and noncurrent inventories recorded other than those of Aquila, are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. Inventories of Aquila are valued at the lower of cost (determined on a average cost method) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The Company’s inventory allowance is based on management’s estimates and reviews of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead. As needed, the Company may purchase critical raw materials that are used in the core production process in quantities that exceed anticipated consumption within the normal operating cycle, which is 12 months. The Company classifies such raw materials that the Company does not expect to consume within the normal operating cycle as noncurrent.

Property and Equipment

Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter.

F-11

Table of Contents

Goodwill and Finite Lived Intangible Assets and Long-Lived Assets, Net

Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and long-lived intangible assets are tested for impairment at least annually in accordance with the provisions of ~~Accounting Standards Codification (“~~ASC”) No. 350, “Intangibles- Goodwill and Other” (“ASC No. 350”). ASC No. 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit.

As of December 31, ~~2024~~2025, the Company had two reporting units, the Benchtop Laboratory Equipment Operations and the Bioprocessing Systems Operations. Goodwill is tested for impairment by reporting unit on an annual basis as of December 31, the last day of its fiscal year, and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered in the Company’s goodwill impairment testing include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. The fair value is determined using the income approach, which utilizes the present value of expected future cash flows for each reporting unit based on estimate future cash flows, the timing of these cash flows, and a discount rate based on a weighted average cost of capital. The assumptions used to estimate future cash flows and the development of forecasts used in the fair value determination were based on assumptions made using the best information available at the time, subject to inherent risk and judgement. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. To the extent additional information arises, market conditions change, or our strategies change, it is possible that the conclusion regarding whether our remaining goodwill is impaired could change and result in future goodwill impairment charges that will have a material effect on our consolidated financial position or results of operations.

During the year ended December 31, ~~2024~~2025, the Company elected to perform the qualitative analysis for the Benchtop Laboratory Equipment Operation reporting unit. This qualitative analysis evaluated factors, including, but not limited to, economic, market and industry conditions, cost factors and the overall financial performance of the reporting unit. In completing these assessments, the Company noted no changes in events or circumstances that indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount.

As of December 31, ~~2024~~2025 and ~~2023~~2024 there was no remaining goodwill to the Bioprocessing System Operations reporting unit.

Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, intellectual property in-process research and development (“IPR&D”), trademarks and trade names. All intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization. The Company reviews the recoverability of our finite-lived intangible assets and long-lived assets, when events or conditions occur that indicate a possible impairment exists. Determining whether impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. The assessment for recoverability is based primarily on our ability to recover the carrying value of its long-lived and finite-lived intangible assets from expected future undiscounted net cash flows. If the total of expected future undiscounted net cash flows is less than the total carrying value of the assets the asset is deemed not to be recoverable and possibly impaired. We then estimate the fair value of the asset to determine whether an impairment loss should be recognized. An impairment loss will be recognized if the asset’s fair value is determined to be less than its carrying value. Fair value is determined by computing the expected future discounted cash flows.

F-12

Table of Contents

Impairment of Long-Lived Assets

The Company follows the provisions of ASC No. 360-10, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC No. 360-10”). ASC No. 360-10 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If ~~required~~such assets are considered to be impaired, anthe impairment ~~charge~~to be recognized is ~~recorded~~measured ~~based~~by onthe anamount ~~estimate~~that the carrying amount of ~~future~~the ~~discounted~~assets ~~cash~~exceeds ~~flows~~the fair value of the assets. The Company concluded that as of December 31, ~~2024~~2025, ~~and~~an ~~2023~~impairment loss of $291,000 ~~respectively~~was required against long-lived intangible by the Company's Bioprocessing Systems Operations reporting unit as of December 31, ~~there~~2025. There was no impairment recorded by the Company as of ~~long-lived~~December ~~assets~~31, 2024.

Leases

The Company accounts for its leases under ASC 842, “Leases”. The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.

The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs.

Advertising

Advertising costs are expensed as incurred. Advertising expense amounted to $~~324~~278,~~600~~000 and $~~474~~324,~~200~~600 for the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

Research and Development

Research and development costs consisting of expenses for activities that are useful in developing and testing new products, as well as expenses that may significantly improve existing products, are expensed as incurred.

Stock Compensation Plan

Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. With limited exceptions, the amount of compensation cost is measured based on the grant-date fair value of the equity or liability instruments issued. In addition, liability awards are measured at each reporting period. Compensation costs are recognized over the period that an employee provides service in exchange for the award.

F-13

Table of Contents

The Company estimates the fair value of each stock-based grant using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award. The estimate expected term is based on management’s analysis of historical exercise activity. The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term. The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future. The Company has elected to account for forfeitures only when they occur.

Foreign currency translation and transactions

The Company has determined that the functional currency and reporting currency for its Aquila operations in Germany is the Euro and the U.S. Dollar, respectively. All assets and liabilities of Aquila are translated at the current exchange rate as of the end of the reporting period, and revenue and expenses are translated at average exchange rates in effect during the period with the resulting gain or loss reflected as a foreign currency cumulative translation adjustment and reported as a component of accumulated other comprehensive income (loss). Gains and losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income.

Income taxes

ASC ~~No.~~ 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC ~~No.~~ 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.

The Company recognizes interest and penalties on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits. The Company is subject to U.S. federal income tax, as well as various state jurisdictions. The Company is currently open to audit under the statute of limitations by the federal and state jurisdictions for the fiscal years ended June 30, ~~2021~~2022 and after. The Company is currently open to audit under the statute of limitations by German tax authorities for the years ended December 31, ~~2019~~2020 and thereafter. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

Earnings (Loss) Per Common Share

Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings or loss per common share includes the dilutive effect of stock options and warrants, if any. The Company was in a net loss position for ~~during~~ the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively, therefore the basic loss per share is the same as dilutive loss per share as the inclusion of the weighted-average number of all potential dilutive common shares which consists of stock options and warrants are anti-dilutive.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation.

Recent Accounting Pronouncements not yet adopted

In ~~December~~July ~~2023~~2025, the FASB issued ASU ~~2023~~2025-0905, ~~Income~~ ~~Taxes~~“Financial Instruments - ~~Improvements~~Credit toLosses ~~Income~~(Topic ~~Tax~~326): ~~Disclosures.~~Measurements ~~This~~of ~~standard~~Credit ~~includes~~Losses ~~enhanced~~for ~~income~~Accounts ~~tax~~Receivable ~~disclosures~~and ~~primarily~~Contract Assets”, which provides a practical expedient related to the ~~effective~~estimation ~~tax~~of ~~rate~~expected ~~reconciliation~~credit losses for current accounts receivable and ~~income~~current ~~taxes~~contract ~~paid~~assets that arise from transactions accounted for ~~annual~~under ~~periods~~ASC 606, “Revenue from Contracts with Customers”. ~~The~~Under ~~amendments~~ASU in2025-05, ~~this~~an ~~update~~entity is required to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collection are ~~effective~~evaluated. The ~~for~~ASU ~~public~~is ~~companies~~effective ~~with~~for ~~fiscal~~annual ~~years~~reporting periods beginning after December 15, ~~2024~~2025, ~~with~~and ~~early~~interim ~~adoption~~reporting ~~permitted.~~periods ~~The~~within ~~Company~~those ~~has~~annual ~~not~~reporting ~~early~~periods. ~~adopted~~The ~~and~~Company ~~adoption~~is ofcurrently ~~this~~evaluating ~~standard~~ASU is2025-05 ~~not~~to ~~expected~~determine tothe ~~have~~impact ait ~~material~~may ~~impact~~have on ~~the~~its ~~Company’s~~ consolidated financial statements.

In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270)”, which is intended to improve the navigability of the guidance in ASC 270, “Interim Reporting”, and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides interim financial statements and notes in accordance with U.S. GAAP. ASU 2025-11 also addresses the form and content of such financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2025-11 to determine the impact it may have on its consolidated financial statements.

F-14

Table of Contents

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” and in January 2025, the FASB issued ASU No. 2025-01, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date”, which clarified the effective date of ASU 2024-04. The ASU requires, among other things, more detailed disclosures about types of expenses in commonly presented expense captions such as cost of sales and selling, general and administrative expenses and is intended to improve the disclosures about an entity's expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization. ASU 2024-03 will also require the Company to disclose both the amount and the Company's definition of selling expenses. The guidance, as clarified by ASU 2025-01, is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, on a prospective or retrospective basis. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our disclosures.

There are no other recent accounting pronouncements issued but not yet adopted that would have a material effect on our consolidated financial statements.

3. Fair Value of Financial Instruments

The Company follows ASC 820, “Fair Value Measurement”, which has defined the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets

Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly

Level 3 Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. For Level 3 instruments, where observable inputs are not available, the fair value was determined based on the price shares were purchased and redeemed as of December 31, 2025 by the funds. These investments which seek high current income, comprise of private credit funds which deal in first lien senior secured debt and asset based lending in the United States that are issued in private offerings. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.

The carrying amounts of cash, cash equivalents, accounts receivable, and accounts payable approximate their fair value due to their short-term maturity and insignificant risk of value changes.

F-15

Table of Contents

The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, according to the valuation techniques the Company used to determine their fair values:

	Fair Value Measurements as of December 31, 2024
	Fair Value Measurements as of December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Investment securities - Mutual Funds	$	1,985,000	$	-	$	-	$	1,985,000
Investment securities
Total	$	1,985,000	$	-	$	-	$	1,985,000
Mutual funds	$	5,198,600	$	-	$	-	$	5,198,600
Private Credit Funds			$	-	$	506,400	$	506,400
Total	$	5,198,600	$	-	$	506,400	$	5,705,000

	Fair Value Measurements as of December 31, 2023
	Fair Value Measurements as of December 31, 2024
	Level 1		Level 2		Level 3		Total
Assets:
Investment securities – Mutual Funds	$	4,928,700	$	-	$	-	$	4,928,700
Investment securities – Mutual funds	$	1,985,000	$	-	$	-	$	1,985,000
Total	$	41,~~928~~985,~~700~~000	$	-	$	-	$	41,~~928~~985,~~700~~000

Investments in marketable securities by security type as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, consisted of the following:

As of December 31, 2024:	Cost		Fair Value		Unrealized HoldingGain
As of December 31, 2025:	Cost		Fair Value		Unrealized HoldingGain(Loss)
Mutual funds	$	15,~~729~~198,000	$	15,~~985~~198,~~000~~600	$	~~256,000~~(600	)
Total	$	1,729,000	$	1,985,000	$	256,000
Private Credit Funds	$	504,600	$	506,400	$	(1,800	)
Total	$	5,702,600	$	5,705,000	$	(2,400	)

As of December 31, 2023:

Cost

Fair Value

Unrealized Holding Gain (Loss)

As of December 31, 2024:

Cost

Fair Value

Unrealized HoldingGain (Loss)

Mutual funds

41,~~929~~729,~~300~~000

41,~~928~~985,~~700~~000

~~(600~~256,000

)

Total

41,~~929~~729,~~300~~000

41,~~928~~985,~~700~~000

~~(600~~256,000

)

The table below presents a reconciliation of all assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2025 and 2024

F-16

Table of Contents

	Collateralized Debt Obligations
	2025		2024
Balance of recurring Level 3 assets at January 1	$	-	$	-
Total gains or losses for the period:
Purchases		500,000		-
Sales		-		-
Issuances		-		-
Settlements		6,400		-
Transfers into Level 3				-
Transfers out of Level 3		-		-
Balance of recurring Level 3 assets at December 31	$	506,400	$	-

4. Inventories

	As of December 31,
	2024		2023
	2025		2024
Raw materials	$	3892,~~015,700~~200	$	31,~~436~~200,~~300~~500
Work-in-process		28,500		23,200
Finished goods		856,100		1,368,100
Finished goods		1,551,200		2,033,400
Total Inventories	$	1,748,300	$	2,568,600
Total Inventories	$	4,595,400	$	5,492,900
Inventories - Current Asset	$	1,401,500	$	2,059,100
Inventories - Current Asset	$	4,085,900	$	4,883,900
Inventories - Noncurrent Asset		346,800		509,500
Inventories - Noncurrent Asset		509,500		609,000

5. Property and Equipment, Net

	Useful Lives		As of December 31,
	(Years)		~~2024~~2025		~~2023~~2024
Automobiles	5		$	22,000	$	22,000
Computer equipment		3-5	$	459,800	$	475,000
Computer equipment	3-5			475,000		497,300
Machinery and equipment		3-7		1,167,200		1,084,300
Machinery and equipment	3-7			1,664,000		1,624,300
Furniture and fixtures		4-10		44,100		103,700
Furniture and fixtures	4-10			106,600		108,500
Leasehold improvements		3-10		287,400		257,400
Leasehold improvements	3-10			257,400		279,600
				1,958,500		1,920,400
				2,525,000		2,531,700
Less accumulated depreciation			$	1,267,600	$	1,124,100
Less accumulated depreciation			$	1,640,000	$	1,449,400
Property and Equipment, Net			$	690,900	$	796,300
Property and Equipment, Net			$	885,000	$	1,082,300

Depreciation expense was $~~243~~258,~~000~~500 and $~~240~~243,~~900~~000 for the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

~~During~~Certain ~~the~~Property ~~year~~and ~~ended~~Equipment ~~December~~were ~~31,~~sold ~~2024~~as ~~and~~part ~~2023,~~of ~~respectively,~~ the ~~Company~~sale ~~wrote~~of ~~off~~the ~~fully~~Genie ~~depreciated~~Division ~~property~~ and ~~equipment~~are ~~assets~~presented ~~for~~within the ~~cost~~Gain ~~amount~~on Sale of ~~$29,600~~Discontinue ~~and~~Operations ~~$38,600~~as ~~and~~further ~~for~~discussed ~~the~~in ~~accumulated~~note ~~depreciated amount of $29,600 and $38,600, respectively~~17.

6.During ~~Goodwill~~the year ended December 31, 2025, the Company wrote off fully depreciated property and ~~Finite~~equipment ~~Lived~~assets ~~Intangible~~for ~~Asset~~the cost amount of $180,100 and for the accumulated depreciated amount of $180,100.

~~Goodwill~~During ~~represents~~ the ~~excess~~year ofended ~~the~~December ~~purchase~~31, ~~price~~2024, ~~over~~ the ~~fair~~Company ~~value~~wrote ofoff ~~the~~fully ~~net~~depreciated ~~assets~~property ~~acquired~~and inequipment ~~connection~~assets ~~with~~for the ~~Company’s~~cost ~~acquisitions.~~amount ~~Goodwill~~of ~~amounted to~~ $~~115~~29,~~300~~600 asand offor ~~December~~the ~~31,~~accumulated ~~2024~~depreciated ~~and~~amount ~~2023, respectively, all~~ of ~~which is expected to be deductible for tax purposes~~$29,600.

6. Goodwill and Finite Lived Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $115,300 as of December 31, 2025 and 2024, respectively, all of which is expected to be deductible for tax purposes.

F-17

Table of Contents

The components of finite lived intangible assets are as follows:

	Useful Lives	Cost		Accumulated Amortization		Net
As of December 31, 2024
As of December 31, 2025
Technology, trademarks	3-10 yrs.	$	1,216,800	$	1,~~020~~216,~~100~~800	$	~~196,700~~-
Trade names	3-6 yrs.		592,300		~~417~~592,300		~~175,000~~-
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		~~221~~372,200		~~151,000~~-
Sublicense agreements	10 yrs.		294,000		294,000		-
Non-compete agreements	4-5 yrs.		1,060,500		~~993~~1,~~200~~060,500		~~67,300~~-
Patents	5-7 yrs.		~~605~~408,~~600~~800		~~443~~305,300		~~162~~103,~~300~~500
		$	4,~~351~~154,~~400~~600	$	34,~~599~~051,100	$	~~752~~103,~~300~~500
	Useful Lives	Cost		Accumulated Amortization		Net
As of December 31, 2023
Technology, trademarks	3-10 yrs.	$	1,216,800	$	870,900	$	345,900
Trade names	3-6 yrs.		592,300		341,600		250,700
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		193,600		178,600
Sublicense agreements	10 yrs.		294,000		294,000		-
Non-compete agreements	4-5 yrs.		1,060,500		797,600		262,900
Patents	5-7 yrs.		595,800		384,000		211,800
		$	4,341,600	$	3,091,700	$	1,249,900

Total amortization expense was $507,700 and $513,100 for the years ended December 31, 2024 and 2023, respectively.

	Useful Lives	Cost		Accumulated Amortization		Net
As of December 31, 2024
Technology, trademarks	3-10 yrs.	$	1,216,800	$	1,020,100	$	196,700
Trade names	3-6 yrs.		592,300		417,300		175,000
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		221,200		151,000
Sublicense agreements	10 yrs.		294,000		294,000		-
Non-compete agreements	4-5 yrs.		1,060,500		993,200		67,300
Patents	5-7 yrs.		408,800		252,800		156,000
		$	4,154,600	$	3,408,600	$	746,000

~~Estimated~~Total ~~future~~ amortization expense ofwas ~~intangible~~$351,500 ~~assets~~and as$507,700 offor the years ended December 31, ~~2024~~2025 isand as2024, ~~follows:~~respectively.

As of December 31,
2025	$	373,500
2026		193,900
2027		97,900
2028		43,700
2029		28,300
Thereafter		13,000
Total	$	752,300

During the year ended December 31, 2025 the Company assessed the recoverability of intangible assets, consisting primarily of customer relationships, technologies, software and trademarks, for impairment in accordance with ASC 350-360. It was determined that the future cash flows from these assets are lower than the carrying amount on the consolidated balance sheet. Therefore, an impairment charge of $291,000 was recorded for the SBHI unit intangible assets.

7.Estimated ~~Line~~future amortization expense of ~~Credit~~intangible assets as of December 31, 2025 is as follows:

The Company has a Demand Line of Credit through December 2025 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at 7.50%. The agreement does not contain any financial covenants and borrowings are secured by a pledge of the Company’s assets including inventory, accounts receivable, chattel paper, equipment and general intangibles of the Company. The borrowings outstanding under the line of credit as of December 31, 2024 and 2023 were $0 and $50,000, respectively.

As of December 31,
2026	$	44,200
2027		43,900
2028		15,400
Total	$	103,500

F-18

Table of Contents

7. Line of Credit

As of December 31, 2025 the Company had terminated its Demand Line of Credit with First National Bank of Pennsylvania which had provided borrowings up to $300,000 for regular working capital needs and bore interest at the U.S. Prime Rate. The line of credit was secured by a pledge of the Company's assets and as a result of the sale of the Genie® Division of the Benchtop Laboratory Equipment Operations on August 7, 2025, the Company terminated the line of credit. There were no borrowings outstanding as of December 31, 2025 or 2024.

8. Commitments and Contingencies

Legal Matters

~~During~~The ~~the normal course of business, the~~ Company may be named from time to time as a party to claims and ~~litigations~~litigation arising in the ordinary course of business. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with ASC 450, “Contingencies”. Litigation and contingency accruals are based on our assessment, including advice of legal counsel, regarding the expected outcome of litigation or other dispute resolution proceedings. If the Company determines that an unfavorable outcome is probable and can be reasonably assessed, it establishes the necessary accruals. As of December 31, ~~2024~~2025, the Company is not aware of any contingent legal liabilities that should be reflected in the consolidated financial statements.

Employment Agreements

The Company has an employment agreement with its Chief Executive Officer ~~and~~ /President, which expires on June 30, ~~2025~~2026. The agreement contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for “cause” or the Chief Executive Officer/President terminates the employment for “good reason”, the Chief Executive Officer/President will have the right to receive a lump sum payment equal to three times the average of their total annual compensation paid for the last five years preceding such termination. The employment agreement also contains a termination ~~provisions~~provision stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if the relevant employee resigns for “good reason” (as such term is defined therein), the Company shall pay severance payments equal to one year’s salary at the rate of the compensation at the time of termination, and continue to pay the regular benefits provided by the Company for a period of one year from termination.

The Company has an employment agreement with its ~~Chief Financial Officer~~Chairman, which expires on June 30, ~~2025~~2026. The ~~agreement contains a provision that within one year of a change of control, if either the Company terminates the~~ employment for any reason other than for “cause” or the employee terminates the employment for “good reason”, the employee will have the right to receive a lump sum payment equal to one times the average of their total annual compensation paid for the last five years preceding such termination. The employment agreement ~~also~~ contains a termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if the ~~relevant~~ employee resigns for “good reason” (as such term is defined ~~therein~~in the agreement) , the Company shall pay severance payments equal to ~~one~~six ~~year~~months’s salary. atThe ~~the~~Company ~~rate~~will ofcontinue to pay the ~~compensation~~regular atbenefits provided by the ~~time~~Company offor ~~termination,~~the ~~and~~period ~~continue~~equal to ~~pay~~ the ~~regular~~length ~~benefits~~of ~~provided~~the byseverance ~~the~~payments ~~Company~~and ~~for~~pay a ~~period~~pro rata portion of ~~one~~any ~~year~~bonus ~~from~~achieved prior to such termination of employment.

The Company has an employment ~~agreement~~agreements with ~~its Chairman, which expires on June 30, 2024. The employment agreement contains termination provisions stipulating that if~~ the ~~Company~~Chief ~~terminates~~Executive ~~the~~Officer ~~employment~~of ~~other~~Aquila ~~than~~and ~~for~~three ~~death,~~managing ~~disability,~~directors orof ~~cause~~Aquila ~~(as such term is defined therein), or if the employee resigns~~ for ~~“good~~an ~~reason”(as~~indefinite ~~such~~ term ~~is defined in the agreement)~~ , ~~the~~which ~~Company~~can ~~shall~~be ~~pay~~terminated ~~severance~~by ~~payments equal to~~ either ~~one~~party ~~year’s~~upon ~~salary~~a attwelve ~~the~~month ~~rate~~written ofnotice ~~the~~for ~~compensation at~~ the ~~time~~Chief ofExecutive ~~termination~~Officer isand ~~employee~~a ~~is terminated within 12 months of the date of the agreement or~~ six ~~months’~~month ~~salary~~written isnotice ~~the employee is terminated after 12 months of the date of the agreement. The Company will continue to pay the regular benefits provided by the Company~~ for the ~~period~~three ~~equal~~managing todirectors, ~~the~~in ~~length~~accordance ofwith ~~the~~German ~~severance payments and pay a pro rata portion of any bonus achieved prior to such termination of employment~~law.

The Company has an employment ~~agreements~~agreement with the ~~Chief~~President ~~Executive~~of ~~Officer~~the Torbal® Division of ~~Aquila~~the ~~and~~Benchtop ~~three~~Laboratory ~~managing~~Equipment ~~directors~~Operations, ofwhich ~~Aquila~~expires ~~for~~on anDecember ~~indefinite~~31, ~~term~~2028, which ~~can~~may be ~~terminated~~extended byfor ~~either~~two ~~party~~additional ~~upon~~one-year aperiods ~~twelve~~unless ~~month~~and ~~written~~until the Company or the employee provides no less than ninety days’ notice ~~for~~prior to the ~~Chief~~end ~~Executive~~of ~~Officer~~the ~~and~~term. The agreement contains a ~~six~~provision ~~month~~that ~~written~~if ~~notice~~the Company terminates the employment for any reason other than for “cause” or the employee terminates the employment for “good reason” as defined in the agreement, the employee will have the right to receive a lump sum payment equal to three ~~managing~~times ~~directors~~the then current annual compensation preceding such termination, inplus ~~accordance~~any ~~with~~accrued ~~German~~and ~~law~~unused vacation and sick time, and health benefits for twelve months following the termination. The ~~agreements~~employment ~~include~~agreement also contains a ~~retention~~termination ~~bonus~~provisions ofstipulating 25that if the Company terminates the employment other than for death,~~000~~ ~~euros~~disability, or cause (as such term is defined therein), or if the ~~employees~~relevant doemployee ~~not~~resigns ~~terminate~~for ~~their~~“good ~~employment~~reason” ~~with~~(as such term is defined therein), the Company ~~within~~shall ~~two~~pay ~~years~~severance ~~after~~payments equal to one year’s salary at the ~~agreement~~rate ~~date~~of orthe compensation at the ~~Company~~time ~~does~~of ~~not~~termination, ~~terminate~~and ~~their~~continue ~~employment~~to pay the regular benefits provided by the Company for ~~good~~a ~~cause~~period of one year from termination.

9. Related Parties

Consulting Agreement

On September 19, 2023, the Company’s Bioprocessing System segment entered into a one year consulting agreement with John Nicols, ~~which~~a ~~renewed~~Director ~~for~~of ~~one~~the ~~year~~Company, onwith ~~September~~automatic 19renewals, ~~2024~~unless either party gives a thirty-day notice. The agreement provided that the consultant be paid a monthly retainer fee of $8,000. ~~For the year ended December 31, 2023, the Company paid fees of $19,200~~ and issued 35,000 stock options which vested monthly over a one year period, valued at $114,700 on the grant date using the Black-Scholes-Merton option pricing model. For each of the ~~year~~years ended December 31, 2025 and 2024, the Company paid fees under the consulting agreement of $96,000, respectively.

F-19

Table of Contents

10. Leases

The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) which was amended in September 2021 to increase the space by approximately 25% and extend the lease term through October 2028. The Company leased a 1,200 square foot facility in Orangeburg, New York where it conducted its sales and marketing functions, primarily for the Torbal® Products Division of the Benchtop Laboratory Equipment operations, which expired at the end of October 2024 and was not renewed and continued as a monthly lease through the end of December 31, 2024. On January 1, 2025, the Company entered into a lease for a 220 square foot facility in Pearl River, New York where it conducts its sales and marketing functions, primarily for the Torbal® Products Division of the Benchtop Laboratory Equipment operations, expiring in December 2027. The Company’s Bioprocessing Systems operations are conducted in co-sharing office space in Pittsburgh, Pennsylvania, ~~expiring~~which expired in March 2025 ~~with~~and ~~option~~is currently on a month-to-month ~~renew~~basis, and a 5,252 square foot facility in Baesweiller, Germany, the lease which was renewed in December ~~2023~~2025 to extend the lease term to December 31, ~~2025~~2027, comprised of manufacturing, engineering, and administrative space. InThe ~~August and September 2022, the~~ Company entered into ~~two~~various lease agreements to lease motor vehicles ~~for~~and ~~certain~~other ~~employees~~equipment. The contractual period of each vehicle lease is generally 36 months and the ~~lease~~leases ~~was~~were determined to qualify for operating lease treatment upon the lease commencement date. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities. Any rent escalations incorporated within the Company’s leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases.

	As of December 31, 2024			As of December 31, 2023
	As of December 31, 2025			As of December 31, 2024
Weighted Average Years		32.5773			43.3557
Weighted Average Discount		5.2710	%		5.4327	%

	Year ended December 31, 2024		Year ended December 31, 2023
	Year ended December 31, 2025		Year ended December 31, 2024
Total Cash Payment	$	381,200	$	334,600
Total Lease Expense	$	257,100	$	326,600
Total Cash Payments	$	408,400	$	381,200

The Company’s approximate future minimum rental payments under all operating leases as of December 31, ~~2024~~2025 are as follows:

Year ended December 31,	Amount
For the years ended December 31,	Amount
2025	$	354,200
2026	$	418,800
2026		266,600
2027		409,200
2027		274,600
2028		209,400
2028		201,000
Total future minimum payments	$	1,037,400
Total future minimum payments	$	1,096,400
Less: Imputed interest		(60,000	)
Less: Imputed interest		(94,700	)
Total Present Value of Operating Lease Liabilities	$	977,400
Total Present Value of Operating Lease Liabilities	$	1,001,700

11. Loss Per Common Share

~~The~~Basic ~~Company~~Earnings ~~presents~~Per ~~the~~Share ~~computation of earnings per share~~ (“EPS”) ~~on a basic basis. Basic EPS~~ is computed by dividing net income or loss by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed ~~similarly~~similar to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive. The following table sets forth the weighted average number of common shares outstanding for each period presented.

F-20

Table of Contents

	Year ended December 31,			Year endedDecember 31,
	2024			2023
	2025			2024
Weighted average number of common shares outstanding		1011,~~503~~344,~~599~~823			10,~~145~~503,~~211~~599
Effect of dilutive securities:		-			-
Weighted average number of dilutive common shares outstanding		1011,~~503~~344,~~599~~823			10,~~145~~503,~~211~~599
Basic and diluted loss per common share:
Continuing operations	$	(0.6116	)	$	(10.2776	)
Discontinued operations	$	0.05		$	0.15
Consolidated operations	$	(0.6111	)	$	(10.2761	)

Approximately 12,~~835~~246,~~447~~100 and 8,~~232~~111,~~510~~700 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended December 31, ~~2024~~2025. Approximately 55,000 total options and warrants were excluded from the calculation for Discontinued operations because the effect of such securities is anti-dilutive because they are out of the money.

Approximately 1,~~120~~835,~~097~~400 and 78,~~856~~232,~~203~~500 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended December 31, ~~2023~~2024. There were no options and warrants excluded from the calculation for Discontinued operations because the effect of such securities is anti-dilutive because they are out of the money.

12. Common Stock and Warrants

Authorized Shares

OnThe ~~February 25, 2022, at the~~ Company’s ~~Annual~~total ~~Stockholders Meeting, the stockholders of the Company approved an amendment to its Certificate of Incorporation to increase the~~ number of authorized shares of ~~the Company’s common stock, par value $0.05 per share (“~~Common Stock”) byare 530,000,000 ~~shares~~since November ~~from 15~~29,~~000,000~~ to2023 ~~20,000,000~~as ~~shares~~approved by majority shareholders’ consent.

AtThe ~~such~~shareholders ~~Annual Stockholders Meeting, the stockholders also approved an amendment to the Company’s 2012 Stock Option Plan (the “2012 Plan”) to increase the number~~ of ~~shares of Common Stock available under~~ the ~~Plan by 943,000 shares, from 307,000 to 1,250,000 shares, which, together with 150,000 shares that were added to the 2012 Plan in 2020, were registered by the~~ Company ~~on a Form S-8 Registration Statement with the Securities and Exchange Commission on March 15, 2021. In addition, the stockholders also~~ approved the adoption of the Company’s 2022 Equity Incentive Plan (the “2022 Plan”) providing for the issuance of up to 1,750,000 shares of Common Stock plus outstanding options granted under the Company’s 2012 Stock Option Plan that expire or are forfeited. The 2022 Plan provides various stock awards including incentive and nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards, which can be awarded to employees and directors of the Company and its subsidiaries. Subsequent to year end at the Annual Meeting of Shareholders on January 22, 2026 the shareholders approved an amendment to the Company’s 2022 Plan to increase the number of shares of Common Stock available for issuance thereunder to 3,750,000.

On November 29, 2023, the board of directors of the Company adopted a resolution approving a certificate of amendment to the Company’s Certificate of Incorporation, as amended, to increase in the number of authorized shares of Common Stock from 20,000,000 shares of Common Stock, to 30,000,000 shares of Common Stock, (the “Authorized Capital Increase”). On December 7, 2023, the Company obtained the written consent of stockholders of the Company holding greater than 50% of the voting securities of the Company approving the Authorized Capital Increase.

F-21

Table of Contents

Issuance and Sale of Common Stock

2023 Securities Purchase Agreement

On December 13, 2023, the Company entered into a Securities Purchase Agreement (“the 2023 Purchase Agreement”) with certain investors (collectively, the “Investors”) pursuant to which the Investors agreed to subscribe and purchase up to 3,500,000 Units at a price per Unit of $2.00, or an aggregate purchase price of $7,000,000 at ~~one~~which orincluded ~~more~~warrants ~~closings~~ (the “~~Offering”), with each Unit comprised of (a) one newly-issued share of Common Stock, par value $0.05 per share (the “Shares”), and (b) a warrant (the “~~Warrants”) to purchase either 100% or 160%, depending on the number of Units purchased by an Investor, of the number of shares of Common Stock included in the Units purchased by an Investor (the “Warrant Shares”) at an exercise price of $2.50 per share. The Warrants ~~are~~were immediately exercisable and expire five years from their date of issuance. If at any time commencing 12 months from the date of the issuance of a Warrant, but before the expiration of the Warrant, the volume weighted average pricing of the Company’s common stock exceeds $5.00 (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like) for each of thirty consecutive trading days, then the Company may, at any time in its sole discretion, call for the exercise of the Warrants, in their entirety.

On ~~December~~January 1317, ~~2023~~2024, the Company ~~issued~~completed ~~and~~the last closing of its sale of securities pursuant to the 2023 Purchase Agreement discussed above. On this closing, the Company sold an aggregate of 2358,~~638,076~~388 Units, ~~comprised~~comprising ~~of 2~~358,~~638,076~~388 shares of the Company’s common stock and Warrants to purchase 3358,~~673,076~~388 ~~Warrant~~shares ~~Shares~~of Common Stock for a total consideration of $5716,~~276,152 pursuant to the Company’s 2023 Purchase Agreement~~776. The Company recognized $~~970~~98,~~200~~700 of issuance cost, which includes $~~427~~71,~~500~~100 attributable to legal and placement agent fees and $~~542~~27,~~700~~600 attributable to the fair value of ~~131,904~~ warrants, issued to the ~~private~~ placement agent, to purchase up to ~~131~~17,~~904~~919 shares of Common Stock at an exercise price of $2.00 per share on substantially the same terms as the Warrants issued to the ~~Investors. The~~purchasers ~~Company intends to use the net proceeds from the sale~~ of ~~the~~ Units ~~for working capital needs of its Bioprocessing Systems Operations~~.

On2025 ~~December~~Securities 19, 2023, and December 20, 2023 the Company sold an aggregate of 432,935 and 70,601 Units, respectively, comprised of 432,935 and 70,601 shares of the Company’s Common Stock and Warrants to purchase 432,935 and 70,601 shares of Common Stock for a total consideration of $865,870 and $141,202, respectively, pursuant to the Company’s 2023 Purchase Agreement. The Company recognized $206,900 of issuance cost, which includes $104,500 attributable to legal and placement agent fees and $102,400 attributable to the fair value of 25,177 warrants, issued to the private placement agent, to purchase up to 25,177 shares of Common Stock at an exercise price of $2.00 per share on substantially the same terms as the Warrants issued to the Investors. The Company intends to use the net proceeds from the sale of the Units for working capital needs of its Bioprocessing Systems Operations.

~~2024~~On April 18, 2025, the Company entered into a Securities Purchase Agreement (the “April 2025 Purchase Agreement”) with certain investors (each an “April Investors”) pursuant to which the Company sold in a private placement, and the April Investors purchased, an aggregate of 1,550,000 units, which comprised of (i) 1,050,000 shares of the Company’s Common Stock, (ii) pre-funded warrants to purchase 500,000 shares of Common Stock, and (iii) warrants to purchase 1,550,000 shares of Common Stock, for a total consideration of $1,550,000. The Company recognized $97,800 of issuance costs, which was attributable to legal and placement agent fees.

On January 17, 2024, the Company completed the last closing of its sale of securities pursuant to the 2023 Purchase Agreement. On this closing, the Company sold an aggregate of 358,388 Units, comprising 358,388 shares of the Company’s common stock, par value $0.05 per share (“Common Stock”) and warrants (“Warrants”) to purchase 358,388 shares of Common Stock for a total consideration of $716,776. The Company recognized $98,700 of issuance cost, which includes $71,100 attributable to legal and placement agent fees and $27,600 attributable to the fair value of warrants, issued to the placement agent, to purchase up to 17,919 shares of Common Stock at an exercise price of $2.00 per share on substantially the same terms as the Warrants issued to the purchasers of Units (“Investors”).

Warrants

In connection with a private placement transaction completed on April 18, 2025, the Company issued 1,050,000 of common stock and 500,000 pre-funded warrants to purchase common stock at an exercise price of $1.00 per share. The warrants are immediately exercisable, have no expiration date and are subject to a beneficial ownerhip limitation of 9.99%. In October 2025, an additional 125,000 prefunded warrants were issued in connection with warrant exercises under the same terms.The warrants are classified in equity pursuant to ASC 480 and ASC 815-40 as they are indexed to the Company’s own stock and require settlement in a fixed number of shares.

As of December 31, 2025, 625,000 pre-funded warrants remain outstanding. These warrants are included in both basic and diluted EPS as they are exercisable for nominal amount and are considered common stock equivalents

Replacements Warrants

As an incentive to certain Investors of the Company who participated in previous private placements (“Existing Investors”) and received as part of those financings, warrants (“Outstanding Warrants”) to purchase shares of Common Stock, the Company agreed that, if any Existing Investor were to purchase Units at a certain level in the offering thereof under the 2023 Purchase Agreement (the “Offering”), the Company would reduce the exercise price of the Outstanding Warrants held by such Existing Investor to $2.50 per share and extend the period in which such Outstanding Warrants could be exercised to the period ending on the fifth anniversary of the date on which the Existing Investor purchased Units under the 2023 Purchase Agreement. Each such Existing Investor purchasing Units at the requisite level received a new warrant (the “Replacement Warrants”) to replace such Existing Investor’s Outstanding Warrants.

As a result of their December 13, 2023, December 19, 2023, and December 20, 2023 purchase of Units, Existing Investors received Replacement Warrants to replace 1,257,331, 559,905 and 17,631, respectively, of their Outstanding Warrants. The Company measured and recognized a fair value change of $2,112,800 related to the modification and issuance of the Replacement Warrants, recorded as equity issuance cost in the statement of changes in.

F-22

Table of Contents

On January 17, 2024, ascertain ainvestors ~~result of their purchase of Units, Existing Investors~~ became entitled to receive Replacement Warrants to replace 333,884 Outstanding Warrants, with each Replacement ~~Warranting~~Warrant having a reduced exercise price of such Outstanding Warrants of $2.50 per share and exercisable until the fifth anniversary of the relevant closing under the 2023 Purchase Agreement. The Company measured and recognized a fair value change of $423,800 related to the modification and issuance of the Replacement Warrants, recorded as equity issuance cost in the consolidated statement of changes in Shareholders’ equity for the year ended December 31, 2024.

Underwriter Warrants

As part of its compensation as placement agent for the 2023 Purchase Agreement described above, the Company issued to the placement agent or its designees warrants to purchase up to 157,081 shares of Common Stock at an exercise price of $2.00 per share on substantially the same terms as the Warrants issued to the Investors . The Warrants were valued on each closing grant date, using the Black-Scholes-Merton option pricing model and the Company recognized $645,100 as equity issuance cost in the statement of changes in Shareholders’ equity for the year ended December 31, 2024.

During the year ended December 31, 2023, in connection to underwriter/consulting services, the Company issued 100,000 warrants to purchase up to 100,000 shares of Common Stock at an exercise price of $2.50 per share. The Warrants are immediately exercisable and expire five years from their date of issuance. If at any time commencing 12 months from the date of the issuance of a Warrant, but before the expiration of the Warrant, the volume weighted average pricing of the Company’s common stock exceeds $5.00 (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like) for each of thirty consecutive trading days, then the Company may, at any time in its sole discretion, call for the exercise of the Warrants, in their entirety. The Warrants were valued on the grant date of December 13, 2023, using the Black-Scholes-Merton option pricing model and the Company recognized $161,000 as general and administration expense during the year ended December 31, 2023.

Warrant Summary

The following table summarizes information about shares issuable under warrants outstanding during the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

	Warrant Shares Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Life
Outstanding and exercisable as of December 31, 2022		3,422,510		$	8.98		3.10
Issued		6,268,560			2.49		4.96
Exercised		-			-		-
Expired or cancelled		(1,834,867	)		8.87		2.36
Outstanding and exercisable as of December 31, 2023		7,856,203		$	3.82		4.32
Issued		710,191			2.49		4.05
Exercised		-			-		-
Expired or cancelled		(333,884	)		9.03		1.56
Outstanding and exercisable as of December 31, 2024		8,232,510		$	3.505		3.49
Issued		2,050,000			1.00		1.37
Exercised		(375,000	)		1.00		-
Expired or cancelled		(1,795,850	)		4.32		5.19
Outstanding and exercisable as of December 31, 2025		8,111,660		$	3.89		4.88

F-23

Table of Contents

Terms of the outstanding warrants as of December 31, ~~2024~~2025 are as follow:

Warrant Issue Date	Outstanding Warrants		Exercise Price		Expiration Date
6/19/2020		745,850	$	9.00	6/18/2025
4/30/2021		437,997	$	9.50	4/29/2026
6/21/2021		46,313	$	9.50	6/18/2026
3/2/2022		23,599	$	5.50	3/2/2027
12/13/2023		5,030,407	$	2.50	12/13/2028
12/13/2023		131,904	$	2.00	12/13/2028
12/19/2023		992,840	$	2.50	12/19/2028
12/19/2023		21,647	$	2.00	12/19/2028
12/20/2023		88,232	$	2.50	12/20/2028
12/20/2023		3,530	$	2.00	12/20/2028
1/17/2024		692,272	$	2.50	1/17/2029
1/17/2024		17,919	$	2.00	1/17/2029
		8,232,510
4/17/2025		625,000	$	0.0001	Indefinite
		8,111,660

13. Stock Options

The Company’s 2022 Equity Incentive Plan (“2022 Plan”) provides for the issuance of up to 1,750,000 shares of the Company’s Common Stock, par value $0.05 per share, plus outstanding options granted under the Company’s previous 2012 Stock Option Plan that expire or are forfeited. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Nonstatutory stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. Both Incentive and Nonstatutory stock options cliff-vest over five years. As of December 31, 2025, 53,151 combined shares of Common Stock were available for grant of options under the 2022 Plan.

The Company’s 2012 Plan expired in February 2022, which provided for the grant of options to purchase up to 1,193,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”).

The 2012 Plan provided for the granting of incentive or non-incentive stock options. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant and vested as to 1/3 on each of the first, second, and third anniversaries from the grant date. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant.

2022 Plan

The Company’s 2022 Plan provides for the issuance of up to 1,750,000 shares of the Company’s Common Stock, par value $0.05 per share, plus outstanding options granted under the Company’s 2012 Stock Option Plan that expire or are forfeited. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Nonstatutory stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. Both Incentive and Nonstatutory stock options cliff-vest over five years. As of December 31, 2024, 463,848 shares of Common Stock were available for grant of options under the 2022 Plan, of which 231,270 shares of Common Stock are from either terminated or expired options from the 2012 Plan.

F-24

Table of Contents

Salary for Equity Incentive Options

On April 1, 2024 and May 17, 2024, as part of the Company’s strategic initiatives to reduce operating costs and conserve cash for operations, the Company offered a voluntary Salary/Compensation Waiver Program pursuant to which each director, officer and employee of the Company and its subsidiaries could elect to waive a portion of his or her salary/compensation for twelve months and receive separately options to purchase shares of the Common Stock of the Company (the “stock options”). Under this program, the Company issued 10-year options to purchase 628,960 shares of Common Stock, each having an exercise price of $2.50 per share, vesting monthly over twelve months, valued at $948,200 on the grant date using the Black-Scholes-Merton option pricing model, recorded as stock-based compensation during the applicable period.

Equity Cancel and Replacement Options

On April 1, 2024, as part of the Company’s strategic initiatives to incentivize current employees, the Company entered into a cancellation and replacement agreement regarding certain out-of-the money outstanding employee stock options (the “replacement stock options”), whereby employees surrendered out-of-the-money outstanding stock options (“cancelled option awards") and the Company granted replacement stock options in the same number, having an exercise price of $2.50 per share, which replacement options vest monthly over three years from their date of issuance. The Company accounted for the issuance of these replacements options as a modification of the terms of the cancelled option awards and in accordance with ASC 718-20-35-2A the Company will recognize $613,400 stock compensation expense over the three-year vesting period, which was determined by the grant-date fair value of the ~~original~~ award for which the service is expected to be rendered at the cancellation date, plus incremental costs measured as the excess of the fair value of the replacement options on the grant date using the Black-Scholes-Merton option pricing model over the fair value of the cancelled option award at the cancellation date in accordance with ASC 718-20-35-3.

Board of Director Stock Options

On April 12, 2024, the Board of Directors of the Company (the “Board”) appointed Michael Blechman (“Mr. Blechman”) as (i) a Class B Director of the Company, (ii) a member of the Board’s audit committee, (iii) a member of the Board’s compensation committee, and (iv) the Chair and a member of the Company’s Nominating Committee. On May 17, 2024, in connection with such appointment, the Company granted and issued to Mr. Blechman stock options to purchase 25,000 shares of the Common Stock of the Company with an exercise price of $1.75 which vest monthly over three years, valued at $34,500 on the grant date using the Black-Scholes-Merton option pricing model.

On July 1, 2024, the Company granted and issued stock options to purchase 10,000 shares of the Common Stock to each of Christopher Cox, John Nicols, and Jurgen Schumacher, as part of their annual compensation serving as independent Board members of the Company. These stock options have a 10-year life, an exercise price of $1.29, vest 100% one year after the grant date, and valued at $10,400 on the grant date using the Black-Scholes-Merton option pricing model.

On July 1, 2024, the Company granted and issued stock options to purchase 5,000 shares of the Common Stock to each of Michael Blechman, Christopher Cox, and John Nicols, as part of their annual compensation serving as independent Committee ~~Chairmens~~Chairmen of the Company. The stock options have a 10-year life, an exercise price of $1.29, vest 100% one year after the grant date, and valued at $5,200 on the grant date using the Black-Scholes-Merton option pricing model.

On July 1, 2025, the Company granted and issued stock options to purchase 15,000 shares of the Common Stock to each of Michael Blechman, Christopher Cox and John Nicols as well as 10,000 shares to Jurgen Schumacher, as part of their annual compensation serving as independent Board members of the Company. These stock options have a 10-year life, an exercise price of $0.65, vest 100% one year after the grant date, and valued at $9,750 for Blechman, Cox and Nicols and $6,500 for Schumaher on the grant date using the Black-Scholes-Merton option pricing model.

Other Stock Options

On July 21, 2023, the Company’s Bioprocessing System segment entered into a separation agreement with their VP of Sales (“former employee”). In connection with the separation agreement, the Company extended the exercisability of the former employee’s vested stock options up through the ~~original~~ expiration date of July, 13, 2030, which the Company recorded aan additional $684,900 of noncash stock-based ~~base~~ compensation expense related to the modification of the exercisability of the vested stock options.

F-25

Table of Contents

The following table summarizes the weighted-average assumptions used for the Black-Scholes option pricing model to determine the fair value of our stock options for the year ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively:

	Year ended December 31,			Year ended December 31,
	2024			2023
	2025			2024
Expected term (in years)		10			10
Risk-free interest rate		4.2942	%		4.4929	%
Expected volatility		7074.6667	%		7270.5066	%
Dividend rate		0			0

Expected volatility is estimated based on historic volatility of the Company’s common stock. The expected term of the option is estimated based on historic data. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of the grant of the option.

Total stock-based compensation costs were $1520,~~165,400~~700 and $21,~~240~~165,~~100~~400 for the year ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

Stock-based compensation costs related to nonvested awards expected to be recognized in the future are $464,200 and $757,100 as of December 31, 2025 and 2024, respectively.

~~$450,100~~The asweighted-average ofperiod over which the nonvested awards is expected to be recognized are 2.04 years and 1.55 for the year ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

The ~~weighted-average~~following ~~period~~table ~~over~~summarizes ~~which~~option ~~the~~activity ~~nonvested~~under ~~awards~~all isplans ~~expected to be recognized are 1.55 years and 0.87~~ for the year ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.:

The following table summarizes option activity under all plans for the year ended December 31, 2024 and 2023, respectively:

	Year Ended December 31,							Year Ended December 31,
	2025							2024
Shares	Shares			Weighted-Average Exercise Price		Aggregate Intrinsic Value		Shares			Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding, beginning		1,835,447		$	3.58	$	-		1,120,097		$	8.32	$	-
Granted		451,907			0.89		-		1,482,422			2.48		-
Exercised		-			-		-		-			-		-
Forfeited/Cancelled		(41,210	)		2.64		-		(767,072	)		8.31		-
Outstanding, end		2,246,144		$	3.07		-		1,835,447		$	3.58		-

Options exercisable end of the period		1,449,911		$	3.89				943,275		$	4.69
Weighted average fair value per share of options granted during the period				$	0.95						$	2.93

	Year Ended December 31,							Year Ended December 31,
	2024							2023
Shares under option:	Shares			Weighted-Average Exercie Price		Aggregate Instrinsic Value		Shares			Weighted-Average Exercie Price		Aggregate Instrinsic Value
Outstanding, beginning		1,120,097		$	8.32	$	-		1,115,810		$	8.4	$	129,900
Granted		1,482,422			2.48		-		35,000			4.09		-
Exercised		-			-		-		-			-		-
Forfeited/Cancelled		(767,072	)		8.31		-		(30,713	)		6.62		2,500
Outstanding, end		1,835,447		$	3.58		-		1,120,097		$	8.32		-
Options exercisable end of the period		943,275		$	4.69				963,228		$	8.45
Weighted average fair value per share of options granted during the period				$	2.93						$	3.28

F-26

F-26 Table of Contents

	Year Ended December 31,					Year Ended December 31,
	2025					2024
NonVested Shares:	Shares			Weighted-Average Grant Date Fair Value		Shares			Weighted-Average Grant Date Fair Value
Outstanding, beginning		892,172		$	5.13		156,869		$	5.60
Granted		435,240			0.60		1,482,422			2.93
Vested		(517,303	)		4.14		(631,084	)		3.31
Forfeited		(13,333	)		4.30		(116,035	)		6.28
Outstanding, end		796,776		$	3.31		892,172		$	5.13

	Year Ended December 31,					~~Year Ended December 31,~~
	2024					2023
	2025
NonVested Shares under option	Shares			Weighted-Average Grant Date Fair Value		Shares			Weighted-Average Grant Date Fair Value
	Shares			Weighted-Average Exercise price		Weighted-Average Remaining Contractual term
Outstanding, beginning		156,869		$	5.60		483,635		$	6.76
Vested Shares:		1,449,911		$	3.89		7.33
Granted		1,482,422			2.93		35,000			3.28
Vested		(631,084	)		3.31		(351,453	)		6.98
Forfeited		(116,035	)		6.28		(10,313	)		5.09
Outstanding, end		892,172		$	5.13		156,869		$	5.60

	Year Ended December 31,
	2024
	Shares		Weighted-Average Exercise price		Weighted-Average Remaining Contractual term
Vested Shares under option:		943,275	$	4.69		7.79
Vested Shares:		943,275	$	4.69		7.79

	Year Ended December 31,
	2023
	Shares		Weighted-Average Exercise price		Weighted-Average Remaining Contractual term
Vested Shares under option:		963,228	$	8.45		6.47

F-27

F-27 Table of Contents

	As of December 31, 2025 Options Outstanding						As of December 31, 2025 Exercisable
	Number		Remaining Contractual Life		Average Exercise		Number		Remaining Contractual Life		Average Exercise
Range Exercise Price	Outstanding		(Years)		Price		Outstanding		(Years)		Price

$5.35 - $ 11.30		264,320		4.52	$	9.93		264,320		4.52	$	9.93
$2.91 - $ 4.65		84,705		4.12	$	3.60		84,705		4.12	$	3.60
$0.65-$2.50		1,897,119		8.53	$	2.09		1,100,886		8.26	$	2.44
		2,246,144						1,449,911

	As of December 31, 2024 Options Outstanding						As of December 31, ~~2024 Excercisable~~2024Exercisable
	Number		Remaining Contractual Life		Average Exercise		Number		Remaining Contractual Life		Average Exercise
Range Exercise Price	Outstanding		(Years)		Price		Outstanding		(Years)		Price
$5.35 - $ 11.30		264,320		5.52	$	9.93		264,320		5.52	$	9.93
$2.91 - $ 4.65		88,705		4.9	$	3.6		88,705		4.9	$	3.60
$1.29-$2.50		1,482,422		9.26	$	2.45		590,250		9.25	$	2.50
		1,835,447						943,275

	As of December 31, 2023 Options Outstanding						As of December 31, 2023 Excercisable
	Number		Remaining Contractual Life		Average Exercise		Number		Remaining Contractual Life		Average Exercise
Range Exercise Price	Outstanding		(Years)		Price		Outstanding		(Years)		Price
$5.35 - $ 11.30		1,029,392		6.84	$	8.73		893,773		6.84	$	8.18
$2.91 - $ 4.65		90,705		2.29	$	3.61		64,455		2.29	$	3.41
		1,120,097						958,228

14. Segment Information

F-28

Table of Contents

Segment and geographical information is reported as follows

Year Ended December 31, 2024	Benchtop Laboratory Equipment			Bioprocessing Systems			Corporate			Consolidated
Year Ended December 31, 2025	Benchtop Laboratory Equipment			Bioprocessing Systems			Corporate			Consolidated
United States revenue	$	53,~~970~~753,~~100~~800		$	~~563~~424,~~900~~400		$	-		$	64,~~534~~178,~~000~~200
Foreign revenue		~~3,052,700~~-			1875,~~125,900~~600			-			4875,~~178,~~600
Total Revenue	$	93,~~022~~753,800		$	1,~~689~~300,~~800~~000		$	-		$	105,~~712~~053,~~600~~800
Segment Significant Expenses:
Cost of revenues		52,~~265~~677,~~200~~500			~~713~~1,~~800~~073,200						53,~~979~~750,~~000~~700
Compensation and other personnel expenses		1709,~~547,900~~700			3,~~899~~964,~~000~~300			~~462~~388,~~900~~000			5,~~909~~062,~~800~~100
Other expenses		1774,~~417,600~~100			21,~~151~~785,~~400~~800			1961,~~073,900~~000			43,~~711~~520,~~300~~900
Depreciation and Amortization		8545,~~000~~600			~~665~~564,~~700~~400			-			~~750~~610,~~700~~000
Segment Income (Loss) From Operations	$	707,100		$	(5,808,500	)	$	(1,536,800	)	$	(6,638,200	)
Segment Loss From Operations	$	(453,100	)	$	(6,087,700	)	$	(1,349,000	)	$	(7,889,900	)
Assets		53,~~751~~392,~~500~~000			3,~~824~~510,~~300~~600			15,~~985~~705,000			1112,~~560~~607,~~800~~600
Long-Lived Asset Expenditures		7516,~~900~~300			2346,~~000~~900			-			9863,~~900~~200

Year Ended December 31, 2023

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate

Consolidated

Year Ended December 31, 2024 Adjusted

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate

Consolidated

United States revenue

63,~~879~~107,~~500~~300

~~471~~563,~~500~~900

73,~~351~~671,~~000~~200

Foreign revenue

~~2,865,900~~-

~~894~~1,~~600~~125,900

31,~~760~~125,~~500~~900

Total revenue

93,~~745~~107,~~400~~300

1,~~366~~689,~~100~~800

114,~~111~~797,~~500~~100

Segment Significant Expenses:

Cost of revenues

52,~~489~~076,~~500~~700

~~520~~713,~~000~~800

62,~~009~~790,500

Compensation and other personnel expenses

1900,~~541,800~~100

63,~~237~~899,~~900~~000

~~526~~418,~~000~~700

85,~~305~~217,~~700~~800

Other expenses

1916,~~909,000~~700

12,~~690~~219,~~300~~800

1,~~702~~118,~~900~~000

54,~~302~~254,~~200~~500

Depreciation and Amortization

8485,~~900~~000

~~669~~665,~~100~~700

~~754~~750,~~000~~700

Segment Income (Loss) From Operations

720,200

(7,751,200

)

(2,228,900

)

(9,259,900

)

Segment Loss From Operations

(871,100

)

(5,808,500

)

(1,536,800

)

(8,216,400

)

Assets

65,~~832~~751,~~400~~500

43,~~969~~824,~~400~~300

41,~~928~~985,~~700~~000

1611,~~730~~560,~~500~~800

Long-Lived Asset Expenditures

2975,~~700~~900

~~102~~23,000

~~131~~98,~~700~~900

F-29

Table of Contents

Geographical Information

Year Ended

December 31, 2024

December 31, 2023

December 31, 2025

December 31, 2024

Revenue (a)

Long-Lived Assets

Revenue (a)

Long-Lived Assets

United States

64,~~534~~178,~~000~~200

1969,~~157,700~~400

73,~~351~~671,~~000~~200

1,~~414~~157,~~200~~700

All Other Foreign Countries

3621,~~615,800~~400

3563,~~027,500~~100

Germany

~~562~~254,~~800~~200

~~738~~631,300

~~733~~562,~~000~~800

1738,~~007,500~~300

Total

105,~~712~~053,~~600~~800

1,~~896~~600,~~000~~700

114,~~111~~797,~~500~~100

21,~~421~~896,~~700~~000

(a) Revenues are attributed to countries based on location of customer

For the year ended December 31, ~~2024~~2025, one customer accounted for approximately $1,~~118~~577,~~600~~100, revenue from the Benchtop Laboratory Equipment Segment, of which the revenue is 10% or more of the Company’s total revenue.

For the year ended December 31, ~~2023~~2024, one customer accounted for approximately $1,~~301~~119,~~400~~000 revenue from the Benchtop Laboratory Equipment Segment, of which the revenue is 10% or more of the Company’s total revenue.

For the year ended December 31, 2025, purchases from one vendor, represented in the aggregate 15.2% and 15.0% of consolidated net purchases for the years ended December 31, 2025 and 2024, respectively

F-30

Table of Contents

A reconciliation of the Company's consolidated segment ~~income/~~loss from operations to consolidated income (loss) from operations before discontinued operations and income taxes for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively, are as follows:

Year ended December 31, 2024	Benchtop Laboratory Equipment			Bioprocessing Systems			Corporate			Consolidated
Year ended December 31, 2025	Benchtop Laboratory Equipment			Bioprocessing Systems			Corporate			Consolidated
Income (Loss) from Operations	$	707,100		$	(5,808,500	)	$	(1,536,800	)	$	(6,638,200	)
Loss from Operations	$	(412,900	)	$	(6,128,000	)	$	(1,349,000	)	$	(7,889,900	)
Other income (expense), net		(35,~~600~~263,300	)		27736,~~700~~600			~~168~~114,~~700~~300			~~192~~6,~~800~~114,200
Income (Loss) from operations before discontinued operations and income taxes	$	703,500		$	(5,780,800	)	$	(1,368,100	)	$	(6,445,400	)
Loss from operations before discontinued operations and income taxes	$	4,850,400		$	(5,391,400	)	$	(1,234,700	)	$	(1,775,700	)

Year ended December 31, 2023	Benchtop Laboratory Equipment			Bioprocessing Systems			Corporate			Consolidated
Year ended December 31, 2024	Benchtop Laboratory Equipment			Bioprocessing Systems			Corporate			Consolidated
Income (Loss) from Operations	$	720,200		$	(7,751,200	)	$	(2,228,900	)	$	(9,259,900	)
Loss from Operations	$	(871,100	)	$	(5,808,500	)	$	(1,536,800	)	$	(8,216,400	)
Other income (expense), net		10(3,~~500~~600	)		1427,~~300~~700			~~145~~168,~~300~~700			~~170~~192,~~100~~800
Income (Loss) from operations before discontinued operations and income taxes	$	730,700		$	(7,736,900	)	$	(2,083,600	)	$	(9,089,800	)
Loss from operations before discontinued operations and income taxes	$	(874,700	)	$	(5,780,800	)	$	(1,368,100	)	$	(8,023,600	)

15. Employee Benefit Plans

The Company has a 401(k) profit sharing plan covering all its employees, which provides for voluntary employee salary contributions not to exceed the statutory limitations provided by the Internal Revenue Code. The plan provides for Company matching contribution equal to 100% of employee’s deferral up to 3% of pay, plus 50% of employee’s deferral over 3% of pay up to 5%. Total matching contributions amounted to $9980,~~200~~400 and $~~122~~99,~~400~~200 for the ~~year~~years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

16. Income Taxes

The domestic and foreign components of income or loss from continuing operations before taxes are:

	Year Ended December 31,			Year Ended December 31,
	2024			2023
	2025			2024
U.S. operations	$	(21,~~811~~647,~~900~~100	)	$	(54,~~352~~390,~~700~~100	)
Non-U.S. operations		(3,~~633~~422,~~500~~800	)		(3,~~737~~633,~~100~~500	)
Total loss before taxes	$	(61,~~445~~775,~~400~~700	)	$	(98,~~089~~023,~~800~~600	)

F-31

Table of Contents

Total provision for income taxes allocated to continuing operations for the year ended December, 31, ~~2024~~2025 and ~~2023~~2024, was $04,600, and $0, respectively.

Total provision for income taxes allocated to discontinued operations for the year ended December, 31, ~~2024~~2025 and ~~2023~~2024, was $0, and $0, respectively.

In accordance with ASC 740 ~~“Accounting for Income Taxes” (“ASC 740”)~~, the Company evaluated the deferred tax assets to determine if valuation allowances are required or should be adjusted. ASC 740 requires that companies assess whether valuation allowances should be established against their deferred tax assets based on consideration of all available evidence, both positive and negative, using a “more likely than not” standard of whether the deferred tax assets will be realized. As of and for the year ended December 31, ~~2024~~2025, the Company maintains a full valuation allowance of $912,~~839~~928,~~400~~000 against the consolidated net deferred tax assets as the Company determined the net deferred tax assets which includes net operating loss carry-forwards and other tax credits, are more likely not to be realized and therefore the Company recorded a full valuation allowance. As of and for the year ended December 31, ~~2023~~2024, the Company maintained a full valuation allowance of $9,~~302~~839,~~300~~400 against the consolidated net deferred tax assets as the Company determined the net deferred tax assets which includes net operating loss carry-forwards and other tax credits, are more likely not to be realized and therefore the Company recorded a full valuation allowance. If in the future the Company changes the determination as to the amount of deferred tax assets that can be realized, the Company will adjust the valuation allowance with a corresponding impact to the provision for income taxes in the period in which such determination is made.

The ~~reconciliation~~Company ofadopted ASU 2023-09 "Income Taxes (Topic 740): “Improvements To Income Tax Disclosures" on a prospective basis beginning with the ~~provision~~year ~~for~~ended ~~income~~December ~~taxes~~31, at2025. The following table presents required disclosure pursuant to ASU 2023-09 and reconciles the U.S. federal statutory ~~rate~~tax ofamount ~~21%~~and rate to ~~the~~our actual ~~income~~global ~~tax~~effective ~~expense~~amount ~~(benefit)~~and rate for the ~~applicable~~year ~~fiscal~~ended December 31, 2025. The effective tax rate for the current year is reflects the classification of certain operations as ~~follows~~discontinued operations, which were included in continuing operations in the prior year:

	Year Ended December 31,			Year Ended December 31,
		Year EndedDecember 31, 2025
	2024			2023
		Amount			Percent
Computed "expected" income tax benefit	$	(1,353,500	)	$	(1,908,900	)
U.S. federal statutory taxrate	$	(372,900	)	$	21.00	%
Research and development credits		(39,900	)		(9,400	)
State income taxes, net of federal income taxeffect		3,600			-0.20	%
Incentive Stock Option Expense		38,700			73,300
Foreign tax effects
Valuation allowance		537,100			2,883,700
Germany
Aquila Biolabs GmbH operating loss		(1,069,900	)		(1,150,800	)
Return to provision and other true ups		(2,025,500	)		114.07	%
Return to provision and other true-ups		1,887,500			112,100	)
Changes in valuation allowance		2,025,475			-114.07	%
Other, net		-		-
Changes in valuation allowance		1,167,225			-65.73	%
Income tax expense	$	-		$	-
Nontaxable or nondeductible items
Incentive Stock Options		21,600			-1.22
Other		3,700			-0.21
Return to Provision and other true ups
Depreciation		6,800			-0.38	%
Amortization		(1,247,200	)		70.23	%
Net Capitalized R&D Expenses		466,900			-26.29	%
Inventory Reserve		(11,300	)		0.64	%
Net Operating Loss		(36,700	)		2.07	%
Other		2,900			-0.17	%
Effective tax rate	$	4,600			-0.26	%

~~Income~~The ~~tax~~following ~~expense~~table ~~allocated~~presents the required disclosures prior to ~~continuing~~the ~~operations~~adoption of ASU 2023-09 and reconciles the U.S. federal statutory income tax rate to the actual global effective income tax rate for the year ended December 31, 2024 ~~and~~for ~~2023,~~continuing ~~was $0,~~ and ~~$0,~~discontinued ~~respectively.~~ operations:

Income tax expense allocated to discontinued operations for the year ended December 31, 2024 and 2023, was $0, and $0, respectively.

	2024
	Amount

Federal tax expense	$	(1,353,500	)
State tax expense		-
Research and Development Credits		(39,900	)
Incentive stock options		38,700
Changes in valuation allowance		537,100
Aquila Biolabs GmbH operating loss		(1,069,900	)
Return to provision and other true ups		1,887,500
Provision for income taxes	$	-

The Company’s ~~expected~~evaluated ~~income~~the ~~tax~~impact ~~expense~~of ~~differs~~the ~~from~~One ~~its~~Big ~~provision~~Beautiful ~~for~~Bill ~~income~~Act ~~tax~~(“OBBBA”), ~~expense~~enacted ~~due~~on toJuly ~~the~~4, ~~net~~2025, ~~operating loss~~which, ~~adjustments~~among ~~from~~other things, permits the ~~tax~~immediate ~~return~~expensing toof domestic R&D expenditures and allows for the ~~provision~~deduction of previously capitalized, ~~and~~unamortized amounts. Based on this new law, management concluded the Company’s ~~assessment~~is eligible to ~~record~~apply athese ~~full~~provisions. ASC ~~valuation~~740 ~~allowance~~requires ~~against~~that ~~those~~the ~~net~~effect ~~deferred~~of ~~tax~~changes ~~assets~~ in ~~applying~~laws be recognized in the ~~more-likely~~period ~~than~~in ~~not~~which ~~standard~~the ~~that~~applicable legislation is ~~required~~enacted. Consequently, the Company evaluated all deferred tax balances under the ~~applicable~~newly ~~guidance~~enacted ~~under~~tax ~~Generally~~law ~~Accepted~~and ~~Accounting~~reflected ~~Principles~~such effects in ~~the~~its USfinancial statements.

The Company’s expected income tax expense differs from its provision for income tax expense due to the net operating loss, adjustments from the tax return to the provision, and the Company’s assessment to record a full valuation allowance against those net deferred tax assets in applying the more likely than not standard that is required under the applicable guidance under Generally Accepted Accounting Principles in the US.

F-32

Table of Contents

~~Deferred~~Significant ~~tax~~components ~~assets~~of ~~and~~the ~~liabilities~~Company’s ~~consist~~deferred oftax ~~the~~assets ~~following~~are as follows:

	As of December 31,			As of December 31,
Deferred tax assets:	~~2024~~2025			~~2023~~2024
Amortization of intangible assets, including goodwill	$	-1,016,800		$	~~106,300~~-
Research and development credits		~~466~~445,~~300~~000			~~426~~466,~~400~~300
Goodwill impairment		~~898,800~~-			898,800
Capitalized research and development expenses		1,509,700			957,900
Net Capitalized R&D		1,373,400			1,509,700
Various accruals		~~134,000~~-			~~103~~134,~~300~~000
Stock options expense		1,~~531~~625,~~900~~200			1,~~486~~531,~~400~~900
Net operating loss		57,~~422~~401,900			5,~~383~~422,~~200~~900
Other		211,~~100~~175,300			2721,~~200~~100
Subtotal	$	913,~~984~~037,~~700~~600		$	9,~~389~~984,~~500~~700
Deferred tax liability:
Amortization of intangible assets, including goodwill		(98,500	)		-
Depreciation	$	(109,600	)	$	(46,800	)
Depreciation of property		(46,800	)		(87,200	)
Amortization of intangible assets, including goodwill		-			(98,500	)
Subtotal		(~~145~~109,~~300~~600	)		(~~87200~~145,300	)
Less valuation allowance		(912,~~839~~928,~~400~~000	)		(9,~~302~~839,~~300~~400	)
Net deferred tax assets	$	-		$	-

The Company has federal net operating loss (“NOL”) carryforwards of $15,~~248~~026,~~600~~854 and $2015,~~154~~248,~~400~~600, as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, with no expiration date, which are available to reduce future taxable income. The Company has foreign NOL carryforwards of $1216,~~757~~188,~~000~~634 and $912,~~330~~757,~~700~~000, as of December 31, ~~2024~~2025, and ~~2023~~2024, respectively, with no expiration date, which are available to reduce future taxable income. Under the 2017 Tax Cuts and Jobs Act ~~(the “TCJA”)~~, federal carryforwards may be carried forward indefinitely. Utilization of the Company’s federal NOL carryforwards and certain tax credit carryforwards may be subject to an annual limitation under IRC Section 382 if an ownership change, as defined by the IRC, has occurred or occurs in the future. There have been no ownership changes as of December 31, 2025 that would cause a Section 382 limitation. If an ownership change has occurred or were to occur, the Company’s ability to utilize its pre-change tax attributes could be limited.

The Company adopted ASU 2023-09 on a prospective basis for the year ended December 31, 2025. The company made no state or foreign tax payments for the year ended December 31, 2025; therefore, no table is needed as a result of the adoption.

17. Discontinued Operations

On August 7, 2025, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company sold substantially all of the assets of the Genie Division of the Company’s Benchtop Laboratory Equipment Operations located in Bohemia, New York to Troemner, LLC (the “Buyer”). Such assets consisted primarily of fixed assets, inventory, and intangible assets, of which the Company has no remaining assets or liabilities as of December 31, 2025. The purchase price consisted of $9,600,000 less certain working capital adjustments plus an earn-out up to an aggregate of $1,500,000, of which $1,140,000 is guaranteed if the Seller performs certain obligations under a separate Manufacturing and Supply Agreement (“MSA”) and a separate Transition services agreements (“TSA”), under which the Company will supply products currently produced by the Division to the Buyer for a period of up to twelve months, plus transition services which include training and transfer of knowhow by the Company to the Buyer. The amounts earned by the Company under the earn-out provision of the MSA and TSA are recorded as earned based on the contractual services performed and are recorded as a reduction of its operating expenses which amounted to $300,000 during the year ended December 31, 2025.

At December 31, 2025, the Current Assets for Discontinued Operations of $272,900 reflect a receivable from the Buyer while the Current Liabilities for Discontinued Operations of $12,300 reflect a payable to the buyer. As of December 31, 2024, historical assets and liabilities were reclassified to derecognize those assets and liabilities related to the Genie product line.

The gain on disposal was calculated as follows:

Carrying value of net assets of the Genie Division
Inventory	$	2,259,800
Fixed Assets		88,700
Intangible Assets (Patents)		5,300
		2,353,800

Total consideration received, net of transaction costs
Cash		9,600,000
Less: transaction costs and closing adjustments		(1,025,800	)
Less: Escrow balance to be recognized upon successful transition		(960,000	)
		7,614,200

Gain on disposition	$	5,263,400

The following is the breakdown of the income generated from discontinued operations.

	For the years ended
	December 31,
	2025		2024

Net Revenue	$	3,139,900	$	5,915,500
Cost of Goods Sold		1,564,500		3,188,500
Gross Profit		1,575,400		2,727,000
Operating Expenses:
General and Administrative		652,100		703,300
Selling		259,300		437,300
Research and Development		104,100		8,200
Total Expenses	$	1,015,500	$	1,148,800
Income from Discontinued Operations	$	559,900	$	1,578,200

F-33

Filing Compare · SCIENTIFIC INDUSTRIES INC